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The presence of human pharmaceuticals in the aquatic environment is now becoming a well-
established fact. The identified problems associated with their presence include the fact that these 
compounds are biologically active, some of them are toxic in nature, and a number of compounds 
have potential to foster and maintain drug resistant microorganisms. They are discharged into the 
aquatic environment from a variety of sources, but mainly by the excretion of incompletely 
metabolized pharmaceuticals by individuals into the wastewater. This situation makes finding a 
source-control strategy difficult. However, healthcare facility (hospitals and long-term-care homes) 
effluents are suspected to have relatively higher concentrations of these compounds, as such facilities 
use pharmaceuticals in large amounts for diagnostic, cure and research purposes. It is expected that 
controlling discharges from these facilities may provide a cost-effective solution to reduce the 
pharmaceutical loads entering the aquatic environment.  
Published literature indicates that very few studies have exclusively investigated the relative 
contribution of pharmaceutical compounds by hospitals to wastewater treatment plants (WWTPs). No 
study known to this author explores either discharges from or contributions by long-term-care homes. 
The current study investigates both types of healthcare facility effluents for occurrence and mass 
flows of nine therapeutic compounds and the corresponding relative contribution of these compounds 
to the respective downstream WWTPs.   
Results support the idea that healthcare facility effluents may contain elevated concentrations of 
pharmaceutical compounds. The maximum concentrations of the antibiotic compounds detected in 
the hospital effluents were Sulfamethoxazole (10.9 g/L), Trimethoprim (10.3 g/L), and 
Ciprofloxacin (1.24 g/L). The maximum concentrations of these antibiotics in the long term care 
facility effluent were 2.3 g/L, 6.5 g/L and 1.4 g/L, respectively. The concentration of 
Acetaminophen was detected in levels of up to 134 g/L in the hospital and 116 g/L in the long-
term-care home effluents. The contributions of pharmaceutical loads by healthcare facilities to their 
downstream WWTPs were found to be affected by the size of the facility, its service spectrum, and 
the size of the community contributing to the loads of these compounds to the same WWTPs.  
Relatively higher contributions were observed for antibiotic compounds; the maximum contributions 
of Ciprofloxacin were 26.6% for hospitals and 37% for long-term-care homes. 
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As hospitals vary considerably in the services they provide and thus the drugs they use, the findings 
of this study may not be representative for all the hospitals. Long-term-care homes, on the other hand, 
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In recent years, the occurrence of the pharmaceuticals in various environmental compartments has 
extensively been reported (Heberer, 2002a; Kolpin et al., 2002; Mompelat et al., 2009; Rabiet et al., 
2006; Stackelberg et al., 2004). Their presence in the aquatic environment is of great concern mainly 
because these compounds are designed to be biologically active (Lissemore et al., 2006), and some 
have the potential to foster drug-resistant bacteria. 
 
For both risk assessment and risk management it is important to identify the major sources of 
pharmaceuticals emissions.  The main pathway whereby human pharmaceuticals enter the aquatic 
environment is patient excretion of incompletely metabolized pharmaceuticals (Brown et al., 2006), 
which then enter the sewerage system and subsequently reach water bodies either though direct 
WWTP effluent discharge or though sludge disposal sites. 
Healthcare facilities (i.e., hospitals and long term care facilities) are suspected to be substantial point 
sources of many pharmaceuticals as a considerable amount of pharmaceuticals are administered in 
these facilities. The main entrance route of human pharmaceuticals into the water sources is WWTPs 
(Daughton, 2004). Therefore, determining the relative contribution of healthcare facilities to the total 
pharmaceutical load of the WWTPs was identified by the US EPA as an important research need 
(Daughton, 2004). 
 
The emission of pharmaceuticals from healthcare units is still not well investigated. Limited reports 
characterizing hospital effluents are available but are not consistent in terms of experimental 
conditions, target compounds and extraction methods to precisely define these specialized streams. In 
addition, climatic conditions and pharmaceutical use trends that vary from country to country make it 




Very few studies have exclusively investigated the relative contributions of hospitals to downstream 
WWTPs, but they only consider discharges from hospitals and assume that households are the only 
other contributors to the influent load of  WWTPs. Thus they largely underestimate the total 
healthcare facility contribution to the WWTPs, through ignoring long-term-care homes.   
 
This study is the first to date that considers both types of healthcare facilities for the occurrence and 
mass flows of PhACs in their effluents, and their relative contributions to downstream WWTPs.  
  
1.2 Project Objectives 
 The goal of this project was to determine the relative contribution of healthcare facilities (hospitals 
and long-term-care-homes) to the overall mass loading of selected human pharmaceuticals to 
WWTPs. The specific objectives of the project were to 
 
1. Determine the occurrence of target pharmaceutical compounds in healthcare facility effluents 
and their downstream WWTP influents.  
2. Determine day-to-day variability of pharmaceutical compounds in healthcare facility 
effluents. 
3. Determine the mass flows of pharmaceutical compounds in healthcare facility effluents. 
4. Investigate the relative contributions of target pharmaceuticals by healthcare facilities to the 
overall mass loading of WWTPs. 










This literature review consists of three sections. Section-1 covers background information about 
pharmaceuticals, section-2 examines studies on the occurrence of pharmaceuticals in healthcare 
wastewaters and section-3 deals with the existing theories used to predict the concentration of 
pharmaceutical compounds in raw wastewater.   
2.2   Pharmaceuticals as Emerging Environmental Contaminants-EECs 
The term Emerging Environmental Contaminants (EECs) refers to compounds of domestic, 
municipal, industrial or agricultural origin which are not currently regulated or monitored but possess 
eco-toxic potential, and may be future candidates for regulation. (Glassmeyer et al., 2008; Petrovic et 
al., 2008). Pharmaceutically Active Compounds (PhACs), among all other EECs, have received more 
attention because of their special physicochemical and biological properties (Glassmeyer et al., 2008; 
Kümmerer, 2008b). 
The presence of pharmaceuticals in the aquatic environment was initially noticed in the 1970s 
(Kümmerer, 2001a; Santos et al., 2010) but received more attention in the mid 1990s with the 
advancement of analytical methods to detect chemicals at very low concentration (parts per billion) 
(Glassmeyer et al., 2008; Mompelat et al., 2009). Since then, the occurrence of pharmaceuticals in 
various environmental compartments has frequently been reported, i.e., in surface water (Loos et al., 
2009; Mompelat et al., 2009; Zhang et al., 2008), ground water (Barnes et al., 2008; Batt et al., 2006; 
Rabiet et al., 2006), drinking water (Heberer, 2002b; Heberer, 2002a; Putschew et al., 2000; Ternes, 
2001; Wasik et al., 2007) and even finished drinking water supplies (Benotti et al., 2009; Reddersen 
et al., 2002; Stackelberg et al., 2004; Stackelberg et al., 2007) in a ng- g/L range. The first extensive 
study of the occurrence of pharmaceuticals, hormones, and other organic compounds in water sources 
was carried out by the US Geological Survey. This study revealed the presence of 82 out of 95 target 
compounds in 135 US streams (Kolpin et al., 2002). 
 
The characteristics of PhACs that make them different from the other environmental pollutants 
include 1) a tendency of the parent neutral compound and its salts to form polymorphic solid states,  
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2) they mostly enter into the environment after human metabolism, 3) the frequent presence of large, 
complex molecular structure with multiple ionizable sites spread throughout the molecule, and 4) 
higher water solubility relative to molecular weight (Cunningham, 2008). 
 
The entrance of PhACs into the aquatic environment is constant and unavoidable (Santos et al., 2010) 
because these compounds are considered necessary to life as they are used to maintain and restore 
human health. Thus, unlike other contaminants, they are marketed as an important product for use, 
and in contrast to conventional contaminants which have well defined point sources, they are 
discharged from widespread sources, from individual households to communal service facilities 
(Daughton, 2007).  
 
The identified problems associated with the presence of PhACs in the aquatic environment include 
the intrinsic toxicity of PhACs like cytostatic agents and antibiotics; the fact that they are biologically 
active as these compounds are designed to produce biological responses in the receptors (Boillot et 
al., 2008; Christen et al., 2010), and the possibility that the drug effectiveness could be compromised, 
especially antibiotics  as bacteria can develop and maintain resistance from their constant exposure to 
low concentrations of these drugs.  
 
In addition there are concerns about the magnitude of the issue and the difficulty in the removal of 
some of these compounds in wastewater treatment processes.  PhACs are produced and used in huge 
amounts- about 60,000 compounds are in use worldwide (Tropsha, 2000) with wide variations in their 
physicochemical properties (Kümmerer, 2008b).  The difficulty in source identification and control 
arises because these compounds are discharged from wide spread point and non-point sources; 
furthermore, most of these compounds are very polar and mobile. Persistency in wastewater treatment 
processes is usually due to the resistance to biodegradation e.g. antiepileptic Carbamazepine and most 





2.3 Background Concepts of Pharmaceuticals 
The U.S. Food and Drug Administration Center defines a drug as ―A substance intended for use in the 
diagnosis, cure, mitigation, treatment, or prevention of disease‖ (F.D.A, 2004). Pharmaceuticals 
include a large number of compounds, prescription and non-prescription drugs, and diagnostic aids 
for both human and veterinary use.  They include antibiotics, anti-inflammatories, antiepileptics, beta- 
blockers, anti-depressants, painkillers, lipid regulators, antineoplastics, antihistamines, tranquilizers 
diagnostic aids, and cytostatic agents. Approximately 60,000 drug compounds are used worldwide  
(Tropsha, 2000), and in Canada,  15,331 approved drug compounds are currently in the market (DPD 
April, 2010). The world wide consumption of antibiotics has been reported to be in the range of  
100,000 – 200,000 tons per year, with an average annual per capita consumption of 15 g (Wise, 
2002).  
 
Drugs are classified in various ways including by origin, action, therapeutic use, site of action, and, 
by chemical structure (Nadendla, 2005). In addition, they can be sub-divided based on their chemical 
molecules. For example β-lactams, fluoroquinolones, sulfonamides, macrolides, etc., are all 
antibiotics.  All β-lactam antibiotics share a common β-lactam ring; the parent compound of 
fluoroquinolones is nalidixic acid, with a fluorine atom attached to central ring; and sulfonamides 
contain a sulfonamide functional group in their structure. From an environmental perspective, 
considering drug  sub-groups based on chemical molecules is more helpful, although differing 
behaviors of drug molecules belonging to the same subgroup of compounds in water treatment 
systems has been observed for certain compounds (Choi et al., 2008; M. C. Dodd et al., 2005). For 
analytical purposes PhACs are often grouped based on functional groups such as acidic (compounds 
containing carboxylic moieties and one or two phenolic hydroxy groups), basic and neutral 
(containing no acidic functional groups (Ternes, 2001). 
 
The properties of a drug molecule are typically designed to facilitate transport from the site of 
administration to the site of action. For chemical interaction with the target receptor without binding 
with other receptors, drug molecules are developed with an appropriate size, shape, electrical charge, 
and atomic composition (Correia, 2007). The molecular size of the drugs varies widely from less than 
10 to about 60,000 (Diaz-Cruz et al., 2007) Dalton; most of the drugs are in the range of 100 to 1000 
Dalton (Correia, 2007) . The molecules can exist in anionic, cationic or zwitterionic states under 
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various environmental conditions. Furthermore they often have acidic or basic functionalities 
(Kümmerer, 2001b). 
 
2.3.1 Active Pharmaceutical Ingredient-API  
It is important to note that from an environmental perspective, the term pharmaceutical generally 
refers to the active component in a pharmaceutical composition. This component of the drug is 
measured in different environmental compartments, and prediction models use consumption data on 
this component (model input data) to estimate the concentration of this portion of the drug (tablets, 
capsules, etc). Pharmaceuticals are composed of Active Pharmaceutical Ingredients or APIs, and 
inactive or inert ingredients e.g. excipients, adjuvant, and, in some cases, pigments and dyes. Inactive 
ingredients are typically considered to be less important to the environment (Kümmerer, 2008b), 
although in some cases, they can affect the absorption or metabolism of APIs (Daughton, 2007). 
APIs, are complex molecules having different physicochemical and biological properties. They are 
used because of their specific biological activity and usually characterized by their ionic nature. This 
component is of interest to researchers, in the environment (Kümmerer, 2008b). 
 
2.3.2 Metabolism and Transformation Products 
Pharmaceuticals are eliminated from the human body by metabolism and subsequent excretion. Drugs 
are xenobiotics (compounds that do not belong to or  are not expected to be in organisms bodies), and 
metabolism is the process that either breaks them down or transforms these foreign compounds when 
they come in contact with organisms so that they can be easily removed (King, 2009). Knowledge of 
drug metabolism can facilitate evaluating the environmental concentrations of pharmaceuticals, risk 
assessment strategies, and an understanding of consumption and excretion relationships.  
 
Drugs, once administered, are metabolized in the human body. During metabolism the lipophilic 
compounds are changed into more water- soluble (hydrophilic) compounds, and are more easily 
excreted (Stephen et al., 2004). Drug metabolism is usually divided into two phases:  phase-I 
functionalization reactions, including oxidation, reduction, hydrolysis, and hydration and phase-II 
conjugation reactions (Gibson et al., 2001). Phase-I reactions convert the drug into more-polar 
metabolites by adding or unmasking a functional group (-OH, -NH2, -SH) (Correia, 2007). The 
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increased polarity helps the body to readily excrete these compounds. These metabolites are mostly 
biologically inactive; however, in some cases though activity can be changed or enhanced. For 
example O-desmethylvenlafaxine is a major active metabolite of the antidepressant venlafaxine 
(Merck & Co, 2004).  Drug metabolites are typically believed to be more persistent in the aquatic 
environment than the original compounds because of their increased polarity (Petrovic et al., 2008).  
 
If Phase-I reactions do not produce metabolites that are sufficiently polar, to be excreted from the 
body, then the metabolites often undergo a second reaction that involves; attaching a polar and 
ionizable endogenous molecule such as glucuronic acid, sulfate, glycine, or glutamine to form highly 
polar conjugates (Stephen et al., 2004) that can be then excreted. Some compounds which already 
have a required functional group can directly form conjugates (Correia, 2007). Phase-II reactions are 
considered to be true detoxification reactions (Gibson et al., 2001) ; however, there are exceptions. 
Some conjugates have proved to be even more potent than the parent compound, for example, 
glucuronidation of the analgesic morphine. In fact morphine-6-glucuronide is twice as potent as 
morphine itself (Smith et al., 2001). Conjugates especially formed with glucuronic acid, have the 
tendency to be cleaved during sewage transit and during sewage treatment processes to produce their 
parent compound (Alder et al., 2006; Khan et al., 2004). 
 
Factors that affect drug metabolism include physicochemical properties of the drug compound, route 
of administration, genetics, sex, age, heath condition, diet, and environmental factors (people exposed 
to certain environment e.g. industrial workers) (Correia, 2007; Nadendla, 2005). The administered 
parent compound may be excreted via urine and feces as unchanged, major metabolites, glucuronide 
or sulfate conjugates and a complex mixture of metabolites (Kümmerer, 2008b).  
 
Significant amounts of administered drugs are excreted though urine (70%) (Alder et al., 2006). Other 
excretion routes include saliva, sweat, and mother’s milk; however these are not typically significant. 
The metabolism and excretion step may not be present in external (dermal) drug applications. Drugs 
are metabolized in human bodies to differing extents, and  the excretion of unchanged drugs as a 
percentage of an administered dose varies from less than 5% (acetaminophen, carbamazepine) to 
more than 90% (contrast agents, e.g., Iohexole) (Sweetman et al., 2007; Glassmeyer et al., 2008).  
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2.4 Consumption Pattern of PhACs and Occurrence in the Aquatic 
Environment 
 
There is a direct relationship between the consumption of pharmaceuticals and their occurrence in the 
aquatic environment; generally, higher concentrations are expected for highly used compounds. The 
drug consumption varies between countries. Hence, recognizing these differences is important when 
the findings about the occurrence of pharmaceutical compounds of any study carried out in one 
country are extended to others without taking into account these differences.  
The use pattern of pharmaceuticals varies from region to region and country to country, depending 
upon existing legislation, treatment guidelines, marketing strategies, regulations, climatic conditions, 
personal preference and healthcare systems (Alder et al., 2006; Corcoran et al., 2010; Daughton, 
2007; Goossens et al., 2005; Kümmerer, 2008b). Therefore, understanding these differences is 
required as background to any evaluation of concentrations reported in studies carried out in different 
parts of the world. For example, Vancomycine is a widely used antibiotic in the USA, but its use in 
Europe is very restricted (Kümmerer, 2001b).  In Japan, only 0.4% women of reproductive age take 
contraceptive pills (ethinyl estroadiol), compared to 16% in North America (Kümmerer, 2008b). 
Furthermore, colfibric acid, a metabolite of some fibrate lipid regulators and widely detected in 
Europe, is seldom detected in the USA because these compounds are not often used there (Alder et 
al., 2006).  In addition for the year 2004, the use of 81 antibiotic compounds has been reported in 
USA compared to 153 of such compounds in Europe (Goossens et al., 2007) Wide differences in the 
use of antibiotic compounds within European countries have also been reported (Goossens et al., 
2005). Such differences have been cited in the use of certain compounds and also access to these 
compounds. For example, a number of drugs that are only available on prescription in some countries 
can be purchased over the counter in others (Kümmerer, 2008b), which could affect their 
environmental concentrations. Again there are variations in the trends of pharmaceutical use; 
consumption of certain compounds is increasing in some countries while decreasing in others (Alder 
et al., 2006). All the above differences suggest that regional situations need to be considered by any 
researcher extending study results carried out in one country to another.  
Seasonal variation in consumption patterns is also found to be important (Alder et al., 2006), hence 
affecting the concentration of compounds entering into the aquatic environment at different times of 
the year. For example a higher consumption of antibiotic compounds in ten European countries was 
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observed during the first and last quarter of the year than during the third and fourth (Goossens et al., 
2005). Castiglioni (2006) observed higher WWTP influent loads of his target compounds (including 
Sulfamethoxazole and Ciprofloxacin) in winters than in summer.  
2.5 Healthcare Facilities 
A variety of sources contribute to the emission of PhACs to the aquatic environment and include 
pharmaceutical manufacturers, healthcare facilities, long term care homes, individual households, 
dumps and land-filling of discarded pharmaceuticals, veterinary and agricultural sources, and 
wastewater treatment plants. 
The main pathway of pharmaceuticals to the aquatic environment is excretion of these compounds by 
patients (Chang et al., 2010). Therefore, healthcare facilities (hospitals and long term care homes) are 
considered important source of pharmaceuticals as a considerable amount of PhACs are used within 
these facilities for diagnostic, cure and research purposes (Emmanuel et al., 2005). Higher 
concentrations of pharmaceuticals, especially antibiotics, cytostatic agents, and iodinated contrast 
media have been reported in hospital wastewaters (Alder et al., 2006). Patients in long -term care 
homes also often receive several medications, and their prescriptions are likely to be changed 
frequently (Daughton, 2007). Furthermore unlike hospitals the patients stay in these facilities for 
longer periods. This may result in high discharges of certain compounds from these facilities.   
2.5.1 Hospitals  
This study has been carried out in Ontario, Canada; therefore this section presents information about 
the hospital sector in Ontario and some key terms used for hospital data that may have a connection to 
drug discharges.  
The Canadian Institute of Health Information (CIHI., 2009) defines a hospital as “an institution 
where patients are accommodated on the basis of medical need and are provided with continuing 
medical care and supporting diagnostic and therapeutic services and which is licensed or approved 
as a hospital by a provincial government or is operated by the government of Canada”. Ontario has 
four different types of hospitals: Public, private, federal, and cancer care. According to Public 
Hospital Act-964, hospitals are classified as general hospitals, convalescent hospitals, hospitals for 
chronic patients, active treatment teaching psychiatric hospitals, active treatment hospitals for 
alcoholism and drug addiction and regional rehabilitation hospitals, which are then further graded 
from ―A to V‖ depending upon the size, care services offered by the facility,  and their affiliation. 
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There are a total of 234 hospitals in Ontario, including seven private hospitals (Ministry of Health and 
Long-term care, Ontario). Hospitals in Canada operate under the health authorities in some provinces 
and as separate entities in other provinces (CIHI., 2009).  
Some hospitals also have beds allocated for long term care, known as hospital based continuing care. 
The residents in these facilities are a diverse population with complex health needs, mostly in a 
clinically unstable condition and dependent on others for daily activities. Data from 2004-2005 shows 
that 80% of the patients were admitted from the acute care beds in the hospital.  Their average length 
of stay in these care centers is less than three months (CIHI, 2006).  
The key indicators in hospital data which will likely have a connection with the drug discharges from 
these facilities include number of beds staffed (i.e., ―beds and cribs available and staffed to provide 
services to inpatients‖)(CIHI, 2000) which is also a measure of hospital size, bed density (beds 
available in hospitals /1000 population); and average length of stay for inpatients (days).   
 
2.5.2 Long term care homes 
The Ministry of Health and Long-Term Care defines a long term care (LTC) home as “a home-like 
facility that provides care and services for people who no longer are able to live independently or 
who require onsite nursing care, 24-hour supervision or personal support”. In Ontario such facilities 
are owned and operated by various organizations i.e., municipalities, private corporations, and charity 
organizations. They operate under the regulatory authority of the Ministry of Health and Long-Term 
Care (http://www.health.gov.on.ca/en/). 
 
Long term care facilities are also known as nursing homes, residential care facilities, and personal 
care homes. The residents in these facilities are a more homogenous group of people, than in the 
hospital based continuing care facilities, older in age and stay there for a longer period of time. These 
residents are clinically stable and moderately dependent in their daily activities. Cognitive impairment 
and reduced physical function is mostly observed among these residents (CIHI, 2006).  
 
Drug use in long term care homes is relatively high, especially of antibiotics and antidepressants. This 
situation occurs because older people are highly susceptible to infections (Mody et al., 2007; Monette 
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et al., 2007; Moro et al., 2007).  Over one year in the US, 400,000 deaths in nursing homes were 
found to be infection related (Crnich et al., 2007).  Pneumonia and urinary tract infections (UTIs) are 
common (Nicolle et al., 2000). The chance of pneumonia in elderly people in a long-term-care home 
setup is ten times greater than in a normal community setup. In the US the annual Medicare cost for 
nursing-home-acquired pneumonia is estimated to be over $3 billion (Bonomo et al., 2002). 
 
One important factor that contribute to the high drug use in LTC homes is the physiological responses 
that sometimes change with age create uncertainties in diagnostics, often resulting in more drugs 
being prescribed (Nicolle et al., 2000); for example 20-30% of elderly patients may not present fevers 
even with severe infections (Bonomo et al., 2002). 
 
Antibiotics have been reported to account for 40% of the total prescribed systemic drugs, and 50-70% 
of residents receive at least one antibacterial drug in any particular year (Nicolle et al., 2000). Some 
studies indicate that 15% of the population is prescribed antibiotics at any time (Bonomo et al., 2002). 
(Mylotte, 1996) studied a 150 bed nursing home facility and found that Trimethoprim, 
sulfamethoxazole, and ciprofloxacin together made up 55% of the all prescribed antibiotics.  
 
Depression develops among nursing home residents because of the various losses in old age, 
physically illness, and disability (Llewellyn-Jones et al., 2007; Kramer et al., 2009) leading to high 
use of antidepressants in these homes.  
 
The intensive use of antibiotics has led to LTC homes acting as a reservoir for drug resistant 
organisms (Bonomo et al., 2002; Nicolle et al., 2000; Fluit et al., 2006).  Crnich et al., (2007) have 
indicated that the number of infections related to antibiotic resistant bacteria in US nursing homes 
showed an increasing trend from 2000 to 2004. Additionally, an increasing trend in the prevalence of 
resistance to sulfamethoxazole, trimethoprim and ciprofloxacin in nursing homes in the Netherland 




2.6 Characteristics of Hospital Effluents 
 
Assessing the significance of hospitals as a point source of human pharmaceuticals requires data 
regarding the occurrence of these compounds in the hospital effluents which has been gained by a 
review of the related literature and the concentrations that have been reported are summarized in 
Table 2-2 and Table 2-3. 
 
 The discharges of wastewaters from hospitals depend upon several factors, such as the number of 
beds, medical care services available, and location (Askarian et al., 2004). Hospitals generate large 
amounts of wastewater (between 400 and 1200 L/bed/day, Emmanuel et al., 2005) that contain 
elevated concentrations of chemicals, biological liquids, drug residues, heavy metals, and 
radionuclides (Boillot et al., 2008). 
 
 Qualitatively hospital wastewater can be divided into two classes: one that is similar to municipal 
wastewater and comes from kitchen, laundry, and personal hygiene of patients and staff, and a second 
that is more specific to hospitals, and contains physical, chemical, and microbiological loadings 
(Boillot et al., 2008). Chemical characterization of hospital wastewaters has indicated that they can 
contain a variety of chemical compounds, pharmaceuticals, disinfectants, diagnostic aids, and heavy 
metals (Kümmerer, 2001b). 
 
  The genotoxicity potential of hospital effluent has also been demonstrated (Gautam et al., 2007; 
Giuliani et al., 1996; A. Hartmann et al., 1999). Eco-toxicological risk assessment studies have 
confirmed the presence of hazardous materials in hospital wastewater and suggested that they can 
affect aquatic ecosystems (Emmanuel et al., 2005). Gautam et al. (2007) demonstrated the occurrence 
of cytostatic agents in hospital effluents and their potential as eco-toxicological hazards and the 
possible effects on the WWTPs process. 
 
In addition most hospitals have laboratory facilities for diagnostics, recovery monitoring, and 
research purposes, which generate liquid residues that are heavily contaminated with patient blood 
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and urine and test reagents, and are generally discharged into sewers (Kümmerer, 2004a). Seven out 
of nine samples taken from the laboratory effluent of a hospital were found to be mutagenic, indicated 
by the Ames and hamster cell tests (Gartiser et al., 1996).  
 
 Hartmann et al. (1998) found that fluoroquinolone antibiotics are the main source of genotoxicity in 
umuC tests. The umuC test is a short-term bacterial test, that uses Salmonella typhimurium (TA 
1535/pSK 1002) and monitors the induction of a umuC'-'lacZ fusion gene after DNA damage 
(Giuliani et al., 1996; Oda et al., 1985; Steger-Hartmann et al., 1997). 
 
The characterization of hospital effluent based on conventional wastewater parameters (COD, BOD, 
TSS) shows that hospital effluent is not much different than municipal wastewater (Kümmerer et al., 
1997). The concentrations between 43 and 2464 mg/L for COD, 50 and 530 mg/L for TSS, 16 and 
3000 mg/L for TOC, and 15 and 1560 mg/L for BOD5 have been reported in hospital effluents (Table 
2-1).  
 
Chlorine is present in certain disinfectants that are used in hospitals, and when discharged into 
wastewater, chlorine can react with organic matter producing organic chlorine compounds that can be 
measured as Adsorbable Organic Halogens (AOX). These compounds are toxic to aquatic organisms, 
and their properties make them persistent environmental contaminants (Emmanuel et al., 2004).  
Higher concentrations of these organochlorine compounds are reported and up to 14mg/L 
concentration are measured in German hospital effluent (Kümmerer et al., 1998). The presence of 
AOX in hospital effluent can also include iodinated contrast media released by radiology departments 
(Emmanuel et al., 2004). Oleksy-Frenzel et al. (2000) detected a high concentration (9970 μg/L) of an 
iodinated fraction i.e., adsorbable organic iodine AOI in hospital effluent, apparently contributed by 
X-ray contrast agents.  The higher concentrations of contrast agents in wastewater occur because of 
the higher consumption of these compounds in hospitals for diagnostic purposes and because they are  
metabolically stable in human bodies and therefore excreted mostly unchanged (Hartmann et al., 




Table 2-1: Physico-chemical and microbiological characteristics of hospital effluent.  
Parameter Unit concentrations Cuntry Reference 
TSS mg/L 484 Brazil (Vasconcelos et al., 2009) 
 531 India (Gautam et al., 2007) 
 155-298 France (Emmanuel et al., 2005) 
 197-446 Mauritius (Mohee, 2005) 
 50-80 France (Boillot et al., 2008) 
  339 Spain (Suarez et al., 2009) 
  225 France (Emmanuel et al., 2004) 
TDS  1540 India (Gautam et al., 2007) 
COD mg/L 658 Brazil (Vasconcelos et al., 2009) 
 43-270 France (Boillot et al., 2008) 
 1067 India (Gautam et al., 2007) 
 362-2664 France (Emmanuel et al., 2005) 
 479-636 Mauritius (Mohee, 2005) 
  362-1492 France (Emmanuel et al., 2004) 
  2464 Spain (Suarez et al., 2009) 
BOD5 mg/L 15-120 France (Boillot et al., 2008) 
 149-333 Mauritius (Mohee, 2005) 
 200-1559 France (Emmanuel et al., 2005) 
TOC mg/L 16-82 France (Boillot et al., 2008) 
 160-3095 France (Emmanuel et al., 2005) 
AOX mg/L 0.18-0.82 France (Boillot et al., 2008) 
 0.17-1.61 France (Emmanuel et al., 2005) 
  0.41 Germany (Gartiser et al., 1996) 
  0.7 France (Emmanuel et al., 2004) 
  14.2 Germany (Kümmerer et al., 1998) 
Free Chlorine mg/L 0.09-0.55 France (Boillot et al., 2008) 
Bacterial count CFU/mL 2.5X107 India (Gautam et al., 2007) 
Staphylococci /100mL 608 France (Boillot et al., 2008) 
Fecal bacteria NPP/100mL 1x 106 France (Emmanuel et al., 2005) 
 
Hospital effluents contain lower bacterial concentrations (Table 2-1) than are typically present in 
municipal wastewater (10
8
/100 mL) (Metcalf & Eddy, 1991). The reduced microbial concentrations 
have been attributed to the presence of disinfectants and antibiotics in the hospital effluents 
(Emmanuel et al., 2005; Gautam et al., 2007). Among the most frequently detected microorganisms 
are virus and pathogenic bacteria, including those with the resistant characteristics (Emmanuel et al., 




2.6.1 Drug discharges 
 
In this section, antibiotic drugs are discussed separately from the rest of the PhACs because 
antibiotics are of particular interest to the scientific community based on their potential to develop 
and maintain antibiotic resistance in addition to their biological activity. 
 The published data on the likelihood of antibiotics in hospital wastewater, the amount of antibiotics 
consumed in hospitals and the occurrence of these compounds in hospital effluents have been 
reviewed. The maximum detected concentrations are presented in a tabulated form (Table 2-2).  
 
2.6.1.1 Antibiotics 
The term antibiotic refers to any antimicrobial agent that can come from either natural or synthetic 
sources which can act against micro-organisms (Diaz-Cruz et al., 2007). Antibiotics are widely used 
in human and veterinary medicine to treat microbial infections. In the live stock industry, they are 
also used as growth promoters. Other uses include agricultural and aquaculture, i.e., for fruits 
(Streptomycin), crops, poultry, beekeeping, and fish farming (Kümmerer, 2008b).  
More than ten antibiotic classes (based on chemical structure) are currently used for human 
therapeutic applications (Huang et al., 2001) and this includes aminoglycosides, ansamycins, 
carbapenems, carbacephem, cephalosporins, glycopeptides, macrolides, monobactams, pencillins, 
polypeptides, quinolones, sulfonamides and tetracyclines. Among these classes; aminoglycosides, 
macrolides, ß-lactams, fluoroquinolones, sulfonamides, and tetracyclines are often detected in 
hospital wastewater with fluoroquinolones and sulfonamides present in higher concentrations (Table 
2-2). 
 
The global use of antibiotics per annum ranges from 100 to 200x10
6 
kg (Wise, 2002). The substantial 
consumption of antibiotics has led to their presence in various environmental compartments 
Antibiotic compounds are partially metabolized in the human body and excreted mostly via urine and 
discharged into hospital wastewater to varying degrees (Kümmerer, 2004b).  For example 40 - 50% 
of a ciprofloxacin oral dose is excreted unchanged in the urine and about 70% of a parenteral dose 
may be excreted unchanged within 24 hours. About 80-100% of a dose of sulfamethoxazole is 
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excreted in urine, of which 60% is in the form of acetyl derivatives.  For trimethoprim 40 to 60% of 
the dose is excreted in urine (Sweetman et al., 2007). Many of the antibiotic compounds have been 
reported to be resistant to biodegradation (Martins et al., 2008; Martins et al., 2008; Alexy et al., 
2004), and hence they make their way to the aquatic environment either though WWTP effluents or 
sludge disposal sites (Kümmerer et al., 2003).  The detection of these compounds in wastewater 
treatment effluent indicates partial removal in wastewater treatment processes hence they enter the 
water bodies (Miao et al., 2004). 
 
The presence of antibiotics in the aquatic environment is of concern because of their potential to 
cause genotoxic effects, disturbances of the aquatic ecology, human health risks and formation of 
antibiotic resistant strains of bacteria (Brown et al., 2006; Lindberg et al., 2004).  For instance, the 
antibiotic ciprofloxacin has been reported to be the main source of genotoxicity in hospital effluent 
using a umuC test (Hartmann, 1998). Furthermore, their presence in the aquatic environment can 
challenge water reuse technologies. The continuous exposure to even low level concentrations of 
antibiotics (ng/L- g/L) is expected to develop resistance in bacteria (Chang et al., 2010). There is 
evidence of antibiotic resistant organisms in sewers receiving wastewater from hospitals  (Brown et 
al., 2006). The importance of keeping existing drugs effective is highlighted by the fact that 
introducing new drugs takes about seven to nine years time on average for approval with an 
approximate cost of $700 million to $1 billion (Jambhekar et al., 2009).  
 
The excretion of incompletely metabolized antibiotic compounds is the primary source of antibiotics 
to the aquatic environment (Chang et al., 2010; Alder et al., 2006). Hospitals are believed to be a 
significant point source of antibiotics as considerable amounts of antibiotics are consumed in 
hospitals. Data for various countries indicate that hospitals are responsible for 20 to 70% of the total 
antibiotic consumption of a country (Schuster et al., 2008). In Germany, 1998 pharmaceutical sale 
figures indicated that the fraction of the total antibiotics sales attributed to hospitals varied from a few 
percentages to more than 90% depending upon the compound (Alder et al., 2006). 
  
In summary, drugs have been found to making their way into the aquatic environment: The 
probability of detection of a pharmaceutical in the aquatic environment is a function of its use (initial 
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concentration), extent of metabolism in the human body, and persistency in the aquatic environment. 
Highly used and more persistent compounds are often detected in aqueous samples while those that 
are extensively metabolized have less chances to be detected. For example tetracycline antibiotics are 
highly metabolized in the human body and are therefore barely discharged into wastewater as in the 
form of the parent compound (Kümmerer, 2001a). 
 
Sulfonamide, fluoroquinolone, and macrolide antibiotics show highest persistency in the aquatic 
environment and are frequently detected in wastewater (Brown et al., 2006). The half life of antibiotic 
compounds in the aquatic environment varies from a few days for some ß-Lactams to several hundred 
days for Tetracycline or quinolone antibiotics (Kümmerer, 2001a).  
 
The measured concentrations of the sulfonamide Sulfamethoxazole in hospital effluents were 2μg/L 
in the USA (Brown et al., 2006), 12.8 μg/L in Sweden (Lindberg et al., 2004) and 81 μg/L in India 
(Diwan et al., 2009; Brown et al., 2006). Up to 15 μg/L of Trimethoprim has been detected in a 
hospital effluent (Thomas et al., 2007). Higher concentrations of the fluoroquinolone Ciprofloxacin 
have been reported in many studies, with the measured concentrations in hospital effluents found to 
be around 87 μg/L in Switzerland, 100 μg/L in Sweden, 124 μg/L in Germany, and 236 μg/L in India.  
The highest concentrations of the fluoroquinolone ofloxacin and norfloxacin measured in hospital 
effluent were 35 μg/L and 44 μg/L respectively (Table 2-2). Up to 83 μg/L of the macrolide  
Erythromycin-H2O (a degradation product of erythromycin in aqueous solution) was found in the 
effluent of a German hospital. The concentrations of antibiotic compounds found in hospital effluents 







      Table 2-2: Maximum antibiotic concentrations measured in hospital effluents 
Class,              Compound 
Conc 
(ng/L) 
Country  Reference 
Sulfonamide    
 Sulfamethoxazole 4107a Norway (Thomas et al., 2007) 
2100b USA (Brown et al., 2006) 
1060c China (Chang et al., 2010) 
12800c Sweden (Lindberg et al., 2004) 
81100c India (Diwan et al., 2009) 
7350c Taiwan (Lin et al., 2009) 
300d Australia (Watkinson et al., 2009) 
6000a Germany (Ohlsen et al., 2003) 
Sulfadiazine 253c China (Chang et al., 2010) 
Trimethoprim 14993a Norway (Thomas et al., 2007) 
5000b USA (Brown et al., 2006) 
174c China (Chang et al., 2010) 
7600c Sweden (Lindberg et al., 2004) 
6000a Germany (Ohlsen et al., 2003) 
25e Spain (Gomez et al., 2006) 
300d Australia (Watkinson et al., 2009) 
40e Spain (Gomez et al., 2007) 
Fluoroquinolone    
 Ciprofloxacin 2000b USA (Brown et al., 2006) 
 136c China (Chang et al., 2010) 
 2927a Portugal (Seifrtova et al., 2008) 
 101000c Sweden (Lindberg et al., 2004) 
 124500e Germany (Hartmann et al., 1999) 
 29400a Switzerland (Alder et al., 2004) 
 155000e Brazil (Martins et al., 2008) 
 25800c Vietnam (Duong et al., 2008) 
 236600c India (Diwan et al., ) 
 54049a Norway (Thomas et al., 2007) 
 87000c Switzerland (Hartmann et al., 1998) 
 15000d Australia (Watkinson et al., 2009) 
  5120e Spain (Gomez et al., 2007) 
  51000a Germany (Ohlsen et al., 2003) 
     
    
    
                                                     
a
 24-hr composite samples 
b
 4-hr composite samples 
c
 Grab samples 
d
 18 hr composite samples with 3h interval 
e
 10 & 14 hr composite samples 
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Class,              Compound 
Conc 
(ng/L) 
Country  Reference 
 Ofloxacin 35500b USA (Brown et al., 2006) 
  4240c China (Chang et al., 2010) 
 9451.9b Portugal (Seifrtova et al., 2008) 
 7600a Sweden (Lindberg et al., 2004) 
 31000a Germany (Ohlsen et al., 2003) 
 Norfloxacin 1620a China (Chang et al., 2010) 
 7900b Switzerland (Alder et al., 2004) 
 334a Portugal (Seifrtova et al., 2008) 
 15200c Vietnam (Duong et al., 2008) 
 100d Australia (Watkinson et al., 2009) 
 44000a Germany (Ohlsen et al., 2003) 
 Lomefloxacin 1162c China (Chang et al., 2010) 
 Enrofloxacin 100d Australia (Watkinson et al., 2009) 
Tetracycline    
 Tetracycline 4178b Norway (Thomas et al., 2007) 
 Tetracycline 40e Australia (Watkinson et al., 2009) 
 Tetracycline 455a Taiwan (Lin et al., 2009) 
 Oxytetracyline 3743b Norway (Thomas et al., 2007) 
 Democlocycline 52b Norway (Thomas,et al. 2007) 
 Chloroetracycline 69b Norway  
 Iso-Chlorotetracycline 20a China (Chang et al., 2010) 
 Doxycycline 403b Norway (Thomas et al., 2007) 
 Doxycycline 6700a Sweden (Lindberg et al., 2004) 
 Doxycycline 200e Australia (Watkinson et al., 2009) 
 Meclocycline <7b Norway (Thomas et al., 2007) 
 Sulfadiazine 253c China (Chang et al., 2010) 
 Cefuroxime <125b Norway (Thomas et al., 2007) 
Lincosamides    
 Lincomycin 2000b USA (Brown et al., 2006) 
Lincomycin 1700e Australia (Watkinson et al., 2009) 
 Clindamycin 90e Australia (Watkinson et al., 2009) 
ß-lactams    
 Penicillin G 5200b USA (Brown et al., 2006) 
 Penicillin V 10e Australia (Watkinson et al., 2009) 
 Amoxycillin 900e Australia (Watkinson et al., 2009) 
 Cephalexin 10000e Australia (Watkinson et al., 2009) 
Macrolides    
 Erythromycin 261a China (Chang et al., 2010) 
Erythromycin 27000e Germany (Ohlsen et al., 2003) 
Erythromycin 150e Spain (Gomez et al., 2007) 
Erythromycin-H2O 827
c China (Chang et al., 2010) 
Erythromycin-H2O 6110
c Taiwan (Lin et al., 2009) 
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Class,              Compound 
Conc 
(ng/L) 
Country  Reference 
 Erythromycin-H2O 83000
e Germany (Ohlsen et al., 2003) 
Roxithromycin 2189c China (Chang et al., 2010) 
Roxithromycin 400e Australia (Watkinson et al., 2009) 
Oleandomycin 40e Australia (Watkinson et al., 2009) 
Aminoglycoside    
 Gentamicin 7600f Germany (Loffler et al., 2003) 
 Gentamicin 5000e Germany (Ohlsen et al., 2003) 
Metronidazole 90200c Sweden (Lindberg et al., 2004) 
  3800c China (Chang et al., 2010) 
  5900e Spain (Gomez et al., 2006) 
  3760e Spain (Gomez et al., 2007) 
 
Both antibiotic use and concentrations that have been reported in previous studies suggest that 
hospitals can be considered to be major point sources of antibiotic compounds. The material from this 
review was used to determine target compounds in the current study.  
 
2.6.1.2 Pharmaceutical Compounds  
Compounds other than antibiotics, that are used in hospitals and which have received special attention 
include cytostatic agents, anesthetics, antiepileptics, non-steroidal anti-inflammatory drugs 
(NSAIDs), and diagnostic aids, especially x-ray contrast agents (Kümmerer, 2001a).  
Cytostatic agents are mostly used in hospitals (Kümmerer, 2001a) for cancer treatment and their 
carcinogenicity, and mutagenicity have been reported by several researchers (Hessel et al., 2001; 
Skov et al., 1990). Anesthetics can have ozone depletion and global warming potential (Kümmerer, 
2001a).  Propofol is an important anesthetic compound which is excreted about 90% as an unchanged 
compound (Kümmerer, 2004a). The antiepileptic drug carbamazepine is frequently detected in the 
aquatic environment (Zhang et al., 2008). X-Ray contrast media is one of the widely used 
pharmaceutical for imaging purposes during diagnostic tests. They are mostly derivatives of 2,4,6 tri-
iodobenzoic acid with carboxyl and hydroxyl moieties in their chains (Perez et al., 2007). A single 
dose of an X-ray contrast agent may contain 60-120 g of drug substance (Christiansen, 2005). The 
excretion half life of contrast agents is 2 hours and they are mostly excreted as the unchanged 
                                                     
f
 Composite sample (10 minutes interval), length is not clear 
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compound (Kümmerer, 2004a). It has also been suggested that facilities with specialized radiology 
could contribute more than 50 % of the load to the municipal WWTPs (Kümmerer, 2004a).  
 
The NSAIDs were found in higher concentrations in hospital effluents; with highest detected 
concentration of acetaminophen 329 μg/L, diclofenac 70 μg/L, ibuprofen 74 μg/L, naproxen 18 μg/L, 
and metamizole 77 μg/L. The Beta-blocker metoprolol was measured in relatively higher 
concentrations (5.8 μg/L). Up to 4 μg/L concentration of the anticancer agent cyclophosphamide was 
detected in a German hospital effluent. Carbamazepine which is mostly excreted as its metabolites 
was measured up to 700 ng/L.  The concentrations of these compounds that have been detected in 















Table 2-3  Concentrations ( g/L) of pharmaceuticals reported in literature  
Compound Name Concentration  Country  Reference 
Antineoplastic (anticancer)    
 Cyclophosphamide 4.48 Germany (Hartmann et al., 1997) 
 Ifosfamide 0.056 Norway (Thomas et al., 2007) 
  1914 Germany (Kümmerer et al., 1997) 
Anthracyclines (anticancer)    
 Epirubicin 0.1-1.4 Austria (Mahnik et al., 2006) 
 Doxorubicin 0.1-0.5 Austria (Mahnik et al., 2006) 
NSAIDs    
 Acetaminophen 186.500 Taiwan (Lin et al., 2009) 
  16.02 Spain (Gomez et al., 2006) 
  329.85 Norway (Thomas et al., 2007) 
  3.13 Spain (Gomez et al., 2007) 
  11.27 Spain (Gomez et al., 2007) 
 Diclofenac 70 Taiwan (Lin et al., 2009) 
  1.4 Spain (Gomez et al., 2006) 
  2.73 Norway (Thomas et al., 2007) 
  0.51 Spain (Gomez et al., 2007) 
 Ibuprofen 0.3 Taiwan (Lin et al., 2009) 
  19.77 Spain (Gomez et al., 2006) 
  2.44 Norway (Thomas et al., 2007) 
  74.7 Spain (Suarez et al., 2009) 
  4.57 Spain (Gomez et al., 2007) 
 Naproxen 1.01 Taiwan (Lin et al., 2009) 
  18.1 Spain (Suarez et al., 2009) 
 Metamizole 77.4 Germany (F.D.A, 2004) 
ß-blocker    
 Propranolol 0.225 Taiwan (Lin et al., 2009) 
  1.35 Spain (Gomez et al., 2006) 
 Atenolol 3.4 Spain (Gomez et al., 2006) 
  2.4 Spain (Gomez et al., 2007) 
 Metoprolol 5.8 Norway (Thomas et al., 2007) 
Anti-tumour    
 Ifosfamide 1.914 Germany (Kümmerer et al., 1997) 
Lipid Regulator    
 Gemfibrozil 1.1 Taiwan (Lin et al., 2009) 
Antiepileptic     
 Carbamazepine 0.04 Spain (Gomez et al., 2006) 
  0.07 Spain (Gomez et al., 2007) 
Antidepressant    
 Fluoxetine 0.06 Spain (Gomez et al., 2007) 
Contrast agents    
 Iopromide 1400 Spain (Suarez et al., 2009) 
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2.7  Approaches to Predict Concentration of Pharmaceuticals in Wastewater 
 
The use of models to predict the concentrations of pharmaceutical compounds in the aquatic 
environment is receiving increasing interest. This is because; about 60,000 pharmaceutical 
compounds are used worldwide (Tropsha, 2000). The biotransformation products of these compounds 
(metabolites and conjugates) are also of interest because, certain metabolites may possess reduced or 
similar biological activity to that of the parent compound, and the conjugates have the tendency to 
cleave back into the original compound during sewer transit and WWTP processes. Therefore, it is 
almost impossible to test every single compound of interest. 
 
The physico-chemical properties (molecular structure, molecular weight, and functional groups) of 
PhACs vary widely (Kümmerer, 2001b); moreover, different behavior of the PhACs belonging to the 
same class during water treatment processes has been reported (Choi et al., 2008; Dodd et al., 2005). 
This finding makes it difficult to define indicator compounds.  
 
In addition, the lack of analytical methods for many of the PhACs and the unavailability of deuterated 
standards for PhACs restricts the analysis to certain compounds. Furthermore, the resources, time and 
cost required to detect low concentrations (μg-ng/L) in different environmental matrices is a 
constraint in carrying out such studies on a large scale or with untargeted detection. 
   
Despite the above challenges, there is also an opportunity, as most of the drugs used today are pure 
materials; therefore, it is expected that pharmacokinetic information about these pharmaceuticals can 
be achieved quite accurately using pharmacokinetic principles (Rowland et al., 1995).Thus, although 
prediction models cannot replace experimental studies they may be an attractive option for initial 
screening studies, to identify important PhACs to be monitored (Carballa et al., 2008).  
 
There is a relationship between the consumption of PhACs and their discharge into wastewater 
(Ternes et al., 2006). Therefore, the consumption data along with some pharmacokinetic 
characteristics of the PhACs and daily wastewater flows are required to estimate their concentrations 
in wastewater. Pharmaceutical compounds are xenobiotics that are not normally found in human 
bodies. Therefore, after administration, PhACs pass though different phases such as absorption, 
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distribution, and metabolism and are then eventually eliminated from the body through excretion. 
These processes are generally referred as ADME (Jambhekar et al., 2009). The excreted compounds 
may be present in an unchanged form, or as metabolites or in a conjugated form.   
 
One important consideration in PhAC modeling is the route of administration, which affects the 
extent of PhACs metabolism. The sites of administration of PhACs are classified into two categories: 
1) Intravascular, which refers to introducing the PhACs directly into the blood and 2) extravascular, 
which includes oral, intramuscular, subcutaneous, sublingual, and rectal administration; transdermal 
application; and inhalation.  The main difference between the two types of administration from a 
pharmacokinetic point of view is that the absorption step is not present in the case of intravascularly 
administered doses. Therefore, the excretion of the unchanged PhAC in urine, as a percentage of the 
administered dose, is affected by the route of administration. Higher excretion rates for the 
intravenously administered dose than oral application has been reported. For example the antibiotic 
ciprofloxacin is excreted 40-50% as unchanged compound in the case of oral doses and up to 70% in 
the case of parenteral (administration other than through the digestive tract) doses. Figure 2-1 show a 
schematic view of the pharmacokinetic processes for both intravascularly and extravascularly 
administered doses.  
 
 
a) Extravascular (oral)administration                        b)  Intravascular (intravenous) 
 
 
              
 
  Xo    Administered dose of PhAC on the site of administration   
  Xa    Absorbable fraction of administered dose of PhAC on the site of administration  
  Xu   Amount of PhAC excreted unchanged in urine    
  X    Mass of the PhAC in the human body  
  Ka    First order absorption rate constant  
  Ku    First order elimination rate constant  
(Jambhekar et al., 2009) 
Figure 2-1 Elimination of the PhACs via urinary excretion in different routes of administration 
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2.7.1 Existing Models 
 
Various approaches to predicting pharmaceutical concentrations in wastewater have been published.  
Data on consumption of PhACs for a region or a country is typically not readily available therefore 
different methods have been employed to utilize available data to estimate the consumption of 
PhACs. Data on annual sales and prescription rates have generally been used to calculate PhACs 
consumption. The fractions of the unchanged PhACs that are excreted into wastewaters after 
administration of PhACs along with the typical wastewater volume per capita are used in order to 
convert consumed masses into concentrations in the wastewater. Some authors have used mass 
balances and fugacity calculations to predict the concentrations and behavior in the aquatic 
environment. 
 
A simple prediction model based on annual consumption of target compounds and excretion data was 
presented by Alder et al. (2006). The annual consumption was estimated using annual sales data. The 
model assumes that the pharmaceutical consumption is uniformly distributed over the year, and 
throughout the geographical area.  In addition, it is assumed that the compounds are not biodegraded 
in the sewer system. The concentrations of the target compounds in the environment are predicted 
using the equation 2.1. 
 
   (2.1) 
Where; 
PECSTPin Predicted concentration in raw sewage (ng/L) 
FAPI Amount of active pharmaceutical ingredient consumed in the area per year (Kg/year) 
E Fraction excreted unchanged in urine and faeces.  
Pop Population of the target area (persons) 
AWW Wastewater flow per capita per day (200-400 L/person/day)  
 
The uncertainties associated with estimating pharmaceutical consumption by this include; 
1. Purchased PhACs may not be used during the same year that they were purchased. 
2. Seasonal variations along with regional differences in use of PhACs may result in wide variations     












3. Degradation or hydrolysis processes during sewer transit are not taken into account. 
4. Substances that are excreted in the conjugated form that have the tendency to cleaved back to 
the parent compound in sewers and wastewater treatment are not considered.  
 
(Carballa et al., 2008) estimated the environmental concentrations of the pharmaceuticals in raw 
sewage using the following equation (2.2).  
 
                                                                  (2.2) 
 
 
                                                                
Where 
PEC Predicted environmental concentration(μg/L) 
I  Consumption of the target pharmaceutical compound (mg/capita/year) 
P  Population served by wastewater treatment plant (Persons) 
f Total fraction of  unchanged PhACs that arrives at WWTPs   
Q Average wastewater flow (m3/day) 
 
In the study of (Carballa et al., 2008) the annual consumption I (equation 2.2) of the PhACs was 
calculated using annual prescriptions. The author obtained the prescription data through personal 
communication. The mass of target PhACs consumed per year (M) was calculated using equation 2.3, 
and then using M, per-capita/year mass consumption (I) was determined. 
 
M = (Number of prescriptions/year) x (number of doses per prescription) x (active compound per dose)       2.3 
  
The sources of variability in this model include; 
1.) Calculation of PhAC consumption using prescription data excludes purchases without 
prescriptions. For example, over-the -counter and internet purchases. 
2.) All the prescribed doses are not always administered.  
3.) The routes of administration of PhACs are not considered separately which may affect the 






4.) Degradation processes in the sewer systems are not considered.  
5.) While comparing the predicted and measured concentrations, it is important to consider the 
sorption behavior of the PhACs especially when only aqueous samples are measured.  
 Carballa et al. (2008)attributed the differences between predicted and measured concentrations to; 
1.) Variation in the consumption estimates. 
2.) Incomplete release of PhACs to the sewer systems 
3.) Elimination of compounds by various elimination processes (degradation, dilution, 
sedimentation) between the consumption point and sampling point.  
 
Some authors (Golet et al., 2002; Jones et al., 2002; Kümmerer et al., 1997; Kümmerer et al., 2003; 
Lauridsen et al., 2000) have estimated wastewater treatment plant influent concentrations of PhACs  
in raw sewage using equation (2.4) that was originally presented in the draft guidelines for risk 
assessment of the new pharmaceuticals in the European Union (EU 1994,1995) to predict 
environmental concentrations in surface water. 
 
                                                                 (2.4) 
 
Where 
PEC Predicted environmental concentration (g/Liter) 
A Amount of the compound consumed per year (kg.year -1) 
R Removal efficiency (%). The removal considers both human metabolism and the loss by other 
processes, i.e. adsorption, volatilization, hydrolysis and biodegradations 
P Population of the area considered (persons) and (beds) in case of hospitals 
D Dilution factor (Hospital effluent to communal sewage  for estimating concentrations in 
hospitals effluent or wastewater flow to surface water when predicting concentrations in 
surface water and was set to zero while estimating concentrations in raw wastewater) 
V Wastewater flow (m3/person/day) & (m3/bed/day) for hospitals 
 
The equation (2.4) is a general equation to predict concentrations in wastewater and surface water. 
The strength of the prediction depends on the accuracy of the individual parameters that can be 
obtained. For example the amounts of PhACs consumed, as discussed in the previous models. 
















the tendency to cleaved back to original compound. Additionally different routes of administration 
which affect the extent of metabolism are not accounted for. 
 
Johnson et al., (2004) presented a model to predict concentrations of steroid estrogens, which could 
be extended to pharmaceuticals with slight modification i.e., by excluding the Ss term in equation 
(2.5) which represents the transformation of one estrogen to other during sewer transit and 
considering only glucuronide conjugates in the total mass.  The model addresses excretion of 
estrogens in feces in the deconjugated form, and additionally assumes that all the excreted 
glucuronide conjugates via urine are deconjugated in sewer transit to WWTPs.   
 
                  (2.5)
 
ST Total estrogens arriving in WWTP in all forms  
KT Fraction that is lost during the transit 
UT Total amount of steroid estrogen in urine arrived at the WWTP 
FT Amount of estrogen excreted in feces,  
SS Internal generation of estrogens from other estrogens.  
 
Johnson et al., (2004) used excretion data of estrogens for 5 different population groups (pregnant, 
menstrual, and menopausal females, females taking hormonal replacement therapy and males) in 
estimating total excreted mass. In equation 2.5 UT and FT were calculated as shown in equations (2.6) 
and (2.7). 
 
                                                                                                                                                                              . (2.6)
 
fi Fraction of the group i (population) 
U’i Amount of estrogen excreted by ith fraction of population in particular form(μg/day) 
Ugi Amount in free glucuronide form of estrogen 






                                                  (2.7) 
                                   
Fi Amount of estrogen excreted by i
th fraction of the population (μg/day) 
 
Substituting values of UT & FT from equations (2.6) and (2.7) in equation (2.5) yields 
 
                      (2.8) 
 
The equation (2.7) was then further simplified by (Johnson et al., 2004) for their three target 
estrogens (EE2, E2, and E1) by substituting their respective values for KT and SS.  
 
Johnson et al., (2004) assumed that the consumption of estrogens in the UK would be similar to the 
USA. This assumption may not hold true based on the fact that significant differences exist in the 
pharmaceutical consumptions between different countries (As discussed earlier in this report in 
section 2.4). To extend this model to compounds other than steroidal estrogens including excretion 
rates of different age groups and routes of administrations would be helpful. 
 
Khan et al., (2004) presented a model to predict pharmaceutical concentrations in raw sewage using 
1) data describing pharmaceutical consumption by population, 2) human metabolism and excretion of 
pharmaceutical residues. They used the Australian Health insurance commission reimbursement data 
to find the total prescriptions in the selected region and calculated the total number of quantities 
dispensed (T) as  
T = N x Q                                                                             (2.9) 
Where N is the number of prescriptions dispensed per year and Q is the average dispensed quantity 
per prescription. The active mass of the dispensed amount was calculated by multiplying total 
quantities dispensed (T) with the active mass strength per dose (S) 
















Since prescriptions may have different active mass, the total active mass was obtained by addition of 
the different active mass strength per dose. 
MTOTAL=M1+M2+M3+…………….. 
 
The WWTP influent concentrations (C) were calculated using equation (2.11) 
 
                                                                                          (2.11) 
Where 
Mexc Mass excreted during study period (Kg) 
PSTP Population served by WWTP (Persons)  
R Average wastewater inflow (m3/h) 
T Study period (days) 
Psurvey Population contributed to the prescription data(Persons),(contributed to mass Mexc)  
  
The consumption of the target PhACs was calculated using prescriptions submitted to claim subsidies 
for the purchased pharmaceuticals. Consumption data for the compounds which were not eligible for 
the subsidy was collected from the pharmacy sources. Using this data the per-capita excretion was 
estimated. That was then used along with the population upstream to the WWTP to calculate the 
inflow concentrations.  
Khan et al., (2004) found that these calculations highly underestimated the consumption of 
compounds like paracetamol (Acetaminophen) that are often purchased from markets. In addition, the 
estimated annual per-capita consumption was used to determine the consumption of target 
compounds during the study period. This may lead to wide differences in the actual consumed 
amounts, because seasonal and regional differences in pharmaceutical consumption, as discussed in 
section 2.4. Furthermore only oral route of administration is assumed and median values for excretion 













Heberer et al., (2005) presented an equation (2.10) to calculate the weekly load of PhACs from 
hospitals and households to the municipal wastewater. The equation (2.12) considers consumption 
data, route of administration, and human metabolism to predict the concentration in wastewater.  The 
weekly load of carbamazepine and Diclofenac by a hospital to WWTP was predicted. Actual 
consumption data was collected from the hospital wards during the study period.  
 
                                                                                 (2.12) 
                                      
                              Amount administered  
 
Where  
ai Number of administered packages per week for brand i 
bi Number of units per package of brand i 
mi Content of active compound per unit (mg) 
Si Release rate of pharmaceuticals compound in brand i 
Rp Absorption rate (%) 
Xp Portion of pharmaceuticals excreted unchanged after absorption (%)  
Xc Percentage excreted in conjugated form (%)  
Since the data regarding the absorption (Rp) and exertion rates (Xp & Xc) for pharmaceutical 
compounds are normally available in range therefore it was suggested that maximum and minimum 
concentrations should be calculated for each compound. Equation (2.11) contains the required 









The concentrations of PhACs in the aquatic environment are a function of the initial concentration 
(consumption), the extent of metabolism, and their persistency in the aquatic environment. For 
accurate prediction of these concentrations all three components need to be considered. Typically it is 
difficult to obtain data regarding the consumption of pharmaceuticals so relatively simple models 
have been reported in the literature, consequently their use has relied upon a number of assumptions 
in order to convert consumption data into environmental concentrations. Therefore many 
uncertainties are associated with these calculations. For example consumption estimated using 
country level annual sales data doesn’t consider unused medicines, which could either directly reach 
the aquatic environment in the case of improper disposal (flushing into toilets, or draining in the sink) 
or leaving the consumption data as over estimated. Estimated consumption using prescription data, 
excludes the over the counter, and internet purchases. Seasonal and regional differences in use of 
PhACs made it difficult to use country level annual consumption data to target regions. Furthermore 
many formulations are possible for each prescription of drug, so the mass of the PhAC may be 
different for each dose. 
 
 The extent of metabolism is affected mainly by the sites of administration of the PhACs. For 
example the antibiotic ciprofloxacin is excreted 40-50% as unchanged compound in case of oral dose 
and up to 70% is excreted unchanged in case of parenteral (administration other than through the 
digestive tract) dose in 24 hours ((Sweetman et al., 2007). In addition external applications of PhACs 
are expected to reach wastewater by washing and bathing without going through a metabolism step. It 
is important to note that, for the compounds which are extensively metabolized in the human body the 
contribution of the improper disposal of these compounds to the wastewater is expected to be 
significant. The data about the excretion rates of PhACs is usually available in a range because the 
extent of metabolism varies among individual patients, depending upon age, sex, and health 
condition. Therefore the selection of the right values needs personal information of the patient (sex, 
age, health condition) in addition to administered dose. 
 
The administered dose is excreted either as the unchanged compound, a major metabolite, or in a 
conjugated form (mostly as glucuronide and sulfate conjugates) through urine and feces. Amounts 
excreted in feces are usually considered as unchanged compounds because of the ability of the 
intestinal bacterial flora to de-conjugate the conjugates through bacterial hydrolysis. The conjugates 
excreted via urine, especially glucuronide conjugates are suggested to include along with the 
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unchanged portion to calculate the total load of the compound, because of the tendency of these 
transformation products to cleave back to the original compound in sewer systems.    
After excretion to the sewer, depending upon the physico-chemical properties of the compound itself 
and the sewer conditions (residence time, aerobic or anaerobic conditions, sewer biofilms) a 
compound may either biodegrade, be hydrolyzed, adsorb to solids, etc. For instance, Sulfonamide, 
fluoroquinolone, and macrolide antibiotics show highest persistency in the aquatic environment and 
are frequently detected in wastewater (Brown et al., 2006).The half life of antibiotic compounds in 
the aquatic environment varies from a few days for some ß-Lactams to several hundred days for 
Tetracycline or quinolone antibiotics (Kümmerer, 2001b). ß-Lactams are rapidly hydrolyzed after 
excretion into wastewater (Kümmerer, 2008a). Fluoroquinolone antibiotics posses strong sorption 
tendency to solids (Golet et al., 2002).  All these processes need to be accounted for to predict 
concentrations of these compounds.  
 
For potential point sources of pharmaceuticals like hospitals and nursing homes where self-
medication is not allowed quite accurate consumption data should be available. Furthermore the 
information about the route of administration, patient age, sex, health condition and the length of the 
patient stays is usually maintained in hospitals. This suggests that the emissions of PhACs from these 
healthcare facilities (hospitals & long term care homes) could be reasonably predicted using 





The eco-toxicity of the hospital effluent is well documented and some researchers have attributed its 
genotoxicity to the presence of antibiotic compounds (Giuliani et al., 1996; A. Hartmann et al., 1998) 
The relative contribution from hospitals to WWTPs was identified as an urgent research need 
(Daughton, 2004) but still very little data is available. No data is available for long term care homes 
which employ a considerable amount of PhACs on a regular basis. In addition pharmaceutical use  
varies from country to county making it difficult to draw any conclusions based on these studies.   
 
For both risk assessment and risk management it is important to identify the contributions from 
potential sources of emissions of pharmaceuticals to the aquatic environment. Control of sources like 
health care facilities would be expected to reduce the emission of PhACs into the aquatic environment 
by a considerable amount, which will reduce the unanticipated risks associated with these to the 









3.1 Selection of Target Compounds 
Since 15,331 approved pharmaceutical compounds are currently used in Canada (Health Canada, 
2010), the first task in this study was to prepare a priority list of compounds of interest.  The focus 
was on the occurrence of PhACs in healthcare facility effluents (hospitals and long term care homes). 
A direct relationship exists between the consumption of PhACs and their discharge into wastewater 
(Ternes et al., 2006) therefore, the PhACs consumption data for healthcare facilities was preferred, 
but was not readily available. Instead the drug purchase data for Ontario hospitals in ―extended units‖ 
(number of tablets, capsules, mg etc) for the year 2008 was obtained from the International Medical 
Statistics (IMS) Canada database through Health Canada. The collected data was then subdivided on 
a monthly basis, and it was assumed that the purchase of new PhACs would be indicative of the 
current consumption of PhACs. In addition, through the literature review, fourteen therapeutic classes 
of PhACs were chosen based on their occurrence in and potential risks to the aquatic environment, 
and on their high excretion rates as the parent compound. Then 46 PhACs, that were most purchased 
by Ontario hospitals in 2008, according to IMS database, and belonging to the 14 pre-defined 
therapeutic classes were included in a preliminary list. A short list was then established using the 
following criteria:  
 
1. Specific mode of action, i.e., possible health risks (Ternes 2004). 
2. Persistence in aqueous solution (Bendz et al., 2005). 
3. Representation of different therapeutic groups.  
4. Presence in the Canadian environment as indicated by previous studies (Metcalfe et al. 
2004; Lissemore et al., 2006). 
5. Analytical capabilities of the laboratory at Trent University. 
6. Availability of deuterated standards. 
Eventually seven compounds representing five different therapeutic classes and two metabolites of 
venlafaxine were selected for this study (Table3-1). Antibiotics were deemed to be the most important 
class of PhACs because of their potential to foster antibiotic-resistant bacteria in addition to 
undesirable biological activity. The antibiotic ciprofloxacin has been reported to be a major source of 
genotoxicity in hospital wastewater (Hartmann et al., 1998). The beta-lactum antibiotics were not 
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included because they are rapidly hydrolyzed after excretion (Gobel et al., 2005). The  anesthetic 
propofol (Kümmerer, 2004a) was excluded from the final list because an analytical method was not 
readily available for this compound and the development and validation process was expected to take 
longer than the project duration. X-ray contrast agents were also excluded because of the 
unavailability of deuterated standards for these compounds in Canada at the time of compound 
selection.  
 
Table 3-1  Pharmaceutical compounds selected for the study, their class, CAS registry numbers 
                and therapeutic use 








 Sulfamethoxazole 723-46-6 Sulfmathoxazloe-
13
C6 Antibacterial; antipneumocystic 
Neutral drugs 
 Trimethoprim 738-70-5 Trimethoprim-
13
C3 Antibacterial. 
 Carbamazepine 298-46-4 Carbamazepine-d10 Antiepileptic, Anticonvulsant 
Acidic drug 
 Acetaminophen  103-90-2 Acetaminophen-d3 Analgesic; antipyretic 
Beta-blocker 
 Metoprolol 37350-58-6 Propranolol-d7 Antihypertensive;   antianginal; 
antiarrhythmic (class II). 
Anti-depressant 
 Venlafaxine 93413-69-5 Venlafaxine-d10 Antidepressant; anxiolytic 
Metabolite 
 O-des-Venlafaxine 93413-62-8 Venlafaxine-d10 Antidepressant (active metabolite) 
 N-des-Venlafaxine  Venlafaxine-d10 Metabolite antidepressant 
 
3.2 Identification and Selection of Sampling Sites 
A list of existing health care facilities (hospitals and long term care homes) in the target area was 
obtained though the Internet. The information about care services that these facilities are currently 
offering, was collected from the official website of each facility. Discharges from hospitals depend 
upon various factors, including size of the facility, location, and types of the services available 
(Askararian 2004). Therefore, two hospitals of different size and service spectrum, located in 
different areas, were selected in consultation with the regional municipality of the study area. The 
                                                     
g
 Martindale  & Merck Index 
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long-term care facilities provided similar services, so their selection was based on size and location. 
The two largest facilities (by number of beds) in the project area were selected for sampling. 
Additional factors considered during site selection were availability of access to sampling points, 
available space to install sampling machines, and the possibility of keeping this area reserved for a 
week-long sampling.  
To estimate the mass contribution of target PhACs by the selected healthcare facilities, the 
downstream wastewater treatment plants (that receive discharges from the selected facilities) were 
identified for same day sampling. The identified facilities, i.e., hospitals, long term healthcare 
facilities and their corresponding WWTPs are referred to in this report as HS1, HS2, LTC1, LTC2, 
WWTP-HS1, WWTP-HS2, and WWTP-LTC1, WWTP-LTC2 respectively. Table 3-2 defines the terms 
used in the report and provides information describing the size of the selected facilitates. 
 
Table 3-2 Description of selected healthcare facilities
h
  
Facility description Facility label 
Facility size 
(No of beds / population served) 
Hospital -1 HS1 365 
Hospital -2 HS2 263 
Wastewater treatment plant 
downstream hospital -1 
WWTP-HS1 51,218 
Wastewater treatment plant  
downstream hospital -2 
WWTP-HS2 171,000 
Long term care home-1  LTC1 228 
Long term care home-2 LTC2 200 
Wastewater treatment plant 
downstream long term care home-1 
WWTP-LTC1 80,000 
Wastewater treatment plant 
downstream long term care home-2 
WWTP-LTC2 33,000 
 
                                                     
h




Manholes located on the property line of each facility were selected as sampling points to cover all 
discharges from the facility and ensure representative samples. Regional staff helped to identify 
sampling points.  At the second facility, effluent was discharged at two locations to the municipal 
sewer lines so both streams were sampled and blended for extraction. 
 
3.3 Sampling Protocols  
Twenty-four hour time proportionate composite samples were collected over five consecutive week 
days from each sampling point (Monday to Friday). A total of nine sampling points were selected at 
the eight facilities. Table 3-3 indicates the sampling point details and dates. 
 
Table 3-3 Sampling point description and dates.  
S.No Sampling site Sampling point Sampling dates 
1 HS1 HS1 effluent July 22 to 27,  2009 
2 WWTP-HS1 WWTP-HS1 influent July 22 to 27,  2009 
3 HS2 HS2  effluent (manhole-1) Main facility effluent November 3 to 7, 2009 
4 HS2 HS2  effluent (manhole-2) Cancer clinic effluent November 3 to 7, 2009 
5 WWTP-HS2 WWTP-HS2 influent November 3 to 7, 2009 
6 LTC1 LTC1  effluent  February 23 to 27, 2010 
7 WWTP-LTC1 WWTP-LTC1  influent February 23 to 27, 2010 
8 LTC2 LTC2 effluent March 9 to 13, 2010 
9 WWTP-LTC2 WWTP-LTC2   influent March 9 to 13, 2010 
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3.3.1 Sample Collection 
Samples were collected by regional municipality personnel with training for this type of activity. All 
the selected WWTPs were pre-equipped with refrigerated sampling machines (Auto sampler Sigma 
SD900) at the inflow points.  
The sampling frequency was selected based on the literature review, as variability in the 
concentrations over the weekdays was expected in both types of healthcare facilities. Furthermore 
some of the higher compound concentrations were reported based on grab samples or very short 
sampling events, indicating the possibility of those concentrations being a single even or batch 
discharge, therefore in this study the samples were collected over five consecutive days. The week 
long sampling also helped to identify individual peaks, day-to-day variability and trends in target 
compounds concentrations over the weekdays.  
 
Portable auto samplers (Sigma 900) were used to collect samples from all the healthcare facility 
effluents. The auto sampler directly collected wastewater from sewer lines, and then stored it either in 
one large container or 24 bottles in a tray.  Ice pads (U-Tek refrigerant pak; Fisher Scientific) were 
used to maintain the collected sample reasonably cool. The ice packs were placed in the middle 
hollow portion of the auto-sampler tray in case of 24 bottles, and around the central container where 
one large container was used. Twenty-four hour composite samples were collected from each 
sampling point at a rate of two samples per hour, (a total of 48 sub-samples, 125 mL each, was 
collected over 24 hours). Two 24-hour composite samples, one from the healthcare facility effluent 
and the second from the WWTP influent point that received its discharge, were collected on each day. 
The auto sampler was installed on Monday morning at 9:00 am, and samples were collected, starting 
on Tuesday and continuing till Saturday for each facility.  These samples were then transferred to 1L 
new wide-mouth pre-labeled amber glass bottles. Sampling information was recorded on the site, and 
chain of custody forms were maintained (Appendix A). A total of 2-3 liters of sample volume were 
collected from each sampling point. All the collected samples were stored on ice and transported to 
the Waterloo Aquatic Toxicology and Ecosystem Remediation Laboratory-(WATER Lab) at 
University of Waterloo on the same day.   
 The auto samplers were flushed with DI water each day after transfer of the collected sample to the 
amber glass bottles. New wide-mouth amber glass bottles were used for sample collection to avoid 
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any possible sample carryover or photo-degradation of the analytes of interest during storage and 
transportation. All the samples were immediately transported in coolers to the laboratory within a 
maximum of three hours after the time of collection. 
 
3.4 Analytical Methods 
All the collected samples were prepared and extracted using solid phase extraction (SPE) as described 
by Miao,(2004) and Hongxia (2010) at the Water Aquatic Toxicology and Ecosystem Remediation 
laboratory at the University of Waterloo. The analysis of the extracts was done by Trent University in 
Peterborough, Ontario.  Hospital samples were frozen after  arrival at the laboratory, and extracted 
within a maximum of 10 days from sample collection while samples from the long term care facilities 
were processed (extracted) on the same day of collection and immediately transported to Trent 
University for analysis.  
 
3.4.1 Sample preparation  
The collected samples were vacuum filtered through 1.5 m glass fiber filters to remove suspended 
solids. The glass fiber filters were prewashed in a Soxhlet apparatus with hexane and 
dichloromethane (1:1) for two hours. Three different methods (Table 3-4) were used to extract nine 
compounds and each method was conducted in triplicate. Therefore each filtered sample was 
distributed into nine 125 mL wide mouth amber glass bottles, each containing 100 mL of sample. One 
blank sample containing 100 mL of Milli-Q water was processed with each method.  The 125 mL 
bottles were organized by SPE method in three different trays each containing seven 125 mL bottles 
(thee replicates of each sample and a method blank). Solutions containing Surrogate standards (200 
L for ciprofloxacin and 100 L for all other target analytes), each with a concentration of 250 






3.4.2 Solid Phase Extraction-SPE 
 
Three different extraction methods were used to extract the nine target compounds. Three replicates 
were processed for each sample, and the order of extractions was fully randomized. Each extraction 
also included three lab blanks, with 1 blank/method. Surrogate standards were spiked into each 
sample prior to extraction.  Table 3-4 indicates the target compounds and extraction method details. 
 
Table 3-4 Target compounds and extraction method details 
Extraction Method Target compounds 
Method-1 Ciprofloxacin 
Method-2 








The samples were acidified to a pH of 3 by adding 1.75 M H2SO4.  In addition, 50 mg of Na2EDTA 
was added to each bottle containing 100 mL of the sample, as a chelating agent. Oasis HLB 
(Hydrophilic-Lipophilic Balanced reversed phase) cartridges were preconditioned sequentially with 6 
mL of acetone, 6 mL of methanol and  6 mL of 50 mM Na2EDTA at pH 4 and left for one hour. The 
sample was then passed through the cartridges via teflon tubing at a flow rate of approximately 1 
mL/min. After passing of the entire sample, the bottles were rinsed with 10 mL of high performance 
liquid chromatography (HPLC) grade water at pH 3 that was then passed through the cartridges. Once 
the entire sample passed through the cartridges the teflon tubing was immediately removed and the 
cartridges were rinsed with 2 mL of HPLC grade water at pH 3. The cartridges were then vacuum 
dried for 30 minutes. Elution was done using 2 x 3 mL of 2 % ammonium hydroxide in methanol, and 
then with 3 mL of methanol.  The eluant (9 mL) was collected in 15 mL glass tubes and then 
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subsequently evaporated under a gentle nitrogen stream to almost dryness, and finally reconstituted 
with 1mL of 40 % aqueous methanol.  
 
3.4.2.2 Method – 2 
 
The pH of the samples was adjusted in the range of 2.5-3 using 1.75M H2SO4. Oasis MCX (Mixed 
mode Cation-Exchange) cartridges were preconditioned sequentially with 6 mL of acetone, 6 mL of 
methanol and 6 mL of HPLC grade water adjusted to pH 2.5-3. The sample was passed though the 
cartridge under vacuum via teflon tubing. After passing the entire sample, the bottles were rinsed with 
10 mL of HPLC grade water at pH 2.5- 3 and then passed through the cartridges. The Teflon tubing 
was then removed and cartridges were rinsed with 2 mL of HPLC grade water at pH 2.5-3. The 
cartridges were then dried under vacuum for 30 minutes. Elution was done three times with 3 mL of 5 
% ammonium hydroxide in methanol. The eluents were collected in 15 mL glass tubes which were 
then evaporated to dryness under gentle nitrogen stream. The reconstitution was done using 400 L of 
methanol. 
 
3.4.2.3 Method- 3 
 
The sample pH was adjusted to 8 using 1% NH4OH. Oasis MAX (Mixed mode anionic–exchanged 
reversed phase) cartridges were preconditioned using 6 mL of methanol, 6 mL of 0.1 M NaOH and 6 
mL of HPLC grade water. The sample was then passed though the cartridges via teflon tubing under 
vacuum. After complete transfer of the sample from the bottle, the bottles were rinsed with 10 mL of 
HPLC grade water at pH 8. Once the entire volume had passed through the cartridges, the teflon 
tubing was removed and the cartridges were rinsed with 2 mL of HPLC grade water at pH 8. The 
cartridges were aspirated to dryness for 20 minutes under vacuum. The sample was eluted 
sequentially using 2 mL of methanol and three times with 3 mL of 2% formic acid in methanol. 
Eluants (11 mL) were collected in 15mL glass tubes and under a gentle nitrogen stream, were 




3.4.3 Instrumental Analysis 
The instrumental analysis was conducted at Trent University in Peterborough, as described by Li et 
al., (2010).  Briefly, Sulfamethoxazole, neutral pharmaceuticals and antidepressants were analyzed by 
liquid chromatography with atmospheric pressure chemical ionization and tandem mass spectrometry 
(LC-APCI-MS/MS).  The rest of the PhACs were analyzed by Liquid chromatography with 
electrospray ionization tandem mass spectrometry (LC-ESI-MS/MS) using a Micromass Quattro LC 
triple quadrupole mass spectrometer fitted with a Z electospray interface. The LC-MS/MS 
instruments were operated in positive or negative mode though multiple reaction monitoring for the 




3.5 Nomenclature and Pharmacokinetics of Target Compounds 
The following section provides detailed descriptions of the properties of the target compounds. 
Compound nomenclature and pharmacokinetic information were taken from Martindale (Sweetman et 
al., 2007) and the Merck manual (Merck & Co, 2004), while the chemical structure and dose forms 
were taken from the Drug Bank (Wishart et al., 2010), a database maintained by the Department of 
Computing Science and Biological Sciences, University of Alberta Canada.   
3.5.1 Sulfamethoxazole 
 
Chemical Name: N1-(5-Methylisoxazol-3-yl) sulphanilamide 
Molecular Formula: C10H11N3O3S 




                                                                           Figure 3-1 Chemical structure of Sulfamethoxazole 
Sulfamethoxazole is an important synthetic antibacterial agent, used for both human and animal 
application; it is also used as growth promoter in animal applications. Its administration routes 
include oral, intravenous and ophthalmic. The usual adult dose is 2 g initially and then 1g twice daily. 





-acetylsulfamethoxazole has been found to be transformed back to 
the parent compound during wastewater treatment processes (Gobel et al., 2005).  
3.5.2  Trimethoprim 
Chemical Name: 5-(3,4,5-Trimethoxybenzyl)pyrimidine-2,4-
diamine 
Molecular Formula: C14H18N4O3  
Molecular weight: 290.3 
 





Trimethoprim is broad spectrum synthetic antibacterial agent prescribed as separate therapeutic 
compounds and with sulafamethoxazole  at a ratio of 1:20 . It is orally administered.  The usual oral 
adult dose is 100 or 200 mg twice a day. About 40 to 60% of the administered dose is excreted in 
urine mostly as the parent compound (Sweetman et al., 2007).  
 
3.5.3 Ciprofloxacin  
Chemical Name:  
1-Cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-7-(1-piperazinyl)-3-quinolinecarboxylic acid 
 Molecular formula: C17H18FN3O3 




                                                                               Figure 3-3 Chemical Structure of Ciprofloxacin 
Ciprofloxacin is a broad spectrum synthetic antibacterial agent, active against both gram negative and 
gram positive bacteria. Dose forms include intravenous, oral and ophthalmic. The usual oral adult 
dose of ciprofloxacin is 250-75mg, twice a day, and the intravenous adult dose is 100-400 mg twice a 
day.  
About 40-50% is excreted as the parent compound and 15% is excreted as the metabolites when oral 
dose is administered; while up to 70% is excreted as parent compound, and 10% is excreted as 
metabolites when administered as a parenteral dose in 24 hours. Four active metabolites of 
ciprofloxacin have been identified; the major urinary and fecal metabolites are Oxociprofloxacin and 
Sulfociprofloxacin respectively. About 20-30% of oral and 15% of intravenous doses are excreted 








Chemical Name: 4´-Hydroxyacetanilide; N-(4-Hydroxyphenyl)acetamide 
 Molecular formula: C8H9NO2  





                                                                            Table 3-5 Chemical Structure of Acetaminophen 
Acetaminophen is a para-aminophenol derivative, and has analgesic and antipyretic properties. The 
routes of administration include oral and rectal.  Its usual dose is 0.5 to 1 g every 4 to 6 hours up to a 
maximum of 4 g daily.  It is excreted in the urine mainly as the glucuronide and sulfate conjugates. 
Less than 5% is excreted as parent compound. Previous studies have revealed the re-transformation of 
all the conjugated form to the parent compound during batch scale sewage studies (Khan et al., 2004). 
 
3.5.5 Carbamazepine 
 Chemical Name: 5H-Dibenz[b,f]azepine-5-carboxamide 
 Molecular formula: C15H12N2O  
Molecular Weight: 236.3 
 
 
                                                                              Table 3-6 Chemical structure of Carbamazepine 
Carbamazepine is a dibenzazepine derivative having antiepileptic and psychotropic properties that is 
administered orally. Its initial dose is 100 to 200 mg once or twice daily with a maintenance dose of 
800 to 1200 mg daily.  Carbamazepine is excreted in the urine almost entirely in the form of its 







 Chemical Name: -1-Isopropylamino-3-[4-(2-methoxyethyl)phenoxy]propan-2-ol 
 Molecular formula: C15H25NO3  








                                                                                 Figure 3-4 Chemical structure of Metoprolol 
Metoprolol is a cardio-selective beta blocker; it is administered orally and intravenously. A usual dose 
is 100 to 200mg daily. It is extensively metabolized in the liver. Metabolites are excreted in the urine 
together with only small amounts of unchanged metoprolol 
 
3.5.7 Venlafaxine 
Chemical Name: -(2-Dimethylamino-1-p-methoxyphenylethyl)cyclohexanol hydrochloride 
Molecular formula: C17H27NO2 











Venlafaxine is used to treat depression, and is administered orally with an initial dose of 75mg daily.  
Venlafaxine is excreted mainly in the urine, mainly in the form of its metabolites, either free or in 
conjugated forms. The major active metabolite is o-desmethylvenlafaxine and other metabolites 




Chemical Name: 1-[2-(dimethylamino)-1-(4-hydroxyphenyl)ethyl]cyclohexanol 
 Molecular Formula: C16H25NO2 




                                                               Figure 3-6 Chemical structure of O-desmethylvenlafaxine 
O-desmethylvenlafaxine is an active metabolite of Venlafaxine, and possesses antidepressant 
properties. 
 
The pKa value of sulfamethoxazole indicates that it is found in anionic form in hospital wastewater 
where the pH is typically between 7 and 8. Ciprofloxacin, at pH 7.04 (the isoelectic point of 
Ciprofloxacin) contains both positive and negative charges, although the compound itself is neutral. 
The logKow of Ciprofloxacin at pH 7.04 suggests high hydrophilicity but in contrast to this, it is 
highly sorbed to sludges and sediments. This is presumably due to it planer structure which helps to 
intercalate into the layers of clay minerals (Kummerer, 2008). Acetaminophen had the highest water 
solubility among the target compounds (11 g/L).  Table 3-5 provides the physico-chemical properties 






Table 3-7 : Physico-Chemical properties of target compounds. 
Target 
Compound 
pKa Log Kow 
Log D 











Trimethoprim  pKa= 7.2,6.6 0.91 0.49 199-203
ο 0.5 
Ciprofloxacin pKa1= 6.2 
pKa2= 8.8 
-1.74, -0.28 
(at pH 7.04) 
-0.73 
318-320ο  
Acetaminophen pKa = 9.5 0.27-0.5 0.34 169-170.5
ο 11 
Carbamazepine Neutral 2.45 2.67 190-193ο 0.945 
Metoprolol  pKa = 9.7 1.9    
Venlafaxine     215-217ο  
( Dodd et al., 2004; Jjemba, 2008; Kümmerer, 2008b; Merck & Co, 2004; Yalkowsky, 2003; Zhang 




Occurrence of PhACs in Healthcare Facility Effluents and WWTP 
Influents 
This chapter presents the measured concentrations of the nine target PhACs in the investigated 
healthcare facility effluents and in the downstream WWTP influents. It discusses the day-to-day 
variability in concentration of target compounds in these streams. Further the investigated healthcare 
facility effluent concentrations are compared. The wastewater treatment influents are also compared 
for the occurrence of the target PhACs. 
To assess the discharges of the nine target PhACs by the healthcare facilities, the effluents of the 
selected hospitals and long-term-care homes (two of each type) were sampled over five week days. 
The downstream WWTPs that received discharges from these institutions were also sampled during 
the same days for mass balance calculations. Twenty-four hour composite samples were collected 
from each site, extracted using SPE and then analyzed with LC-MS/MS. 
The following sampling issues arose during the study:  
1. At the HS1 facility twenty-one sub-samples out of 48 that were intended to be composited 
were missed on the second day of sampling. 
2. At the HS2 facility two auto samplers were installed because the discharges from the cancer 
clinic had a second sewer line that was independently connected to the municipal sewer. The 
Tuesday sample from this facility contained only wastewater discharged from the cancer 
clinic because the auto sampler on the main facility was positioned high above the 
wastewater stream and the sampler was unable to draw the effluent.  
3. The volume of the Friday sample collected from the main facility (HS2) manhole was less 
(about 3 L) than expected (5-6 L). It was not clear whether it was due to low flows condition 
or the some strainer openings being closed due to suspended matter.  
4. Some portion of Monday sample from LTC2 facility effluent was lost due to leakage in 





4.1 Occurrence of Target PhACs in the Healthcare Facility Effluents 
 In this study the samples collected on each day were analyzed in triplicate. In the plots that follow, 
the bars present the average of the triplicates, while the error bars represent the range of the 
triplicates. In the text, the average value of the triplicate analyses is discussed as this represents the 
best estimate of the actual values. For example, Table 4-1, shows the calculations for the second day 
sample (the antibiotic Sulfamethoxazole was not tested for on the first day) from the first hospital 
facility HS1 effluent. This sample was analyzed in triplicate as mentioned above and the values 
recorded are referred to as R1, R2 and R3 in Table 4-1.  
Table 4-1 Analytical results for the HS1 effluent day-2 sample 
Compound 
HS1 sample (ng/L) 
Mean Range 
R1 R2 R3 
Sulfamethoxazole  3772 3392 3664 3609 3392- 3772 
Trimethoprim 540 544 568 551 540 - 568 
Ciprofloxacin  382 408 575 455 382 - 575 
Acetaminophen  115200 116400 111600 114400 111600 - 115200 
Carbamazepine  586 550 602 579 550 - 602 
Metoprolol  41 48 42 44 41 - 48 
Venlafaxine  344 321 378 348 321 - 378 
N-desmethylvenlafaxine 177 232 149 186 149 – 232 
O-desmethylvenlafaxine  2252 3172 1456 2293 1456 - 3172 
 
 The day-to-day variability observed in the concentration of target PhACs in the investigated 
healthcare facility effluents presumably occurs due to variation in the consumption of PhACs and 
water usage; higher flow reduces concentrations and vice versa provided that compound consumption 
remains the same. The coefficient of variation (CV = standard deviation/Mean) was used as an 
indicator of the day-to-day variability. The CV normalizes the standard deviation values and allows 
comparison between the variability estimates of the target compounds, regardless of their 
concentration values (Reed et al., 2002). In this study, compounds with higher CV values had 
relatively higher variability than others; further it was assumed that compounds with CV<10% had 
the least or no variability.   
As mentioned, the Tuesday sample from HS1 contained only 27 sub-samples out of the 48 to be 
composited. Similarly, at HS2 the Tuesday sample contained the discharge from the Cancer clinic 























































































4.1.1 Sulfamethoxazole  
Figure 4-1 shows Sulfamethoxazole concentrations measured in the investigated hospital and long-
term-care home effluents (HS1, HS2, LTC1, and LTC2) in ng/L. Sulfamethoxazole was not tested for 






Figure 4-1 Sulfamethoxazole concentrations in healthcare facility effluents 
 
   Relatively higher concentrations were observed in HS2’s effluent than in the rest of the facilities. 
The detected concentration was greater than 6 g/L in all samples. The highest concentration (11 
g/L) was measured on Thursday (Figure 4-1). The weekly maximum concentrations of 
Sulfamethoxazole in the other investigated healthcare facility effluents were HS1 (~ 1 g/L), LTC1 
(2.3 g/L) and LTC2 (0.7 g/L).  
The Sulfamethoxazole concentrations followed similar trends in the HS1 and LTC2 effluents from 
Wednesday to Friday (bars shown in red in HS1 and LTC2), with a maximum concentration on 
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Wednesday and then a decrease over the next the two days (Thursday and Friday). No patterns in 
concentration were found either in the HS2 or LTC1 effluents over the week days.  
The day-to-day variability in concentration allows the identification of extreme individual events 
during week days. Table 4-3 presents the variability in concentrations about the mean values of each 
facility’s effluent.  
Table 4-2 Variability in concentrations of Sulfamethoxazole about the mean in the investigated 
                  healthcare facility effluents  
Facility 
Concentrations (ng/L) 
Mean Sd CV 
Monday Tuesday Wednesday Thursday Friday 
HS1   996 888 440 775 294.82 0.38 
HS2 6573  6160 10933  7889 2645 0.34 
LTC1 378 2292 147 95 330 648 926 1.43 
LTC2 592 100 716 391 260 412 248 0.60 
Sd   = Standard deviation 
Bold values indicate the maximum measured concentrations 
 
  The highest variability in the Sulfamethoxazole concentration over the week days was observed in 
LTC1. It occurred due to the individual peak concentration value on Tuesday (Table 4-2), which may 
have resulted from the disposal of unwanted or expired compounds. Further research is needed to 
clearly identify the sources of an individual spike. The higher day-to-day variability in 
Sulfamethoxazole concentrations in HS2 (263 beds) than in HS1 (365 beds) may have occurred 
because smaller facilities are more affected by individual events than larger facilities.  
                   
4.1.2 Trimethoprim 
The measured Trimethoprim concentrations in HS1, HS2, LTC1, and LTC2 effluents are presented in 
Figure 4-2. Higher concentrations were observed in the HS2 effluent than in others. Up to 10.3 g/L 
of Trimethoprim was detected in HS2 effluent. The weekly maximum concentrations were HS1 (0.5 
g/L), LTC1 (2.3 g/L), and LTC2 (1.3 g/L). 
No consistent concentration patterns over the week days were observed in the facility effluents 




















































































Monday then remained relatively stable between 314 - 336 ng/L from Wednesday to Friday. In the 
HS2 effluent, the concentration was at a minimum on Monday, and then increased over the following 
week days. The maximum concentration was detected on Thursday (10.3 g/L). In the long-term-care 








Figure 4-2 Trimethoprim concentrations in the healthcare facility effluents 
 
Substantial day-to-day variability of Trimethoprim concentrations was observed in all the facility 
effluents (CV >10%) with the maximum variability observed in the long-term-care home effluents 
(Table 4-3). The higher CV values in LTC1 and LTC2 effluents were due to the individual peak 







Table 4-3 Variability in concentrations of Trimethoprim about the mean in the investigated 
                  healthcare facility effluents  
Facility 
Concentrations (ng/L) 
Mean Sd CV 
Monday Tuesday Wednesday Thursday Friday 
HS1 512   321 314 336 371 95 0.26 
HS2 4947  9413 10320  8227 2877 0.73 
LTC1 736 924 451 6573 701 1877 2631 1.40 
LTC2 238 234 1924 847 298 708 727 1.03 
Sd   = Standard deviation 
Bold numbers show the maximum concentrations measured   
 
The individual peak concentrations in LTC1 and LTC2 (Table 4-3) may have resulted from either the 
administration of a single therapeutic dose, or disposals of un-needed and expired compounds. 
Trimethoprim is sometimes used as a single dose (75-450 mg) therapy for urinary tract infections 
(Sweetman et al., 2007). As mentioned earlier, such infections are among the most common diseases 
in long-term-care home setups. About 40 to 60% of the administered dose has been reported to be  
excreted unchanged within 24 hours (Sweetman et al., 2007) ; therefore, the peak concentration value 
in LTC2’s Wednesday sample (1924 ng/L) may have been the results of a single dose therapy, as 
about half of this amount showed up on the next day (Table 4-3).  The peak concentration in LTC1 
(6573 ng/L) on Thursday was less likely  to be a single therapeutic dose, as the concentration on the 
following day was nine times less than this value. Thus this value was assumed to occur due to the 




The weekly maximum Ciprofloxacin concentrations in the HS1, HS2, LTC1, and LTC2 effluents were 
1.2, 0.16, 0.6, and 1.4 g/L respectively (Figure 4-3). Relatively higher concentrations over the week 
days were observed in HS1 effluent, with the mean concentration of 0.79 g/L compared to 0.15, 
0.31, and 0.32 g/L in HS2, LTC1, and LTC2 effluents respectively (Table 4-4).  
The Ciprofloxacin concentrations showed similar patterns over the week days in HS1, HS2 and 

















































































(Monday and Friday), and maximum concentrations observed on Wednesdays. In LTC2, the daily 
concentrations decreased from Monday to Wednesday, with the minimum concentration (31 ng/L) on 
Wednesday and a spike of 1470 ng/L on Thursday (Figure 4-3).  
The findings indicate that the maximum Ciprofloxacin concentrations occurred on Wednesday 
especially in hospital effluents, regardless of the sampling season; because the investigated hospitals 
HS1 and HS2 were sampled in different seasons (summer and winter respectively) and had their 






Figure 4-3 Ciprofloxacin concentrations in healthcare facility effluents 
 
The highest day-to-day variability in Ciprofloxacin concentration was observed in LTC2 and the 
lowest in HS2 (Table 4-4). The higher variability in the LTC2 effluent was due to the individual spike 
in concentration on Thursday (1.4 µg/L), which presumably happened due to disposal of unneeded or 
expired Ciprofloxacin compound ; as the concentrations in other weekdays was always less than 50 
ng/L.    
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Table 4-4 Variability in concentrations of Ciprofloxacin about the mean in the investigated 
                 healthcare facility effluents 
Facility 
Concentrations (ng/L) 
Mean Sd CV 
Monday Tuesday Wednesday Thursday Friday 
HS1 632   1240 843 465 795 335 0.42 
HS2 119  169 155  148 26 0.17 
LTC1 197 345 604 224 214 317 171 0.54 
LTC2 49 41 31 1470 42 327 639 1.96 
Sd   = Standard deviation 
Bold numbers show the maximum concentrations measured   
 
In LTC2 (Table 4-4) the individual peak value of Ciprofloxacin (1470 ng/L) on Thursday shows a 
possible batch discharge, because, this compound is normally administered more than once; therefore, 
a similar concentration range is expected to show up on the following day sample (Friday). In 
addition, the pharmacokinetic information suggests that 40-50% of the oral dose is expected to be 
excreted unchanged in 24 hours (Sweetman et al., 2007). This too supports the idea that a portion of 
the administered compound will be excreted the next day.  
 
In some health conditions Ciprofloxacin is used as a single oral dose. Up to 8 hours of Ciprofloxacin 
elimination half life has been reported for the elderly (Sweetman et al., 2007),  and 5 half-lives are 
normally required to eliminate the drug up to 97%  (Rowland et al., 1995). This information suggests 
that some portion of the administered dose may be excreted during the next day and should show up 
in that day’s sample if a single oral dose was used. Therefore it is reasonable to consider the observed 
peak concentration as being a batch discharge.  
 
4.1.4 Acetaminophen 
The measured concentrations of Acetaminophen in the investigated hospital and long-term-care home 
effluents are shown in Figure 4-8. Relatively higher concentrations were observed in HS1 (the biggest 
facility investigated) with a mean concentration of 99.5 g/L compared to 13.6 g/L in HS2 and 82 to 
88 g/L in long-term-care homes. The weekly maximum concentrations were HS1 (134 g/L), HS2 











































No common patterns were observed among the facilities. The Acetaminophen concentration was 
relatively stable in long term care homes. In LTC2, the concentration varied between 72.8 to 88.8 
g/L over the week days.  While in LTC1, it varied between 77.7 and 85 g/L with an individual spike 




Figure 4-4 Acetaminophen concentrations in healthcare facility effluents 
  
The day-to-day variability in Acetaminophen concentrations (Table 4-5) was lower in long-term-
care homes than in hospital effluents, with the least variability in LTC2 (CV< 10%).  Again, there was 
one peak concentration in LTC1 on Thursday (bold value); otherwise, there was minimal variability 
between rest of the week days (CV = 0.05) in this facility. Relatively higher variability was observed 
in HS1 (a bigger facility). The lower variability in Acetaminophen concentration in long-term-care 











































Table 4-5 Variability in concentrations of Acetaminophen about the mean in the investigated 
                 healthcare facility effluents 
Facility 
Concentrations (ng/L) 
Mean Sd CV 
Monday Tuesday Wednesday Thursday Friday 
HS1 134133   95067 100533 68533 99567 26951 0.27 
HS2 13253  15973 11773  13667 2130 0.16 
LTC1 85600 83867 78667 116267 77733 88427 15917 0.18 
LTC2 72800 88800 85333 85733 78933 82320 6419 0.08 
Sd   = Standard deviation 
Bold numbers show the maximum concentrations measured   
 
4.1.5 Carbamazepine  
 
Higher Carbamazepine concentrations were observed in the HS2 effluent than in the rest of the 
facilities, with a maximum detected concentration of 676  ng/L. The weekly maximum concentrations 
in HS1, LTC1, and LTC2 were 144, 527, and 77 ng/L, respectively (Figure 4-5). 
Carbamazepine had similar concentration patterns during the weekdays in the HS2 and LTC2 
effluents (bars filled red), with higher concentrations on Mondays, minimum concentrations on 
Wednesdays and then increases in the next two days (Thursday and Friday). In the LTC1 effluent the 
concentration showed a rising trend from Monday to Thursday with a peak on Thursday and a dip on 
Friday. The maximum concentration was observed on Monday in both the hospitals (HS1 and HS2). In 









Figure 4-5 Carbamazepine concentrations in healthcare facility effluents  
Day-to-day variability (Table 4-6) in concentration was observed in all the facility effluents (CV > 
10%). Relatively higher variability (CV = 0.69 and 0.76) was observed in the hospital effluents than 
in the long-term-care homes (CV = 0.6 and 0.4).  
 
Table 4-6 Variability in concentrations of Carbamazepine about the mean in the investigated 
                  healthcare facility effluents 
Facility 
Concentrations (ng/L) 
Mean Sd CV 
Monday Tuesday Wednesday Thursday Friday 
HS1 144   34 36 86 75 52 0.69 
HS2 676  76 452  401 303 0.76 
LTC1 182 153 252 527 176 258 155 0.60 
LTC2 64 67 22 33 77 53 24 0.45 
Sd   = Standard deviation 





































































































































































Higher Metoprolol concentrations were detected in the LTC1 effluent than in all the other investigated 
healthcare facility effluents (Figure 4-6) with up to 5 g/L detected in its effluent. The weekly 
maximum concentrations in the other effluents were HS1 (493 ng/L), HS2 (676 ng/L), and LTC2 (321 
ng/L). 
 
The Metoprolol concentrations varied randomly in all the facility effluents. Common patterns were 
observed between hospital effluents HS1 and HS2, with minimum concentrations on the first week day 









The day-to-day variability in concentration of Metoprolol was greatest in LTC1 (CV = 0.92), because 
of the individual peak concentration on Thursday ~ 5 g/L (Table 4-7). The individual peak 
concentration may have been due to the disposal of expired or unwanted compounds down drains.  
The higher variability in HS2 than in HS1 may be because smaller facilities are more affected by 
individual events.  
Table 4-7 Variability in concentrations of Metoprolol about the mean in the investigated 
                  healthcare facility effluents 
Facility 
Concentrations (ng/L) 
Mean Sd CV 
Monday Tuesday Wednesday Thursday Friday 
HS1 306   490 378 493 417 91.17 0.22 
HS2 88  193 175  152 56 0.37 
LTC1 1033 1875 1131 4920 541 1900 1754 0.92 
LTC2 198 321 192 253 157 224 64 0.29 
Sd   = Standard deviation 
Bold numbers show the maximum concentrations measured   
 
4.1.7 Venlafaxine  
Venlafaxine was detected in much higher concentrations in HS2 than in the other healthcare facilities, 
with daily measured concentrations greater than 4 g/L except on Monday. Up to 9 g/L 
(Wednesday) was measured in the HS2 effluent (Figure 4-7). The higher concentrations were 
presumably due to the presence of the cancer clinic in HS2. A Venlafaxine concentration of 35.4 g/L 
was measured in the cancer clinic effluent and this supports this assumption (Figure 4-12). The 
weekly maximum concentrations measured in HS1, LTC1, and LTC2 were 744, 2275, and 716 ng/L 
respectively. 
 
No common concentration patterns were observed between the facility effluents (Figure 4-7). The 
maximum concentrations in hospital effluents were detected either on Thursday or Wednesday (HS1 
and HS2 respectively). Long-term-care homes had individual peaks on Wednesday in LTC1 and on 














































  Figure 4-7 Venlafaxine concentrations in healthcare facility effluents 
 
Venlafaxine concentrations showed higher variability in long-term-care homes than in hospitals, due 
to an individual spike or dip in concentration during week days. For instance, in LTC1 2275 ng/L was 
detected on Wednesday; for rest of the weekdays Venlafaxine concentration varied between 108 and 
547 ng/L. A similar spike was observed in LTC2 on Friday (716 ng/L) and for other week days the 
concentration varied between 38 and 334 ng/L (Table 4-8). The least variability was found in HS1 
effluent (CV = 0.12). The lowest variability in HS1 was perhaps due to the fact that bigger facilities 














































Table 4-8 Variability in concentrations of Venlafaxine about the mean in the investigated 
                  healthcare facility effluents 
Facility 
Concentrations (ng/L) 
Mean Sd CV 
Monday Tuesday Wednesday Thursday Friday 
HS1 552   629 744 647 643 79 0.12 
HS2 761  8893 4059  4571 4090 0.89 
LTC1 547 412 2275 108 243 717 886 1.24 
LTC2 334 144 97 38 716 266 275 1.04 
Sd   = Standard deviation 
Bold numbers show the maximum concentrations measured   
 
 
4.1.8 N-desmethylvenlafaxine  
Relatively higher N-desmethylvenlafaxine concentrations were observed in HS1 effluents than in the 
other facilities. The measured concentrations were greater than 200 ng/L in all samples, with a 
maximum concentration of 416 ng/L (Figure 4-8). The weekly maximum concentrations of N-
desmethylvenlafaxine in other investigated facility effluents were HS1 (457 ng/L), LTC1 (266 ng/L) 
and LTC2 (119 ng/L).  
The N-desmethylvenlafaxine concentrations showed similar patterns from Wednesday to Friday in 
the hospital effluents, with an increasing trend over these days (bars filled red). No trends were found 
in the long-term-care home effluents.  











































N-des-Venlafaxine (LTC2)  
  Figure 4-8 N-desmethylvenlafaxine concentrations in healthcare facility effluents  
 
 
The day-to-day variability in concentration was lower in the hospital effluents than in the long-term-
care-home’s (Table 4-9). HS1 had the least variability (CV = 0.27) and the highest variability was 
observed in LTC2 (CV = 1.11). The higher variability in LTC2 may be because this compound was not 
detected in two samples from its effluent (Wednesday and Thursday).  
 
N-desmethylvenlafaxine is excreted in lesser amounts compared to the parent compound, with 1% of 
administered dose reported to be excreted as N-desmethylvenlafaxine as compared to 1-10% for the 
parent compound (Klamerus et al., 1992). The concentration of Venlafaxine on Wednesday and 
Thursday was 97 and 38 ng/L respectively, so the concentration of N-desmethylvenlafaxine was 












































Table 4-9 Variability in concentrations of N-desmethylvenlafaxine about the mean in the 
                  investigated healthcare facility effluents 
Facility 
Concentrations (ng/L) 
Mean Sd CV 
Monday Tuesday Wednesday Thursday Friday 
HS1 217   283 353 416 317 86.31 0.27 
HS2 217  100 238  185 74 0.40 
LTC1 126 266 95 44 133 133 82 0.62 
LTC2 119 33 0 0 112 53 59 1.11 
Sd   = Standard deviation 




4.1.9 O-desmethylvenlafaxine  
The weekly maximum concentrations of O-desmethylvenlafaxine in the investigated healthcare 
facility effluents were HS1 (2880 ng/L), HS2 (2535 ng/L), LTC1 (6987 ng/L) and LTC2 (2124 ng/L).  
Similar patterns of O-desmethylvenlafaxine concentration were observed in the hospital effluents 
from Wednesday to Friday (bars filled red). The highest concentrations of O-desmethylvenlafaxine in 












































O-des-Venlafaxine (LTC1)  
  Figure 4-9 O-desmethylvenlafaxine concentrations in healthcare facility effluents 
 
The highest day-to-day variability in the concentration of O-desmethylvenlafaxine was observed in 
LTC1 effluent (Table 4-10), due to the individual peak concentration on Friday (6987 ng/L).  
 
Table 4-10 Variability in concentrations of O-desmethylvenlafaxine about the mean in the 
                   healthcare facility effluents 
Facility 
Concentrations (ng/L) 
Mean Sd CV 
Monday Tuesday Wednesday Thursday Friday 
HS1 2880   968 1797 1216 1715 851 0.50 
HS2 956  1127 2535  1539 866 0.56 
LTC1 1301 1276 2272 323 6987 2432 2638 1.08 
LTC2 892 621 485 736 2124 972 661 0.68 
Sd   = Standard deviation 








































4.1.10 Relationship between Venlafaxine and its Metabolites  
 
Venlafaxine and its metabolites have a pharmacokinetic relation that may vary between individuals, 
depending upon, their age, sex and health conditions and route of administration in addition to other 
factors (Correia, 2007). Klamerus et al., (1992) found that the urinary excretion for an oral dose of 
Venlafaxine in healthy adults was 1-10% in the parent form, up to 30% of the active metabolite O-
desmethylvenlafaxine, and about 1% N-desmethylvenlafaxine.  
 
To study whether the concentration of Venlafaxine and its metabolites (N-desmethylvenlafaxine and 
O-desmethylvenlafaxine) in each sample followed this pattern, the measured concentrations of these 
compounds in each facility were plotted together (Figure 4-10). This figure shows that the measured 
concentrations in HS1, LTC1 and LTC2 followed the same order from lowest to highest, as N-
desmethylvenlafaxine, Venlafaxine and O-desmethylvenlafaxine, as proposed by Klamerus et al. ( 
1992). In the HS2 effluent a similar trend was observed only for the Monday sample, while in all 
other samples, the concentration of Venlafaxine was greater than O-desmethylvenlafaxine’s.   
 
To investigate further the relationship between the measured concentration of Venlafaxine and its 
metabolites, the measured concentrations of these compounds for each day  were normalized with the 
concentration of N-desmethylvenlafaxine for that day, i.e., concentrations were divided by the N-
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Figure 4-10 Concentration of Venlafaxine and its metabolites in healthcare facility effluents 
  
Table 4-11 Measured Concentration ratios between Venlafaxine and its metabolites in the 
                    healthcare facility effluent. 
Facility 
N-desmethylvenlafaxine : Venlafaxine : O-desmethylvenlafaxine 
Monday Tuesday Wednesday Thursday Friday 
LTC1 1 4 10 1 2 5 1 24 24 1 2 7 1 2 53 
LTC2 1 3 7 1 4 19       1 6 19 
HS1 1 3 13    1 2 3 1 2 5 1 2 3 
HS2 1 4 4    1 89 11 1 17 11 1 10 4 
N-desmethylvenlafaxine was not detected in two samples of LTC2 (Wednesday & Thursday) 






















The differences in the relationship between measured concentrations of Venlafaxine and its 
metabolites (Table 4-11) may occur due to the difference in the elimination half life of Venlafaxine (4 
hours) and its active metabolite O-desmethylvenlafaxine (10 hours). Therefore, a consistent 
relationship cannot be expected in the healthcare facility effluents, especially in hospitals, where 
patients are frequently admitted and discharged. The excretion of these compounds depends on the 
time patients spent in the hospital; for example if Venlafaxine is administered to patients who spend 
less than 10 hours in the hospital Venlafaxine excretion is expected but not O-desmethylvenlafaxine. 
Patients, who take Venlafaxine at home and visit the hospital after 5 to 6 hours, will excrete only O-
desmethylvenlafaxine in hospital, not Venlafaxine, and vice versa. 
 
The HS2 effluent’s higher concentration of Venlafaxine than O-desmethylvenlafaxine might be 
explained by the disposal of unwanted compounds down drains. These compounds will not pass 
thought the human metabolism, resulting in higher concentrations of Venlafaxine. In addition, 
patients who visit hospitals for less than 10 hours are expected to excrete Venlafaxine only but not O-
desmethylvenlafaxine; this may lead to higher concentrations of Venlafaxine than O-
desmethylvenlafaxine.    
  
In the long-term-care homes, where patients do not frequently change the relation of venlafaxine and 
it metabolites was 1% N-desmethylvenlafaxine 2 to 6% of Venlafaxine and 3 to 19% of O-
desmethylvenlafaxine except for the Wednesday and Friday samples in the LTC1 facility. The 
relatively higher concentrations of Venlafaxine (similar to O-desmethylvenlafaxine concentration) on 
Wednesday in the LTC1 may have been due to the disposal of un-wanted compound leading to a 
higher concentration of the parent compound only.   
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4.1.11 Concentration of Target PhACs in Day-2 Sample from HS1 
As indicated earlier, on the second day of sampling at the HS1 facility the auto-sampler missed 21 
sub-samples out of 48 that were to be composited. Therefore, the Tuesday results are plotted 
separately from those of the other days of the week in Figure 4-11.  
 
 
 Figure 4-11 Concentrations of target compounds in day-2 sample of HS1 effluent 
A comparison of the results of this sample (HS1 day-2) with those of the rest of the week  (Figure 
4-1 to 4-9) shows that the Sulfamethoxazole concentration (3609 ng/L) was higher in this sample than 
in the other weekdays (varied between 456 and 900 ng/L). In contrast Venlafaxine had lower 
concentraion (348 ng/L) compared to the other weekdays (552 to 744 ng/L). For all other target 
compounds, the concentrations were in the same range as found on other weekdays (Table 4-12). This 
may have been due to differences in the dosing patterns of the differing groups of compounds.  
Table 4-12 Comparison between Tuesday sample and other weekday samples  
Target Compound Concentrations (ng/L) 
 Tuesday  Monday to Friday (Range) 
Trimethoprim  550 456 -  900 
Ciprofloxacin  455 465  -  1240 
Acetaminophen  114400 68533  -  134133 
Carbamazepine  44 34.5 -  144 
Metoprolol  579 305  -  490 
N-desmethylvenlafaxine 186 216  -  416 



















































4.1.12 Concentrations of Target PhACs in the Cancer Clinic Effluent and Friday 
Sample from HS2  
 
As mentioned earlier, the Tuesday sample from the HS2 facility effluent contained only discharges 
from the cancer clinic and the Friday sample had a lesser volume than expected; therefore, these 
values were plotted separately from the other days in Figure 4-12.  In the cancer clinic effluent, the 
antidepressant Venlafaxine had the highest concentrations; up to 36 g/L of Venlafaxine and 6.4 g/L 
of its metabolite O-desmethylvenlafaxine were measured. Acetaminophen and Carbamazepine 
concentrations were 13.3 g/L and 0.6 g/L, respectively while the concentrations of the antibiotics 
sulfamethoxazole, trimethoprim, metoprolol and n-desmethylvenlafaxine were in the range of 0.3 to 
0.4 g/L. Carbamazepine levels may be high (628 ng/L) because it also possesses  psychotropic 
properties and can thus be used for neuralgia and other severe pain syndromes connected with 
neurological disorders (Sweetman et al., 2007). The Carbamazepine concentrations on the other 
weekdays (full hospital effluent samples) varied between 76 and 452 ng/L except on Monday (676 
ng/L). The use of Venlafaxine, Carbamazepine and Acetaminophen in certain cancer treatments has 
also been reported (Hardy et al., 2005; Lersch et al., 2002; Tasmuth et al., 2002).  
The Friday sample contained a full sample from the cancer clinic, but a reduced volume from the 
discharge point of the main facility; therefore the concentrations of some compounds in this sample 
were in the same range to those of the cancer clinic (Ciprofloxacin, Sulfamethoxazole and 
Trimethoprim in Figure 4-12). Comparing the concentrations of the target PhACs in this sample to 
those of the rest of the week days shows that on Friday the Sulfamethoxazole and Trimethoprim 
concentrations were much lower (327 and 425 ng/L respectively)  than those for other week days (6.5 
to 11 µg/L for Sulfamethoxazole and 5 to 10 µg/L of Trimethoprim). All other compound 
concentrations were in the same range as for other week days.  
Day-to-day variability in compound discharge is unavoidable, especially in hospitals, where 
patients are frequently discharged and admitted and such variability is often expected. In long-term-
care homes, the higher variability was due to individual concentration peaks that presumably resulted 







Figure 4-12 Concentration of target PhACs in the cancer clinic effluent and Friday sample from 


























































The measured concentrations of Sulfamethoxazole and Trimethoprim were within the range reported 
in previous hospital wastewater studies (Table 2-2). Ciprofloxacin was measured in lower 
concentrations than in hospital effluents studied in Europe; for instance, up to 124 g/L was reported 
in the effluent of a German hospital (Hartmann et al., 1999). 
 
The concentrations of Sulfamethoxazole, Trimethoprim, Carbamazepine and Venlafaxine were higher 
in the HS2 effluent, while Metoprolol, Acetaminophen, and Ciprofloxacin concentrations were found 
to be higher in HS1 effluent. The higher concentration of Sulfamethoxazole (~11 g/L) and 
Trimethoprim (10 g/L) in the relatively smaller facility’s effluent (HS2) than in HS1’s (1 g/L and 
0.5 g/L respectively) may be explained by seasonal variations in the consumption of these 
compounds. The HS1 effluent was sampled in mid-July, while HS2 was sampled in the first week of 
November. Therefore, use of the July and October purchases can be assumed. Figure 4-9 shows 
Ontario hospital purchases for the year 2008 (IMS database), and indicates more Sulfamethoxazole 
and Trimethoprim was bought in October than in June and July.  
 
 
     Figure 4-13 Number of individual units (tablets, capsules etc.) of Sulfamethoxazole and 


































An additional source of variation may be the differences in the service spectrum of the investigated 
hospitals. For instance, higher concentrations of Venlafaxine and Carbamazepine in HS2 effluent than 
in HS1 were presumably due to the presence of a cancer clinic, where such drugs may be prescribed to 
patients. The higher concentrations of Venlafaxine (~36 g/L) and Carbamazepine (0.6 g/L) in the 
cancer clinic effluent supports this hypothesis (Figure 4-12).  
 
The occurrence of target PhACs in the long-term-care home effluents suggests that these streams can 
also contain elevated concentrations of antibiotics and other compounds. Acetaminophen 
concentrations were detected up-to 116 g/L and the maximum concentration of Metoprolol was 
greater (~5 g/L) than that found in hospital effluents (0.57 g/L). Individual day concentration spikes 
were observed in the long-term-care home effluents especially for antibiotic compounds; and were 
attributed to the disposal of un-needed or expired compounds. The increased amounts of un-wanted 
pharmaceutical compounds in these facilities may occur because the prescriptions for the elderly 
often change due to the uncertainties associated in diagnostics with age.   
 
 
All the target PhACs were detected in all samples except for the metabolite of Venlafaxine, N-
desmethylvenlafaxine, which was not detected in the Wednesday and Thursday samples from the 
LTC2. Therefore, the frequency of the target compounds detection in the investigated healthcare 













The maximum detected concentrations of the target PhACs are presented in Table 4-13. The 
maximum concentrations for all the target PhACs in the healthcare facility effluents exceeded 1200 
ng/L, with the exception of Carbamazepine and the metabolites of Venlafaxine. Up to 36 g/L of 
Venlafaxine was detected in the cancer clinic effluent and 134 g/L of Acetaminophen was measured. 
The concentrations of the antibiotic compounds Sulfamethoxazole, Trimethoprim and Ciprofloxacin 
were 10.93 g/L, 10.32 g/L and 1.24 g/L respectively. The results (Table 4-13) support the 
hypothesis that hospital wastewaters contain elevated concentrations of pharmaceutical compounds.  
 Table 4-13: Maximum detected concentrations of the target PhACs  
 Target Compounds 




Maximum Concentrations  
( g/L) 
HS1 HS2 LTC1 LTC2 Hospitals  
Long term care 
homes 
 Sulfamethoxazole 3609 10933 2292 716 10.9  2.29 
 Trimethoprim 550 10320 6573 1924 10.3  6.57 
 Ciprofloxacin 1240 168 604 1470 1.24  1.47 
 Acetaminophen 134133 15973 116266 88800 134  116 
 Carbamazepine 143 676 526 76 0.67  0.52 
 Metoprolol 579.2 337 4920 320 0.57  4.92 
 Venlafaxine 744 8893 2275 892 8.89  2.27 
 N-desmethylvenlafaxine 416 238 265 118 0.45  0.26 






4.2 Comparison of Day- to-day Variability in Concentrations in Healthcare 
Facility Effluents 
Considerable day-to-day variability was observed for all compounds in the investigated facility 
effluents, and may have been due to either variations in the wastewater flow or differences in the 
consumption of PhACs during each day. Higher flows would reduce concentrations and vice versa, 
provided that compound consumption remains the same. If the variability was only from the 
fluctuations in a facility’s wastewater flows, then it should affect all target PhACs similarly (similar 
CV values). This was not the case; the different CV values (Table 4-13) for each compound suggest 
that the observed variability was due to variations in both consumption and wastewater flows.  
 
It is important to note that the consumption of the pharmaceutical compounds within the healthcare 
facility is not directly related to the concentration of these compounds in its effluent; it is strictly the 
excretion of these compounds within the facility after administration. Therefore an important 
consideration in understanding the effects of consumption on the compound’s variability in the 
facility effluent is the consumption and excretion relationship of pharmaceutical compounds. The 
excretion pattern of these compounds depends on various factors.  First, it varies between individual 
patients depending upon age, sex health condition etc, suggesting the possibility of detecting different 
concentrations over time even when the amounts consumed remain the same. Second, the 
administered compounds need a certain time for excretion (elimination half-life) (Jambhekar et al., 
2009); therefore, concentrations will be affected by the length of patient stays. Third, the excretion 
rates depend on the route of administration (Khan et al., 2004; Sweetman et al., 2007); similar 
amounts administered through different routes of administration lead to different excretion patterns. 
Fourth, excretion patterns also depend on the therapeutic dose. For single dose therapy, half of the 
administered dose is expected to be excreted during one half-life period, and then a quarter during the 
next half-life; thus discharge of a compound varies over time. Only in continuous therapeutic 
regimens will a steady state be attained, where consumption and excretion may be directly related in 




As previously mentioned, the coefficient of variation was used as an indicator of day-to-day 
variability of the target compounds in the investigated facility effluents. Statistically, the coefficient 
of variation of two samples is considered significantly different if the absolute difference between 
them is more than the critical value at the considered significance level multiplied by the standard 
error of the coefficient of variations (Pal, 1998; Thomas et al., 2007).  For example, if v1 and v2 are 
the coefficients of variation of two samples with sample size n1 and n2, respectively, their standard 

















If the significance level is α, then the CV of the two samples will be significantly different if  












Figure 4-14 shows the CV values for the target compound concentrations over the week days in the 
investigated healthcare facility effluents. The CV values are taken from Tables 4-3 to 4-11.  For the 
purpose of this report, the day-to-day variability of target compound concentrations were assumed to 
be significantly different only if   
 













t nn  
 
A comparison between the investigated hospitals (HS1 and HS2), and between the two long-term-care 
homes  for the CV values for all compounds, showed no significant differences in the CV for all 
compounds either between the hospital effluents, or between long-term-care homes (details are 
attached in Appendix C).   
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HS1 HS2 LTC1 LTC2 
Sulfamethoxazole  0.38 0.34 1.43 0.60 
Trimethoprim 0.26 0.35 1.40 1.03 
Ciprofloxacin  0.42 0.17 0.54 1.96 
Acetaminophen  0.27 0.16 0.18 0.08 
Carbamazepine  0.69 0.76 0.60 0.45 
Metoprolol  0.22 0.37 0.92 0.29 
Venlafaxine  0.12 0.89 1.24 1.04 
N-desmethylvenlafaxine  0.27 0.40 0.62 1.11 
O-desmethylvenlafaxine  0.50 0.56 1.08 0.68 
 
Considerable day-to-day variability in concentration (CV >10%) was observed for all compounds 
in the hospital effluents. Relatively higher variability in the concentrations of Sulfamethoxazole, 
Trimethoprim and Venlafaxine of these compounds in HS1 effluent (CV values) than HS2 may occur 
because smaller facilities (HS2) may be more affected by individual events than larger facilities. In 
the HS1 effluent, Venlafaxine had the lowest day-to-day variability; the maximum CV was observed 
for Carbamazepine concentrations. In the HS2 effluent, the least variability was observed in 
Ciprofloxacin concentration, and the highest variability in Carbamazepine concentration.     
 
The least day-to-day variability about the mean in the LTC effluents was observed for 
Acetaminophen, (CV = 0.08 in LTC2 and CV = 0.18 in LTC1), indicating that Acetaminophen is used 
in long-term-homes more regularly than other compounds. The higher variability in other compounds 
suggests that their use is less frequent.  
 
To investigate further, the relation between the type of healthcare facility and the compound’s 
variability in its effluent, the maximum and minimum CV values for the target compounds and their 
corresponding facilities are compared (Table 4-15). This table shows higher day-to-day variability in 
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Acetaminophen and Carbamazepine concentrations (rows with blue background in Table 4-15) 
occurred in hospital effluents. For all other target compounds, hospital effluents had lower variability 
than did long-term-care homes. The minimum variability in Acetaminophen concentration (CV= 
0.08) in LTC2 effluents suggest that this compound is most often used in the long-term-care homes by 
a certain number of long-term care home residents.  
 
The relatively lower variability for most of the compounds in hospital effluents may be explained by 
the fact that hospitals have a number of beds designated for each type of treatment, and are 
continuously filled by a series of new patients; overall drug consumption thus stays the same, as does 
the discharge of these compounds to the wastewater. This is not the case in long-term-care homes, 
where very few beds are actually designated for rehabilitation, and most of the beds are occupied by 
the long-term residents. Further, the higher variability in long-term-care homes was mainly due to the 
individual peak concentrations of the target compounds in their effluents.  
Table 4-15 Maximum and minimum CV values in the investigated healthcare facility effluent   
Target Compounds 
Maximum Minimum  
CV Facility CV Facility 
Sulfamethoxazole  1.43  LTC1 0.34 HS2 
Trimethoprim 1.4  LTC1 0.26  HS1 
Ciprofloxacin  1.96  LTC2 0.17 HS2 
Acetaminophen  0.27  HS1 0.08  LTC2 
Carbamazepine  0.76  HS2 0.45  LTC2 
Metoprolol  0.92  LTC1 0.22  HS1 
Venlafaxine  1.24  LTC1 0.12  HS1 
N-desmethylvenlafaxine  1.11  LTC2 0.27  HS1 





4.3 Comparison between Healthcare Facility Effluents for the Occurrence of 
Target PhACs 
Differences in the target compound concentrations between the hospital effluents (HS1 and HS2) were 
observed. Similarly, such differences were found between the two long-term-care home effluents. To 
further investigate whether these differences were statistically significant, ANOVA tests were carried 
out. The results are summarized as follows.   
 
4.3.1 Comparison between HS1 and HS2 Effluents 
 
A comparison of the HS1 and HS2 facility effluents showed that significant differences existed 
between these streams in the concentrations of Sulfamethoxazole, Trimethoprim, Ciprofloxacin, 
Acetaminophen, and Metoprolol (P-values were 0.01, 0.002, 0.02, 0.003, and 0.007 respectively). No 
significant differences were found between the two hospital’s effluent for the concentrations of 
Carbamazepine, Venlafaxine and its metabolites, i.e., N-desmethylvenlafaxine and O-
desmethylvenlafaxine (P-values were 0.08, 0.1, 0.08, and 0.8 respectively. 
 These findings suggest that the effluents of different sized hospitals, (number of beds) may contain 
similar concentrations of certain compounds, and also that the concentration of certain other 
compounds may differ. Therefore information relating to number of beds only, for a hospital, may not 
be useful when estimating the concentration of PhACs in effluents.  
 
 
4.3.2 Comparison between LTC1 and LTC2 Effluents 
Comparing LTC1 and LTC2 facility effluents indicated that these effluents did not significantly differ 
in terms of target compounds concentrations with the exception of carbamazepine (P-value = 0.02). 
This finding may be due to the similar services provided by the long-term-care facilities and partly 
their relatively homogenous population (elderly people) who would be expected to consume similar 
types of drugs.  The differences in Carbamazepine concentrations may occur because this compound 




4.4 Occurrence of Target PhACs in WWTP Influents 
 
The influents of the downstream WWTPs that received discharges from the investigated healthcare 
facilities (two hospitals and two long-term-care homes) were sampled to facilitate mass balance 
calculations. Twenty-four hour composite samples were collected at the influents of the four WWTPs 
during the same week days as that of the respective upstream healthcare facility effluents.  
 
The healthcare facilities were hypothesized to be major contributors of pharmaceutical compounds to 
the WWTPs. To investigate this hypothesis, the WWTPs were identified based on the respective 
upstream healthcare facilities, WWTP-HS1, WWTP-HS2, WWTP-LTC1 and WWTP-LTC2. The 
concentrations in the wastewater treatment facility influents were evaluated considering the 
contributions of upstream healthcare facilities.  
 
   In addition to the type and size of the upstream healthcare facilities, the investigated WWTPs were 
different in terms of the community size they serve and the sampling time.  The WWTP sizes 
according to the population served from largest to smallest facility, were WWTP-HS2 (171000), 
WWTP-LTC1 (80000), WWTP-HS1 (51218), and WWTP-LTC2 (33000). WWTP-HS1 was sampled 
in mid July, WWTP-HS2 in early November, WWTP-LTC1in mid February, and WWTP-LTC2 in the 
first week of March.  
 
The concentrations of each compound measured in the WWTP influents are presented in Figures 4-15 
to 4-24. This presentation allowed comparison of the compound concentrations between WWTPs, 
and identification of any common patterns over the week days. Further, the day-to-day variability in 
target compound concentrations in the WWTP influents was investigated and individual 
concentration peaks were identified. The variability about the mean of the target compounds in the 
influents is presented in Tables 4-15 to 4-23. The tables are organized with the highest to lowest 















































4.4.1 Sulfamethoxazole  
Sulfamethoxazole concentrations detected in the WWTP influents are shown in Figure 4-14. This 
compound was not tested for the Monday sample from WWTP-HS1; therefore, no results are 
available for this day. The weekly maximum concentrations measured in WWTP-HS1, WWTP-HS2, 
WWTP-LTC1, and WWTP-LTC2 influents were 605, 548, 461, and 540 ng/L respectively. 
No common patterns of Sulfamethoxazole concentration among the WWTPs were observed. WWTP-
HS1 and WWTP-HS2 both had their maximum concentrations at the beginning of the week, then a 
decrease over the next days, with a minimum concentration either on Wednesday (WWTP-HS2) or on 
Thursday (WWTP-HS1), followed by an increase. In WWTP-LTC1 influent, the Sulfamethoxazole 
concentration was relatively constant between 378 ng/L to 461 ng/L. In WWTP-LTC2 the maximum 
concentration was on Tuesday, and then concentrations decreased over the next weekdays, with a 
















































Relatively higher variability in Sulfamethoxazole concentration was observed (Table 4-16) in the 
WWTPs that received hospital discharges WWTP-HS1 (CV = 0.51) and WWP-HS2 (CV= 0.33).  
WWTP-LTC1 had the least variability (CV<0.1). This wastewater treatment facility also has a 
hospital upstream, but the size of the hospital was relatively small (68 beds) compared to the 
community size contributing the PhAC loads to this facility (80000 pop). Therefore no noticeable 
effect of the hospital was expected. The variability in WWTP-LTC2 (CV= 0.29) was presumably due 
to its relatively smaller size (30000 population) as smaller size facilities are more affected by 
individual events.   
 
Table 4-16 Variability in Sulfamethoxazole concentration about the mean in WWTP influents 
Facility 
Concentrations (ng/L) 
Mean Sd CV 
Mon Tue Wed Thu Fri 
WWTP-HS1  605 420 171 277 368 188.1 0.51 
WWTP-HS2 548 436 216 389 408 362 119.6 0.33 
WWTP-LTC2 472 540 476 349 252 404 115.4 0.29 
WWTP-LTC1 441 378 461 407 445 423 33.56 0.08 
Sd   = Standard deviation 




The detected Trimethoprim concentrations in the WWTP influents (Figure 4-15) were in the range of 
WWTP-HS1 (153 to 412 ng/L), WWTP-HS2 (217 to 316 ng/L), WWTP-LTC1 (226 to 353 ng/L), and 
WWTP-LTC2 (100 to 244 ng/L). Relatively lower Trimethoprim concentrations were observed in the 















































Figure 4-15 Concentration of Trimethoprim in the influents of WWTPs 
 
 
The highest variability in Trimethoprim concentration about the mean was in WWTP-HS1 (CV= 
0.32), then in WWTP-LTC2 (CV= 0.28). The higher variability in these facility influents may have 
been due to the fact that WWTP-HS1 is relatively smaller in size (51,218 inhabitants) and has a 
relatively bigger hospital (365 beds) upstream; while WWTP-LTC2 was the smallest WWTP (30000 
inhabitants) investigated and had a long-term-care home (200 beds) upstream. Smaller facilities are 
usually more affected by individual events. The least variability occurred in WWTP-HS2, which had a 
relatively smaller hospital upstream (263 beds) and a large community (171000 inhabitants). Again, 
the low variability in WWTP-LTC1influent was perhaps due to its size (80000 inhabitants), as bigger 
size facilities are expected to be less affected by individual events. These findings suggest that the 
variability in WWTP influent concentrations is affected by the size of the treatment facility and also 












































Table 4-17 Variability in Trimethoprim concentration about the mean in WWTP influents 
Facility 
Concentrations (ng/L) 
Mean Sd CV 
Mon Tue Wed Thu Fri 
WWTP-HS1 389 412 309 153 330 319 102 0.32 
WWTP-LTC2 200 244 186 194 100 185 52 0.28 
WWTP-LTC1 226 292 264 271 353 281 47 0.17 
WWTP-HS2 296 237 217 316 285 270 41 0.15 
Sd   = Standard deviation 




Sulfamethoxazole and Trimethoprim are often prescribed together (Sulfamethoxazole: Trimethoprim 
5:1), and their elimination half-lives are within the same range (6-12 hrs and 8-10 hrs, 
respectively)(Sweetman et al., 2007). Therefore, similar trends at the WWTP influent level were 
expected. Such trends were more obvious in WWTP-HS1, WWTP-HS2 and WWTP-LTC2 (Figures 4-
17). In the WWTP-HS1 influent, the concentration of both compounds decreased from Tuesday to 
Thursday then increased again on Friday.  Similarly, in WWTP-HS2 the concentration of both 
compounds was at a maximum on Monday then decreased over the next two days, and was at a 
minimum on Wednesday. In WWTP-LTC2 the concentrations of the two compounds slightly 
increased from Monday to Tuesday then decreased over the next weekdays and reached a minimum 
















The weekly maximum Ciprofloxacin concentrations detected in the WWTP influents (Table 4-17) 
were WWTP-HS1 (105 ng/L), WWTP-HS2 (130 ng/L), WWTP-LTC1 (80 ng/L), and WWTP-LTC2 
(151 ng/L).  No common patterns of Ciprofloxacin concentration were observed in the WWTP 
influents. The maximum Ciprofloxacin concentrations were detected on Thursdays in all the WWTPs 
except WWTP-LTC2, where the maximum concentration was found on Tuesday (Figure 4-17).   In 
WWTP-LTC2, the Ciprofloxacin concentration pattern was similar to those of Sulfamethoxazole and 
Trimethoprim, with an increase from Monday to Tuesday then a decrease over next the few 
weekdays. This finding may suggest similar use patterns of these compounds in catchment area of 








































































































































































Figure 4-17 Concentrations of Ciprofloxacin in the WWTP influents 
The highest variability in the concentration about the mean was observed (Table 4-18) in WWTP-
LTC2 (CV = 0.52), due to the individual peak concentration on Tuesday, then, in WWTP-HS1, with 
(CV=0.34), which perhaps occurs because (as mentioned earlier in this section) of the relatively 
bigger hospital upstream to this WWTP in relation to the community it serves. Lower variability was 
observed in WWTP-HS2, which had a relatively smaller hospital upstream and serves a larger 
community. The least variability was observed in WWTP-LTC1 which serves 80000 people and 








Table 4-18 Variability in Ciprofloxacin concentration about the mean in WWTP influents 
Facility 
Concentrations (ng/L) 
Mean Sd CV 
Mon Tue Wed Thu Fri 
WWTP-LTC2 78 151 68 45 57 80 41 0.52 
WWTP-HS1 97 41 82 105 63 77 26 0.34 
WWTP-HS2 84 91 112 130 103 104 18 0.17 
WWTP-LTC1 57 76 69 80 74 71 9 0.13 
Sd   = Standard deviation 
Bold numbers show the maximum concentrations measured   
 
4.4.4 Acetaminophen 
Acetaminophen was detected in higher concentrations than all other target compounds in the 
investigated WWTP influents. The detected influent concentrations varied from 40-83 g/L for 
WWTP-HS1, 39.5-47.5 g/L for WWTP-HS2, 64-70 g/L for WWTP-LTC1, and 42-68 g/L for 
WWTP-LTC2. The average Acetaminophen concentration was lower (43 g/L) in the biggest WWTP 
(WWTP-HS2). All other WWTP influent concentrations were in the same range 61 to 67 g/L (Figure 
4-18).  
 
In WWTP-HS1, the Acetaminophen concentration was found to be highest on Monday (83 g/L) then 
decreased over the next three days, with a minimum value on Thursday (51 g/L). The concentrations 
then started rising again on Friday. In contrast, in WWTP-LTC1 the lowest values occurred on 
Monday (64 g/L), and then had an increasing trend over the next week days, with a maximum 
concentration on Friday (70 g/L).  In WWTP-HS2, the concentration was relatively stable between 
39 g/L and 47 g/L over the week days. In WWTP-LTC2, the concentrations were stable (between 
63 g/L to 68 g/L from Monday to Thursday) and then dropped on Friday (42 g/L). In the WWTP-
HS1influent, Sulfamethoxazole and Acetaminophen concentrations had quite similar patterns, which 
may suggest that the variability of these compounds was contributed by the same sources (Table 4-






Figure 4-18 Concentrations of Acetaminophen in the WWTP influents   
 
The variability in the Acetaminophen was highest (CV=0.28) in WWTP-HS1, and was probably 
caused by the larger hospital upstream (Table 4-19), than in WWTP-LTC2 (CV=0.18), the smallest 
treatment facility. WWTP-HS2 and WWTP-LTC1 influents had low variability (CV< 0.1%), with the 
least value for WWTP-LTC1 (CV = 0.03), perhaps because Acetaminophen is often used in 
communities, so a consistent discharge of this compound is expected to their treatment plants. 
WWTP-HS2 and WWTP-LTC1 are bigger facilities than the other two, and WWTP-LTC1 had only a 



























































































Table 4-19 Variability in Acetaminophen concentration about the mean in WWTP influents 
Facility 
Concentrations (ng/L) 
Mean Sd CV 
Mon Tue Wed Thu Fri 
WWTP-HS1 83067 75867 65600 39907 51200 63128 17660 0.28 
WWTP-LTC2 67600 63200 64133 68400 42267 61120 10769 0.18 
WWTP-HS2 43600 41600 47600 41680 39573 42811 3033 0.07 
WWTP-LTC1 64400 67333 66533 67600 70267 67227 2113 0.03 
Sd   = Standard deviation 




4.4.5 Carbamazepine  
The weekly maximum concentrations in the WWTP influents (Figure 4-19) were WWTP-HS1 (897 
ng/L), WWTP-HS2 (719 ng/L), WWTP-LTC1 (184 ng/L), and WWTP-LTC2 (104 ng/L). No common 
patterns in the Carbamazepine concentrations were observed over the week days. WWTP-HS1 and 
WWTP-HS2 had individual peak concentrations on Wednesday (897 ng/L) and Thursday (719 ng/L) 
respectively (Figure 4-19). The concentrations over the other weekdays in these WWTP influents 
varied between 151-269 ng/L in WWTP-HS1 and 191-255 ng/L in WWTP-HS2. The Carbamazepine 
concentrations in the WWTP-LTC1 influent were relatively stable over the weekdays, between 158-
184 ng/L. WWTP-LTC2 had a higher concentration on Tuesday (104 ng/L), and the concentration 












































  Figure 4-19 Concentration of Carbamazepine in the WWTP influents 
 
Considerable variability in Carbamazepine concentrations in the WWTP influents was observed 
(Table 4-20) except for WWTP-LTC1 (CV< 0.10). The higher variability in the WWTP-HS1 and 
WWTP-HS2 influents was due to the individual day peak concentrations (bold values Table 4-20). 
WWTPs that received hospital discharges (WWTP-HS1, WWTP-HS2) had an individual peak 
concentration (Wednesday and Thursday respectively in Table 4-20). These individual peaks may 
















































Table 4-20 Variability in Carbamazepine concentration about the mean in WWTP influents 
Facility 
Concentrations (ng/L) 
Mean Sd CV 
Mon Tue Wed Thu Fri 
WWTP-HS1 269 261 897 151 168 349 311 0.89 
WWTP-HS2 255 191 207 719 230 321 224 0.70 
WWTP-LTC2 69 104 75 72 81 80 14 0.18 
WWTP-LTC1 175 164 158 181 184 172 11 0.06 
Sd   = Standard deviation 
Bold numbers show the maximum concentrations measured   
 
 
4.4.6 Metoprolol  
 
The weekly maximum Metoprolol concentrations in WWTP-HS1, WWTP-HS2, WWTP-LTC1, and 
WWTP-LTC2 were 207, 104, 261, and 282 ng/L respectively. WWTP-HS2 influent had relatively 
lower Metoprolol concentrations than other WWTPs investigated (Figure 4-20).  No common patterns 
in the Metoprolol concentrations were found in the WWTP influents. WWTP-HS1 and WWTP-HS2 
had maximum concentrations on Wednesday (Figure 4-20). The Metoprolol concentrations varied 
between 200-261 ng/L in WWTP-LTC1 influent, with the highest concentration detected on Friday. 


















































  Figure 4-20 Concentrations of Metoprolol in the WWTP influents 
 
Considerable variability (CV >0.1) in Metoprolol concentration was observed in all WWTP influents, 
with the highest variability in WWTP-HS1 (CV= 0.4), and the least variability in WWTP-LTC1 
(CV=0.11).   
Table 4-21 Variability in Metoprolol concentration about the mean in WWTP influents 
Facility 
Concentrations (ng/L) 
Mean Sd CV 
Mon Tue Wed Thu Fri 
WWTP-HS1 49 179 207 145 161 148 60 0.41 
WWTP-LTC2 282 227 219 244 135 221 54 0.24 
WWTP-HS2 86 71 104 82 95 88 13 0.14 
WWTP-LTC1 235 257 217 199 261 234 26 0.11 
Sd   = Standard deviation 

























































































































4.4.7 Venlafaxine  
Relatively higher concentrations of Venlafaxine were observed in the WWTP-HS2 influent than in the 
other investigated WWTPs, with a weekly average of 494 ng/L (Figure 4-21). The weekly maximum 
concentrations measured in the WWTP influents were WWTP-HS1 (632 ng/L), WWTP-HS2 (521 
ng/L), WWTP-LTC1 (513 ng/L), and WWTP-LTC2 (456 ng/L). 
In WWTP-HS1 and WWTP-HS2 higher concentrations were detected on Monday (632 ng/L and 526 
ng/L respectively ); then, the concentrations decreased in WWTP-HS1 over the next three days, with a 
minimum value on Thursday (259 ng/L), while in WWTP-HS2, concentrations remained relatively 
stable over the other week days (between 467-509 ng/L Figure 4-21). The WWTP-LTC1 influent 
concentrations varied between 394 to 513 ng/L. In WWTP-LTC2, the influent Venlafaxine 
concentration varied between 427-456 ng/L from Monday to Thursday then dropped on Friday to 308 
ng/L. The concentration patterns of Venlafaxine in all the investigated WWTP influents were similar 
to that of Acetaminophen, suggesting similar use patterns to Acetaminophen (Figure 4-18 and 4-21).    
 
  
  Figure 4-21: Concentrations of Venlafaxine in the WWTP influents 
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The variability in the Venlafaxine concentration in the order from the highest to lowest was WWTP-
HS1 (CV= 0.35), WWTP-LTC2 (CV= 0.15) and WWTP-LTC1 (CV=0.11). The least variability was 
found in WWTP-HS2, with CV= 0.05 (Table 4-22).  
 
Table 4-22 Variability in Venlafaxine concentration about the mean in WWTP influents 
Facility 
Concentrations (ng/L) 
Mean Sd CV 
Mon Tue Wed Thu Fri 
WWTP-HS1 632 439 389 259 325 409 142 0.35 
WWTP-LTC2 427 449 439 456 308 416 61 0.15 
WWTP-LTC1 444 394 402 432 513 437 47 0.11 
WWTP-HS2 521 476 509 499 467 494 23 0.05 
Sd   = Standard deviation 
Bold numbers show the maximum concentrations measured   
 
4.4.8 N-desmethylvenlafaxine  
The WWTP influent concentrations of N-desmethylvenlafaxine  are presented in Figure 4-23. The 
weekly maximum concentrations in the influents of WWTP-HS1, WWTP-HS2, WWTP-LTC1, and 
WWTP-LTC2 were 248, 178, 190, and 177 ng/L respectively. 
 
Similar concentration patterns were observed in WWTP-HS1, WWTP-HS2, and WWTP-LTC1, with a 
maximum concentration on Monday and minimum detected concentrations on Thursday (Figure 4-
22). In WWTP-LTC2, the concentration was relatively stable from Monday to Wednesday (between 




























































































N-des-venlafaxine  (WWTP-LTC2)  
  Figure 4-22 Concentration of N-desmethylvenlafaxine in the WWTP influents 
 
Considerable variability in N-desmethylvenlafaxine concentrations existed in the WWTP influents 
(Table 4-23) except WWTP-HS2 (CV = 0.03).  Similar to Venlafaxine, the highest variability was 
observed in the WWTP-HS1 influent (CV = 0.47).   
 
Table 4-23 Variability in N-desmethylvenlafaxine concentration about the mean in WWTP 
                    influents 
Facility 
Concentrations (ng/L) 
Mean Sd CV 
Mon Tue Wed Thu Fri 
WWTP-HS1 248 120 170 81 99 144 67 0.47 
WWTP-LTC1 190 115 124 114 126 134 32 0.24 
WWTP-LTC2 145 145 143 177 103 143 26 0.18 
WWTP-HS2 178 165 170 162 171 169 6 0.03 
Sd   = Standard deviation 



















































































4.4.9 O-desmethylvenlafaxine  
The weekly maximum concentrations detected in the WWTP influents (Figure 4- 23) were WWTP-
HS1 (6580 ng/L), WWTP-HS2 (1623 ng/L), WWTP-LTC1 (5493 ng/L), and WWTP-LTC2 (1390 
ng/L). Maximum O-desmethylvenlafaxine concentrations occurred on Mondays for all WWTPs 
except for WWTP-LTC2. Monday concentrations in WWTP-HS1 and WWTP-LTC1 influents were 
considerably higher (6.5 and 5.5 g/L respectively) than those for rest of the week days; during which 
influent concentrations varied from 0.6 to 1.8 g/L in WWTP-HS1 and from 2.3 to 3.2 g/L in 
WWTP-LTC1. WWTP-LTC2 had its maximum concentration on Wednesday (1.4 g/L).  
    
  
  Figure 4-23 Concentration of O-desmethylvenlafaxine in the WWTP influents 
The variability in the of O-desmethylvenlafaxine concentrations in WWTP-HS1 and WWTP-LTC1 
was higher (CV=1.07 and 0.35 respectively) than the other two WWTPs, due to the individual  peak 
concentrations of this compound on Monday, 6580 ng/L in WWTP-HS1 and 5493 ng/L in WWTP-
LTC1 influents. WWTP-HS2 and WWTP-LTC2 had the similar variability, CV=0.14 and 0.13, 
respectively (Table 4-24).  
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Table 4-24 Variability in O-desmethylvenlafaxine concentration about the mean in WWTP 
                   influents 
Facility 
Concentrations (ng/L) 
Mean Sd CV 
Mon Tue Wed Thu Fri 
WWTP-HS1 6580 1816 1683 595 776 2290 2458 1.07 
WWTP-LTC1 5493 2897 3185 2328 3269 3435 1208 0.35 
WWTP-HS2 1613 1357 1233 1112 1363 1336 186 0.14 
WWTP-LTC2 1140 1160 1390 1295 969 1191 161 0.13 
Bold numbers show the maximum concentrations measured   
 
4.4.10 Relationship between the Concentrations of Venlafaxine and its Metabolites 
The relationship between the Venlafaxine and its metabolites in urinary excretion for healthy adults 
has been reported to be 1% as N-desmethylvenlafaxine, 1-10% as Venlafaxine and 30% as the active 
metabolite O-desmethylvenlafaxine (Klamerus et al., 1992). The measured concentrations of these 
compounds at the influents of the WWTPs were overall found to be in the range of ratios 1% N-
desmethylvenlafaxine, 1-4% Venlafaxine, and 7-30% O-desmethylvenlafaxine, and their observed 
concentration ratios are presented in Table 4-25. The relationship between Venlafaxine and its 
metabolites differed between the WWTP influents, but remained consistent within WWTPs over the 
week days within a small range. For example In WWTP-HS2 (Table 4-25) the relationship, 1% N-
desmethylvenlafaxine, 3% Venlafaxine and 7-9% O-desmethylvenlafaxine (1:3:7-9) was consistent 
from Monday to Friday. A similar relationship was observed in WWTP-LTC2, with only a slight 
increase in the O-desmethylvenlafaxine range (1:3:7-10%) for all weekdays.  
Table 4-25 Relationship between the concentration of N-desmethylvenlafaxine, Venlafaxine and 
                  O-desmethylvenlafaxine in the WWTP influents  
Facility 
N-desmethylvenlafaxine : Venlafaxine : O-desmethylvenlafaxine 
Monday Tuesday Wednesday Thursday Friday 
WWTP-HS1 1 3 27 1 4 15 1 2 10 1 3 7 1 3 8 
WWTP-HS2 1 3 9 1 3 8 1 3 7 1 3 7 1 3 8 
WWTP-LTC1 1 2 29 1 3 25 1 3 26 1 4 20 1 4 26 
WWTP-LTC2 1 3 8 1 3 8 1 3 10 1 3 7 1 3 9 
Concentration of N-desmethylvenlafaxine was taken as 1 to estimate the concentrations of Venlafaxine 
and O-desmethylvenlafaxine relative to this value. 
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Comparing the size of communities that contributed PhAC loads to the WWTPs reveals that the 
largest (WWTP-HS2, 171000 pop) and the smallest (WWTP-LTC2, 33000 pop) WWTPs had a 
similar relationship (1:3: 7-10%). WWTP-LTC1 (80000 pop) had a relation range of 1:2-4: 20-29%, 
while WWTP-HS1 (51218 pop) varied, with results similar to WWTP-LTC1 during the first two days 
(1:3-4:15-27%), and similar to WWTP-HS2 and WWTP-LTC2 for rest of the days (1:2-3:7-10%). To 
illustrate these finding the data from Table 4-25, are reorganized facility-wise in Table 4-26.  
Table 4-26 Relationship between Venlafaxine and its metabolites in the WWTP influents 
WWTP ID WWTP-HS1 WWTP-HS2 WWTP-LTC1 WWTP-LTC2 
Size (Population served) 51,218 171,000 80,000 33,000 
N-desmethylvenlafaxine  1% 1% 1% 1% 
Venlafaxine  2-4% 3% 2-4% 3% 
O-desmethylvenlafaxine  7-27% 7-9% 20-29% 7-10% 
  
Table (4-26) shows a similar relationship occurred between Venlafaxine and its metabolites in the 
influents of the largest and the smallest WWTPs (columns with blue background). The mid-sized 
WWTP (WWTP-LTC1) showed relatively higher concentrations of O-desmethylvenlafaxine (20-
29%), the mid to lower WWTP size had a wide range O-desmethylvenlafaxine that accommodates 
both the ranges.  
 
Another factor contributing to the differences between Venlafaxine and its metabolites in the 
collected samples may be the sewer travel times for the compounds, from the major discharge points 
(point sources) to the influents of the WWTPs. This may define how many batches of the excreted 
portions reach the WWTP influent in 24hours (the elimination half-life of Venlafaxine and O-
desmethylvenlafaxine is 4 and 10 hours respectively). For example the sewer travel time from HS2 
and LTC2 to their respective WWTPs was the same (0.5 hrs), and similar relationships between 
Venlafaxine and its metabolites existed in their WWTPs (WWTP-HS2 and WWTP-LTC2). The sewer 
travel times were different from HS1and LTC1 to their respective WWTPs (3 and 5 hours 
respectively), and hence, relationships differs in them. Further research is need to identify the main 
sources contributing the differences in relationship between Venlafaxine and its active metabolite O-




All the target PhACs were detected in all the influent samples of the investigated WWTPs. The 
measured concentration of antibiotic compounds ranged Sulfamethoxazole (170 - 605ng/L), 
Trimethoprim (100-412 ng/L), and Ciprofloxacin (40-150 ng/L). Acetaminophen was detected in 
highest concentrations (between 39673 and 83066 ng/L). The measured concentrations of 
Carbamazepine and Metoprolol were (69 -897 ng/L) and (49 -281 ng/L), respectively. The detected 
antidepressant concentrations were venlafaxine (258-632 ng/L), and its metabolites, N-
desmethylvenlafaxine (80-248 ng/L) and O-desmethylvenlafaxine (594-6580 ng/L). 
4.5 Comparison of day to day variability of target compounds in the WWTP 
influents.  
The day to day variability in concentrations of the target PhACs in the WWTP influents were 
estimated as described in section 4.3 (for detailed calculations see Appendix C).  The calculated 
coefficients of variability of all investigated PhACs for each WWTP are shown in Table-4-27, and 
plotted in Figure 4-24.  
 
 
Table 4-27 Variability about the mean concentration of target PhACs in the WWTP influents   
Target Compounds 
CV 
WWTP-HS1 WWTP-HS2 WWTP-LTC1 WWTP-LTC2 
Sulfamethoxazole  0.51 0.30 0.08 0.28 
Trimethoprim 0.32 0.15 0.17 0.28 
Ciprofloxacin  0.34 0.17 0.13 0.52 
Acetaminophen  0.28 0.07 0.03 0.18 
Carbamazepine  0.89 0.70 0.06 0.18 
Metoprolol  0.41 0.14 0.11 0.24 






Figure 4-24 Coefficient of variation for concentration of target compounds in the WWTP 
influents 
The day-to-day variability of the target compound concentrations in the WWTP influents (as 
suggested by CV values) indicates that the highest variability in the target compounds existed in the 
WWTP-HS1 influent which had a relatively larger hospital (365 beds) upstream and a relatively 
smaller community (51218 inhabitants) contributing target compounds to this facility. The next 
lowest variability occured in WWTP-LTC2, which was the smallest facility investigated (30000 
inhabitants) and had a long-term-care home upstream (200 beds). The least variability existed in 
WWTP-LTC1, with a larger treatment facility (80000 inhabitants), a very small hospital (68 beds) and 
a long-term-care home upstream. The least day-to-day variability about the mean occurred in the 
Acetaminophen concentrations in all treatment plant influents. These findings suggest that the 
variability in target compounds concentration may be affected by the size of the hospitals in relations 























4.5.1 Comparison of CV values for Target Compounds in the healthcare facilities and 
downstream WWTPs 
The CV values for the target PhACs in the investigated healthcare facility effluents and their 
respective downstream WWTP influents are plotted in Figures 4-25 and 4-26.  
 
 
Figure 4-25 Coefficient of variation of the target PhACs in the hospital effluents and their  










































The relative trends in CV for target PhACs in the hospital effluents and their downstream WWTP 
influents followed similar tends, especially in HS1 (a relatively bigger facility) and its downstream 
WWTP-HS1 (see the upper chart). This finding may suggest a connection between the variability of 
















Figure 4-26 Coefficient of variation of the target PhACs in the long-term-care home effluents 
                       and their downstream WWTP influents 
The variability in the compounds in the long-term-care effluent was relatively much higher than in 
their respective downstream WWTP influents. The trends in variability between the compounds in the 
















relatively small contribution of the long term care homes to the WWTPs.  Hence, fluctuations in the 
LTC effluents would have insignificant effects on the variability of the WWTPs. 
4.6 Comparison of Target Compound Concentrations in the WWTP influents 
 
The investigated WWTP influent concentrations were compared using SPSS software (ANOVA) 
and Fisher least significant difference (LSD) method for multiple comparisons. No significant 
differences existed between any of the investigated WWTP influents for the concentrations of 
Sulfamethoxazole, Ciprofloxacin, Venlafaxine, and N-desmethylvenlafaxine. Trimethoprim 
concentrations were significantly different between WWTP-HS1and WWTP-LTC2, and between 
WWTP-LTC1 and WWTP-LTC2 influents. Significant differences occurred in Acetaminophen 
concentrations between WWTP-HS2 and all the other WWTPs. Carbamazepine concentrations were 
significantly different between WWTP-HS1 and WWTP-LTC2. Metoprolol concentrations in WWTP 
influent were not significantly different between WWTP-HS1 and WWTP-HS2, and WWTP-LTC1 
and WWTP-LTC2; and significant differences were observed in all other WWTP combinations. 
Significant differences existed in the concentrations of O-desmethylvenlafaxine in WWTP-HS2 and 
WWTP-LTC1, and between WWTP-LTC1 and WWTP-LTC2. No differences were found in any other 
WWTP combinations.   
These findings suggest that in WWTP influents 1) similar concentrations of Sulfamethoxazole, 
Ciprofloxacin, Venlafaxine and N-desmethylvenlafaxine can be expected regardless of the size of the 
WWTP, existing healthcare facilities upstream, and sampling dates. This claim is supported by the 
finding that no significant differences in the concentration of these compounds were observed in the 
influents of wastewater treatment facilities of different sizes (varied between 30,000 and 171,000), 
with different healthcare facilities upstream (hospitals and long-term-care homes), and at different 
sample time/dates (July, November, February and March).  2) Trimethoprim concentrations may vary 
depending upon sizes of the WWTP and sizes of the upstream healthcare facilities. WWTP-LTC2, the 
smallest treatment facility investigated, did not receive hospital discharges, had a lower daily average 
concentration in its influent (184 ng/L) than all other WWTPs (319, 281, 270 ng/L). 3) 
Carbamazepine concentrations seem to be affected by upstream hospital sizes, as its daily average 
concentration varied as 80,172, 320 and 350 ng/L for no hospitals upstream, and for 68, 263 and 365-
bed hospitals respectively. Significant differences in Carbamazepine concentration only existed 
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between WWTP-HS1 (a 365-bed hospital upstream) and WWTP-LTC2 (no hospital discharges). 4) 
Acetaminophen concentrations may differ between WWTPs, provided that substantial differences 
exist in their sizes. In this study only significant differences were observed between the biggest 
WWTP investigated (serves 171000 population) and rest of the WWTPs (for of 80000, 51218, 30,000 
inhabitants). A lower daily average concentration (~43 g/L) of Acetaminophen was found in the 
biggest WWTP (WWTP-HS2) compared to all other investigated WWTPs (average concentration 
varied from 61 to 67 g/L). 5) O-desmethylvenlafaxine concentration may vary between WWTPs 
depending upon the size of the WWTP and the existing hospitals upstream. No significant differences 
were observed between the WWTPs that received hospital discharges. Lower daily average 
concentrations were observed in the biggest and the smallest WWTPs (1.3 and 1.2 g/L respectively) 
than in other WWTPs (3.3 and 3.4 g/L). 










Mass Flows of Target PhACs  
Mass flows were calculated to quantify the total load of target PhACs in the investigated healthcare 
facility effluents and in the downstream wastewater treatment plant influents.  The healthcare facility 
effluents were compared with each other on the basis of the mass flows of target PhACs over week 
days, similarly WWTP influents were compared. The per-bed contributions of PhACs to each 
facility’s effluent load and per-capita mass contributions to the WWTP influent loads were 
investigated.  
 
The wastewater flows of the healthcare facilities (HS1, HS2, LTC1, and LTC2) were calculated from 
the amount of water the facilities purchased during the sampling month. This data was provided by 
the regional municipality of the target area. Using monthly water consumption data, daily water 
consumption was estimated by assuming that the average water consumption during each day of the 
week was the same. It was further assumed that ninety percent of the water consumed within the 
facility was discharged to the sewers (Metcalf & Eddy, 1991). Table 5-1 shows the water consumed 
(m
3
/day) by each facility and wastewater flows.    
 
Table 5-1 : Daily water consumption and wastewater flows of the healthcare facilities 
Target Facilities  
(Size) 
HS1              
(365 beds) 
HS2                         
(263 beds) 
LTC1                     
(228 beds) 












464.4 177.3 68.4 125 
Wastewater flow = 90% of water consumption 
 
The water consumed by LTC2 (200 beds) a relatively smaller facility, was considerably higher than 
by LTC1 with 228 beds (Table 5-1). This difference was presumably due to the presence of private 
showers for the residents in the LTC2 facility, while LTC1 had communal showers. This finding 
suggests that the water consumption estimates for a healthcare facility using typical per-bed 
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consumption values may sometimes lead to wide differences between estimated values and actual 
consumption. 
The daily average wastewater inflow volumes (m
3
/day) of the WWTPs were provided by the 
treatment plant operators (Table 5-2). The per-capita wastewater contribution to the wastewater 
treatment facilities was calculated by dividing the inflow volume with the population served by each 
facility. The average per-capita wastewater generation for the areas investigated varied between 390 
to 620 L/capita/day (Table 5-2).   
 






























Monday 22663 0.44 93784 0.55 36905 0.46 10835 0.36 
Tuesday 27265 0.53 92909 0.54 36717 0.46 11103 0.37 
Wednesday 26157 0.51 89543 0.52 37783 0.47 11068 0.37 
Thursday 49779 0.97 93297 0.55 38162 0.48 10976 0.37 
Friday 31798 0.62 87807 0.51 37839 0.47 14963 0.50 
MEAN  0.62  0.53  0.47  0.39 
   
 
 The mass flows (g/day) of the target compounds in the healthcare facility effluents and the respective 
downstream WWTP influents were calculated using equation 5.1. The results are tabulated in Table 
5-3. This table also shows weekly average mass flows for each compound in the facility effluents. As 
mentioned earlier Sulfamethoxazole was not tested on Monday samples from HS1 effluent and 
WWTP-HS1 influent and  Tuesday samples from HS1 and HS2 effluents did not represent the full 
hospital effluent; therefore, mass flows for these days are not shown in Table 5-3.     
 
Mass flow (g/day) = Concentration (ng/L) x Wastewater Flow (m3/day) x 10




Table 5-3: Daily mass flows of target PhACs in the healthcare facility effluents and WWTP 




Healthcare facility effluent  
(g/day) 
WWTP influents                            
(g/day) 









Sulfamethoxazole Mon  1.17 0.03 0.07  51.39 16.27 5.11 
Tue   0.16 0.01 16.5 40.51 13.88 6.00 
Wed 0.46 1.09 0.01 0.09 10.98 19.34 17.43 5.27 
Thu 0.41 1.94 0.01 0.05 8.49 36.27 15.52 3.84 
Fri 0.20  0.02 0.03 8.81 35.81 16.85 3.77 
Daily average 0.36 1.4 0.05 0.05 11.2 36.7 16.0 4.8 
Trimethoprim Mon 0.24 0.88 0.05 0.03 8.82 27.74 8.34 2.16 
Tue   0.06 0.03 11.24 21.99 10.72 2.71 
Wed 0.15 1.67 0.03 0.24 8.08 19.46 9.97 2.05 
Thu 0.15 1.83 0.45 0.11 7.6 29.47 10.34 2.12 
Fri 0.16  0.05 0.04 10.5 25.03 13.37 1.50 
Daily average 0.18 1.5 0.13 0.09 9.2 24.7 10.5 2.1 
Ciprofloxacin Mon 0.29 0.02 0.01 0.01 2.21 7.88 2.10 0.85 
Tue   0.02 0.01 1.11 9.16 2.81 1.67 
Wed 0.58 0.03 0.04 0.004 2.15 10.03 2.59 0.75 
Thu 0.39 0.03 0.02 0.18 5.2 12.04 3.05 0.49 
Fri 0.22  0.01 0.01 1.99 8.16 2.78 0.86 
Daily average 0.37 0.03 0.02 0.04 2.5 9.5 2.7 0.9 
Acetaminophen Mon 62.29 2.35 5.87 9.10 1882.5 4,088.9 2,376.6 732.4 
Tue   5.75 11.10 2068.5 3,865.0 2,472.2 701.7 
Wed 44.15 2.83 5.39 10.67 1715.9 4,262.2 2,513.8 709.8 
Thu 46.69 2.09 7.97 10.72 1986.5 3,888.6 2,579.7 750.7 
Fri 31.83  5.33 9.87 1628.0 3,474.8 2,658.8 632.4 
Daily average 46.24 2.4 6.06 10.29 1856.3 3915.9 2520.2 705.4 
Carbamazepine Mon 0.07 0.12 0.01 0.01 6.09 23.95 6.47 0.75 
Tue   0.01 0.01 7.12 17.74 6.01 1.16 
Wed 0.02 0.01 0.02 0.003 23.47 18.55 5.97 0.83 
Thu 0.02 0.08 0.04 0.004 7.52 67.05 6.92 0.79 
Fri 0.04  0.01 0.01 5.35 20.23 6.95 1.21 
Daily average 0.04 0.06 0.02 0.01 9.9 29.5 6.5 0.9 
Metoprolol Mon 0.14 0.02 0.07 0.02 1.11 8.09 8.67 3.05 
Tue   0.13 0.04 4.88 6.57 9.42 2.53 
Wed 0.23 0.03 0.08 0.02 5.42 9.29 8.21 2.42 
Thu 0.18 0.03 0.34 0.03 7.22 7.66 7.61 2.67 
Fri 0.23  0.04 0.02 5.12 8.37 9.88 2.02 
Daily average 0.20 0.03 0.13 0.03 4.8 8.0 8.8 2.5 
Venlafaxine Mon 0.26 0.13 0.04 0.04 14.32 48.89 16.39 4.62 
Tue   0.03 0.02 11.96 44.22 14.45 4.99 
Wed 0.29 1.58 0.16 0.01 10.18 45.61 15.20 4.86 
Thu 0.35 0.72 0.01 0.005 12.88 46.52 16.49 5.01 
Fri 0.30  0.02 0.09 10.33 40.98 19.42 4.60 






Healthcare facility effluent  
(g/day) 
WWTP influents                            
(g/day) 











Mon 0.10 0.04 0.01 0.01 5.62 16.68 7.01 1.58 
Tue   0.02 0.004 3.26 15.37 4.23 1.61 
Wed 0.13 0.02 0.01 - 4.46 15.20 4.69 1.58 
Thu 0.16 0.04 0.00 - 4.02 15.15 4.34 1.94 
Fri 0.19  0.01 0.01 3.15 14.99 4.77 1.55 
Daily average 0.15 0.03 0.01 0.01 4.1 15.5 5.0 1.7 
O-
desmethylvenlafaxine  
Mon 1.34 0.17 0.04 0.11 149.12 151.30 202.73 12.35 
Tue   0.03 0.08 49.51 126.11 106.38 12.88 
Wed 0.29 .2 0.16 0.06 44.01 110.44 120.35 15.38 
Thu 0.35 0.45 0.01 0.09 29.60 103.75 88.84 14.21 
Fri 0.30  0.02 0.27 24.67 119.65 123.71 14.50 
Daily average 0.57 0.2 0.05 0.12 59.38 122.24 128.40 13.86 
 
 
Heberer et al., (2005) measured the weekly load (7 days) of 3.6 g of Carbamazepine (0.514 g/day) in 
a German hospital’s (300 beds) effluent. This value was higher than that found in this study, for 
which the maximum carbamazepine load per day was 0.12 g/day on Monday in the HS2 (263 beds) 
effluent (Table 5-3). This may have resulted from differences in the consumption of Carbamazepine 
between the facilities characterized in the two studies.  
 
5.1 Comparison of Healthcare Facility Effluents for the Mass discharges of 
Target PhACs 
5.1.1 Hospitals (HS1 & HS2) 
The hospital effluent mass flows were compared using analysis of variance (ANOVA) to further 
investigate whether the mass flows of target compounds were significantly different between these 
streams. A comparison between the HS1 and HS2 facility effluents (Table 5-4) indicated significant 
differences existed between these facilities in mass flows of Sulfamethoxazole, Trimethoprim, 
Ciprofloxacin, Acetaminophen, Metoprolol and the metabolite of Venlafaxine N-




Table 5-4 Comparison between HS1 and HS2 effluents for the mass flow of target compounds 
Target Compounds Facility 
Daily Mass Flows (g/day) 
P-value 
Mon Wed Thu Fri 
Sulfamethoxazole 
HS1  0.46 0.41 0.20 0.02 
     HS2 1 1.09 2  
Trimethoprim  
HS1 0.24 0.15 0.15 0.16 0.003 
HS2 0.88 1.67 2  
Ciprofloxacin  
HS1 0.29 0.58 0.39 0.22 0.01 
HS2 0.02 0.03 0.03  
Acetaminophen  
HS1 62 44 47 32 0.002 
HS2 2.35 2.83 2  
Carbamazepine  
HS1 0.07 0.02 0.017 0.04 0.27 
HS2 0.12 0.01 0.08  
Metoprolol  
HS1 0.14 0.23 0.176 0.23 0.001 
HS2 0.02 0.03 0.03  
Venlafaxine  
HS1 0.26 0.29 0.346 0.30 0.2 
HS2 0.13 1.58 1  
N-desmethylvenlafaxine 
HS1 0.10 0.13 0.164 0.19 0.005 
HS2 0.04 0.02 0.04  
O-desmethylvenlafaxine 
HS1 1.34 0.45 0.83 0.56 0.08 
HS2 0.17 0.20 0.45  
 
The higher average mass flows of Ciprofloxacin (370 mg/day), Acetaminophen (46240 mg/day), 
Metoprolol (195 mg/day), and N-desmethylvenlafaxine (140 mg/day) in HS1 effluent than in HS2 
Ciprofloxacin (20 mg/day), Acetaminophen (2320 mg/day), Metoprolol (20 mg/day), and N-
desmethylvenlafaxine (40 mg/day) were likely due to the differences in facility sizes, HS1 (365 beds) 
is relatively bigger than HS2 (263 beds). Additionally there may be seasonal differences in 
consumption; drug purchase data shows relatively higher purchases of Ciprofloxacin, Acetaminophen 




















































Figure 5-1 Ciprofloxacin, Metoprolol and Acetaminophen purchases (Kg) by Ontario hospitals 
in 2009 (IMS Canada)  
The higher average daily mass flows of Sulfamethoxazole (1.4 g/day), Trimethoprim (1.5 g/day), 
Carbamazepine (0.1 g/day) and Venlafaxine (0.8 g/day) in HS2 effluent, a relatively smaller facility 
than HS1, may have been due to seasonal variations in pharmaceutical consumption and differences in 
the services provided by each facility. Higher WWTP influent Sulfamethoxazole loads in winters than 
in summer have been reported by (Castiglioni et al., 2006). 
 
The elevated mass flow from the smaller hospital may have been due to differences in the services 
between the two hospitals. The presence of the cancer clinic in HS2 may lead to higher mass 
discharges of Venlafaxine in its effluent than in HS1’s. The higher detected concentration of 
Venlafaxine in the cancer clinic effluent (36 g/L) supports this assumption (Figure 4-12). These 
findings suggest that the information about the number of beds in a hospital is not enough data to 
explain the mass flows of target compounds in its effluent. The type of services available in the 








5.1.2  Long-Term-Care Homes (LTC1 & LTC2) 
The long-term-care home effluents were compared to identify differences between these streams for 
the daily mass flows of target compounds.  The homes differed slightly in terms of size (LTC1 has 
228 beds and LTC2 has 200 beds) and location. However no significant difference was detected 
between these streams (Table 5-5) except in the mass flow of Acetaminophen (P = 0.000), which was 
higher (10290 mg/day) for LTC2 than for LTC1 (6062 mg/day). 
The similar mass flows for most of the compounds may have occurred because long-term-care homes 
provide similar services, the residents are relatively homogenous group (the elderly), and also the 
facility sizes were not substantially different. The significant differences in Acetaminophen mass 
flows between the homes of almost the same size is an interesting finding, potentially occurs due to 
different approaches to medication, but needs need further investigation for other possible causes. 
 
Table 5-5 Comparison between LTC1 and LTC2 effluents for the mean mass flows of target 
                 compounds 
Target Compounds Facility 
Daily Mass Flows (g/day) 
P-value 
Mon Tue Wed Thu Fri 
Sulfamethoxazole  
LTC1 0.026 0.157 0.010 0.006 0.023 
0.83 
LTC2 0.074 0.013 0.090 0.049 0.033 
Trimethoprim 
LTC1 0.050 0.063 0.031 0.451 0.048 
0.66 
LTC2 0.030 0.029 0.241 0.106 0.037 
Ciprofloxacin  
LTC1 0.014 0.024 0.041 0.015 0.015 
0.61 
LTC2 0.006 0.005 0.004 0.184 0.005 
Acetaminophen  
LTC1 5.868 5.749 5.393 7.971 5.329 
0.000 
LTC2 9.103 11.10 10.67 10.72 9.870 
Carbamazepine  
LTC1 0.012 0.010 0.017 0.036 0.012 
0.054 
LTC2 0.008 0.008 0.003 0.004 0.010 
Metoprolol  
LTC1 0.071 0.129 0.078 0.337 0.037 
0.094 
LTC2 0.025 0.040 0.024 0.032 0.020 
Venlafaxine  
LTC1 0.037 0.028 0.156 0.007 0.017 
0.62 
LTC2 0.042 0.018 0.012 0.005 0.090 
N-desmethylvenlafaxine  
LTC1 0.009 0.018 0.006 0.003 0.009 
0.56 
LTC2 0.015 0.004 0.000 0.000 0.014 
O-desmethylvenlafaxine  
LTC1 0.089 0.087 0.156 0.022 0.479 
0.62 




Relatively higher mass flows were observed in the hospital effluents than in the long-term-care homes 
(Table 5-3). This difference perhaps occurred because more pharmaceutical compounds are 
consumed in hospitals than in long-term-care homes as all the people admitted in hospitals are 
presumably ill and often need drug therapy. While in long term-care homes only a fraction of the 
population is expected to receive pharmaceutical compounds for any given time, resulting higher 
mass flows in hospital effluents.  
The mass flows of target compounds in long-term-care homes over the weekdays indicate that only 
Acetaminophen is regularly being used in long-term-care homes (Table 5-5). The mass flow of this 
compound varied between 9 and 11 g/day in LTC2 effluent and in LTC1 effluent it varied only 
between 5.3 and 5.8 g/day except on Thursday (7.9 g/day).  
5.2 WWTP Influent Mass Flows and Per-Capita Mass Contributions 
Per-capita mass contribution is often used to predict mass flows of PhACs to WWTPs, and is usually 
calculated using county-level prescription or sales data along with the pharmacokinetic properties of 
the PhACs. The estimated figures are then assumed to be uniformly distributed over the year and 
throughout the geographical area. To test this assumption for this study the per-capita mass 
contributions to each WWTP influent load were calculated.  In the per-capita mass contributions only 
parent compounds were considered because the metabolites are generated by the breakdown of parent 
compounds, and once the mass of the parent compounds is known, the mass of the metabolites can be 
estimated using the pharmacokinetic relationship between the parent compound and its metabolites. 
In addition the sales and prescription data is not applicable to the metabolites, so comparison with the 
sales data is only possible for the parent compounds. 
 The per-capita mass contribution of the target PhACs to the influent load of WWTPs was calculated 
by dividing WWTP influent mass flows of the target PhACs by the size of the WWTPs (population 
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Table 5-6 Per-capita mass contribution range to the WWTPs   
Compound Range 
Per-Capita Mass inflow (mg/day) 
WWTP-HS1 WWTP-HS2 WWTP-LTC1 WWTP-LTC2 
Sulfamethoxazole 
Min 0.166 0.113 0.174 0.114 
Max 0.322 0.301 0.218 0.182 
Trimethoprim 
Min 0.148 0.114 0.104 0.045 
Max 0.219 0.172 0.167 0.082 
Ciprofloxacin 
Min 0.022 0.046 0.026 0.015 
Max 0.102 0.071 0.038 0.051 
Acetaminophen 
Min 31.78 20.32 29.70 19.16 
Max 40.38 24.92 33.23 22.75 
Carbamazepine 
Min 0.104 0.104 0.075 0.023 
Max 0.458 0.392 0.087 0.037 
Metoprolol  
Min 0.022 0.038 0.095 0.061 
Max 0.141 0.054 0.123 0.092 
Venlafaxine  
Min 0.199 0.240 0.181 0.139 
Max 0.280 0.286 0.243 0.152 
 
Table 5-6 shows the range of per-capita mass contributions to the influent load of each investigated 
wastewater treatment facility. The differences in the per-capita-per-day mass contributions, estimated 
using data for the four different facilities, were apparently caused by regional differences in PhAC 
consumption. Relatively higher per-capita-per-day mass contributions of Sulfamethoxazole, 
Trimethoprim, Ciprofloxacin, Carbamazepine and Venlafaxine were observed for WWTP-HS1 and 
WWTP-HS2 (Figure 5-3). These differences may be attributed to the presence of hospitals in these 
communities. The per-capita contribution of Acetaminophen varied between all the communities with 
the lowest value of 19-22 mg/day for the community of size 30,000 (WWTP-LTC2) and highest value 
of 31-40 mg/day for the WWTP-HS2 which serves for 51218 people (Table 5-6). These findings 
suggest that the assumption in the prediction models, that pharmaceutical consumption is evenly 
distributed over a year and throughout geographical locations may not hold true for all compounds. 
The per-capita values from Table 5-6 is plotted in Figure 5-3 to better visualize the range of values in 
investigated communities and to compare these with each other. 
 
A comparison of these results with other WWTP influent studies showed differences in 
Carbamazepine per-capita contributions and comparable values for Sulfamethoxazole contributions. 
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Heberer et al., (2005) found the mass flow of carbamazepine in the influent of  a WWTP that served 1 
million people to be 3218 g/week, giving a per-capita-per-day mass contribution of 0.46 mg/day, 
which was slightly higher than that found in this study (max 0.32mg). A Sulfamethoxazole load of 
209 mg/1000 inhabitants in the influent of a WWTP in Italy was reported in winter (January to 
March) and was comparable to the maximum influent loads of WWTP-LTC1 and WWTP-LTC2 that 
were sampled in February and March (208 and 182 mg/1000 inhabitants respectively) (Castiglioni et 
















































































































































































































5.2.1 Mass contribution of PhACs Per- bed to Effluents  
Estimating the per-bed mass contribution of target compounds allows comparison of healthcare 
facilities regardless of their size. It may be used to extend the results from one facility to estimate the 
discharges of PhACs by the other similar type of facilities. The per-bed mass contributions of all the 
four investigated healthcare facility effluents were determined. To calculate mass flow per-bed-per-
day, the daily mass flow of target PhACs in the effluent of each healthcare facility was divided by its 
number of beds, as described in Equation 5.3.  
 




The calculated per bed mass contributions of the target PhACs to the effluent load of each facility are 
shown in Tables 5-7 and 5-8.  The results indicate (Table-5-7) that in the case of hospitals, 
considerable differences existed between the facilities in the average per bed contribution of all target 
PhACs. These differences may have been caused by seasonal variations in pharmaceutical 
consumption or by differences in the services provided by the facilities. For example (Table 5-7) the 
mean per-bed mass contributions of Sulfamethoxazole and Trimethoprim in HS1 were 0.99 mg/day 
and 0.47 mg/day, while in HS2, these contributions were is 4 and 4.2 mg/day. The per-bed mass flow 
of ciprofloxacin was 10 times higher in HS1 than in HS2.  The per-bed contribution range of 
Acetaminophen in HS1 was 87-170 mg/day while in HS2 this range was 7.7-10.7 mg/day. These 
findings suggest that knowing only the number of beds for a healthcare facility is not sufficient to 
predict the mass flow of any particular PhAC in its wastewater. The number of staffed and in-
operation beds for any type and level of service may impact on the mass flow of PhACs related to that 
service. Since group-wise (for condition being treated/ investigated) breakdown of the number of 
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Table 5-7 Per-bed mass contribution of target PhACs to each hospital effluent  
Target Compounds Facility 
Mass discharge (g/day) 
Number of 
Beds 
Per Bed Mass 
Contribution (mg/day) 
Min Max Mean Min Max Mean 
Sulfamethoxazole 
HS1 0.20 0.46 0.36 365 0.56 1.27 0.99 
HS2 1.09 1.94 1.40 263 4.15 7.37 5.32 
Trimethoprim 
HS1 0.15 0.24 0.17 365 0.40 0.65 0.47 
HS2 0.88 1.83 1.46 263 3.33 6.96 5.55 
Ciprofloxacin 
HS1 0.22 0.58 0.37 365 0.59 1.58 1.01 
HS2 0.02 0.03 0.03 263 0.08 0.11 0.10 
Acetaminophen  
HS1 31.83 62.29 46.24 365 87.20 170.66 126.68 
HS2 2.09 2.83 2.42 263 7.94 10.77 9.21 
Carbamazepine 
HS1 0.02 0.07 0.03 365 0.04 0.18 0.10 
HS2 0.01 0.12 0.07 263 0.05 0.46 0.27 
Metoprolol 
HS1 0.14 0.23 0.19 365 0.39 0.63 0.53 
HS2 0.02 0.03 0.03 263 0.06 0.13 0.10 
Venlafaxine 
HS1 0.26 0.35 0.30 365 0.70 0.95 0.82 
HS2 0.13 1.58 0.81 263 0.51 6.00 3.08 
N-desmethylvenlafaxine  
HS1 0.10 0.19 0.15 365 0.28 0.53 0.40 
HS2 0.02 0.04 0.03 263 0.07 0.16 0.12 
O-desmethylvenlafaxine 
HS1 0.45 1.34 0.80 365 1.23 3.66 2.18 
HS2 0.17 0.45 0.27 263 0.64 1.71 1.04 
 
 
The calculated per-bed mass contributions to the long-term-care home effluents are presented in 
Table 5-8. These values could be considered representative of the per-capita mass contribution by the 
elderly population (as each bed is assigned to one person). A comparison of these values with the per-
capita contributions by the community (mixed aged group) calculated in Table 5-6, showed relatively 
higher mass contribution of certain compounds by the elderly population than the mixed population in 
the community. For example, Acetaminophen which is often used in communities had a maximum 
per-capita range in WWTP-HS1 of 31-40 mg/day (Table 5-6), while the per-capita contribution by the 
elderly (per-bed mass contribution) was 45-55 mg/day. The Metoprolol maximum per-capita 
contribution range for the community was 0.1-0.2 mg/day, and its maximum contribution by the 





Table 5-8 Per-bed mass contribution of target PhACs to each long-term-care home effluent 
Target Compounds Facility 
Mass discharge (g/day) 
Number of 
Beds 
Per Bed Mass 
Contribution (mg/day) 
Min Max Min Max 
Sulfamethoxazole 
LTC1 0.006 0.157 228 0.028 0.689 
LTC2 0.013 0.090 200 0.063 0.448 
Trimethoprim 
LTC1 0.031 0.451 228 0.136 1.976 
LTC2 0.029 0.241 200 0.146 1.203 
Ciprofloxacin 
LTC1 0.014 0.041 228 0.059 0.182 
LTC2 0.004 0.184 200 0.020 0.919 
Acetaminophen  
LTC1 5.32 7.97 228 23.37 34.95 
LTC2 9.10 11.10 200 45.51 55.51 
Carbamazepine 
LTC1 0.010 0.036 228 0.046 0.158 
LTC2 0.003 0.010 200 0.014 0.048 
Metoprolol 
LTC1 0.037 0.337 228 0.163 1.479 
LTC2 0.020 0.040 200 0.098 0.200 
Venlafaxine 
LTC1 0.007 0.156 228 0.033 0.684 
LTC2 0.005 0.090 200 0.023 0.448 
N-desmethylvenlafaxine  
LTC1 0.003 0.018 228 0.013 0.080 
LTC2 0.000 0.015 200 0.000 0.074 
O-desmethylvenlafaxine 
LTC1 0.022 0.479 228 0.097 2.101 

















The per-bed contributions of the target PhACs to each healthcare facility’s effluent load were 
compared using ANOVA. The P-values for the comparisons are presented in Table 5-9. 
 
Table 5-9 Comparison of Healthcare facility effluent results for per bed contribution of target 
                    PhACs    







Target compounds P-value 
Sulfamethoxazole  0.015 0.673 
Trimethoprim 0.003 0.773 
Ciprofloxacin 0.015 0.562 
Acetaminophen 0.002 0.000 
Carbamazepine  0.160 0.076 
Metoprolol 0.002 0.106 
Venlafaxine 0.150 0.736 
N-desmethylvenlafaxine  0.010 0.739 
O-desmethylvenlafaxine  0.163 0.765 
 
The highlighted P-values in Table 5-19 show the significant differences in per-bed mass 
contributions to each facility’s effluent. More compounds showed significant differences in hospitals 
than in long-term-care homes. The per-bed contributions of Sulfamethoxazole, Trimethoprim 
Ciprofloxacin, Acetaminophen, Metoprolol, and N-desmethylvenlafaxine were significantly different 
between the two investigated hospitals (HS1 and HS2). Seasonal variations may have contributed to 
these differences, as HS1 and HS2 were sampled in July and November respectively.  In the long-
term-care homes, the per-bed contribution of only Acetaminophen was significantly different between 
the two homes.  These findings may be explained by the similar services provided in the long term 
care homes, as compared to the hospitals.  
The significant differences in the per-bed contributions of six out of nine target compounds 
between the two hospitals which are located in different communities, but in the same region, 
undermine the idea of using per-bed contributions of one facility to estimate the discharges of PhACs 




5.2.2 Comparison with other Hospital Effluent Studies  
The reported mass flows per-bed of the PhACs in the hospital effluents, in various studies shows that 
there are considerable variations in the per-bed mass contributions of different-sized hospitals. Table 
5-10 shows the results of this study and those of others; HS3 (Heberer et al., 2005) and HS4 (Thomas 
et al., 2007). The per-bed mass flow of Carbamazepine (HS3 in Table 5-9) was higher (1.71 mg/day) 
than that in this study (0.27 and 0.1 mg/day). Similarly, the per-bed contributions reported (HS4 in 
Table 5-9) for Ciprofloxacin (23.91 mg/day) and Metoprolol (0.92 mg/day) were higher than that 
found in this study (between 0.1 and 1 mg/day). In contrast, the per-bed mass flows of 
Sulfamethoxazole (5.52 mg/day), Trimethoprim (5.5 mg/day), and Acetaminophen (126.8 mg/day) 
were higher in this study than the other two studies (0.25, 1.83, 46.6 mg/day respectively). Therefore, 
it would appear that the mass flows in hospital effluents are not related to facility size only, as defined 
by number of beds, but services provided by each facility need to be considered and further research 
about the causes of variability need to be investigated.  
 
Table 5-10  Per-bed mass contributions of target PhACs to hospital effluents, comparison with 
                    other studies.   
Target PhACs  
Mass flows in hospital effluents (mg/bed /day) 
        263
a
(This Study)      300
a
 (HS3)       365
a
(This Study)       1200
a
 (HS4) 
Sulfamethoxazole 5.32  0.98 0.25 
Trimethoprim 5.55  0.48 1.83 
Ciprofloxacin 0.10  1.01 23.91 
Acetaminophen 9.21  126.68 46.66 
Carbamazepine 0.27 1.71 0.10  
Metoprolol 0.10  0.53 0.92 
Venlafaxine 3.08  0.82  
The average mass flows are divided with the number of hospital beds 
a






Contribution of Target PhACs by Healthcare Facilities to WWTPs 
 
Healthcare facilities, especially hospitals are suspected to be the major contributors of PhACs to 
WWTPs because they use considerable amounts of these compounds. To investigate this assumption 
the relative contributions of hospitals and long-term-care homes to their respective downstream 
WWTPs were studied. The mass flow of the target PhACs discharged by each investigated healthcare 
facility was compared with the mass flow entering the respective downstream WWTPs. The relative 
contributions were calculated using mass balances. An important consideration in this comparison is 
the sewer travel times. Sewer travel time (for this study) was defined as ―the time taken by the 
pharmaceutical compound to travel from the sampling point at the healthcare facility (discharge 
point) to the sampling point at the influent of its downstream WWTP‖. It was appropriate to compare 
same day composite samples from the two points only when the sewer-travel times were in a 
reasonable range (< 6 hours was assumed for this study using 24-hours composite samples).  
Sewer travel times were estimated using a minimum sewer velocity of 2 ft/sec (Stephenson, 1998), 
and sewer line lengths were estimated based on measurements taken of the roads running above them. 
Table 6-1 shows the estimated travel times between the investigated healthcare facilities and their 
respective downstream WWTPs.     
A maximum sewer travel time of five hours was found between LTC1 and WWTP-LTC1 (Table 6-
1); for the rest of the healthcare facilities, it varied from <1 to 3 hours. This finding suggests that for 
24- hour composite samples, the healthcare facility effluents arrive on the same day (24 hours) in the 


















time      
(hr) 
HS1 WWTP-HS1 7000 36.57 191 3 
HS2 WWTP-HS2 1000 36.57 27 0.5 
LTC1 WWTP-LTC1 11000 36.57 300 5 




6.1 Target Compound Contributions by Healthcare Facilities to WWTPs 
 
The relative contribution of PhACs by the healthcare facilities to their respective WWTPs’ influent 
loads were calculated using mass balances. The mass flows of the target compounds in the healthcare 
facility effluents during 24 hours and the total influent loads of these compounds in the respective 
downstream WWTPs were compared to estimate the relative contributions by the investigated 
facilities. For example the contribution of Sulfamethoxazole by the HS1 to its downstream WWTP 
(WWTP-HS1) is presented in Table 6-2. This table shows that the mass of Sulfamethoxazole 
discharged by HS1 on Wednesday was 0.46 g, which was calculated by multiplying column (1) and 
column (2) of Table 6-2 (Results were then multiplied by 10
-6
 for unit conversions). Similarly the 
influent mass of WWTP-HS1was calculated using column (4) and (5), which yielded 10.98 g for that 
day. Thus, the contribution of HS1 for Sulfamethoxazole on Wednesday (0.46 g) was 4.2% of the 
total influent mass flow of WWTP-HS1 (10.98 g) for that day. Likewise, the daily mass contributions 
of the target compounds by the healthcare facilities to their respective WWTPs were calculated and 






































Sulfamethoxazole Wed 996.0 464.4 0.46 420 26157 10.98 4.2 % 
Thu 888.0 464.4 0.41 171 49779 8.49 4.8 % 
Fri 440.0 464.4 0.20 277 31798 8.81 2.3 % 
Conc = Concentration 
Avg  =  Average  





The contribution of the target compounds by the HS1 facility (Figure 6-1) to the influent load of 
WWTP-HS1 varied over the week days. The contribution varied from 7.5 to 26.7 % for Ciprofloxacin, 
2.4 to 13% for Metoprolol, 2 to 6% for N-desmethylvenlafaxine, 3 to 5% for Sulfamethoxazole, 2 to 
3% for Acetaminophen, 1 to 3% for Venlafaxine and O-desmethylvenlafaxine, 1.5 to 2.5% for 
Trimethoprim, and <1 to 1% for Carbamazepine. The Ciprofloxacin contribution of HS1 was greater 





































The contribution of Trimethoprim, Sulfamethoxazole and Venlafaxine by HS2 to WWTP-HS2 over 
the weekdays varied between 3 and 8.5 %; 2 and 5.6 %; and <1 and 3.4 % respectively (Figure 6-2). 
For the rest of the target compounds its contribution was less than 1%.   




















































The maximum contribution of the target compounds by LTC1 facility to the WWTP-LTC1 was 4.4% 
for Metoprolol (Thursday) and 4.3% of Trimethoprim (Thursday) (Figure 6-3). For the rest of the 
target compounds its contribution was less than 2%. 
 
 




































The maximum contributions of the target compounds by the LTC2 facility to WWTP-LTC2 were 37% 
for Ciprofloxacin, 11.7% for Trimethoprim (Figure 6-4). For all other target compounds its 
contributions was less than 2%. The highest Ciprofloxacin contribution by LTC2 was observed on 
Thursday (37%), and for the rest of the week days, the contribution of this compound was less than 
1%.   
 
 



















































The individual contribution peaks for certain compounds (Figures 6-1 to 6-4) reveal the importance of 
monitoring contributions of PhACs over a reasonable period of time. For instance the contribution of 
Ciprofloxacin by LTC2 to WWTP-LTC2 on Thursday was 37% (Figure 6-4). For the rest of the 
weekdays, its contribution was less than 1%.  Furthermore, the contributions by the healthcare 
facilities varied over the weekdays, with maximum values on a particular day; for example, the 
contribution of Ciprofloxacin by HS1 to WWTP-HS1 was 13% on Monday, 26.7% on Wednesday 
(max), 7.5% on Thursday, and 10.8% on Friday. Therefore, in the first case the 37% contribution, 
which had no apparent relation/trends with other weekdays, was likely to be caused by the disposal of 
un-needed and expired compounds. But in the second case, the 26.7% contribution by HS1, which 
showed an increasing trend from Monday to Wednesday, decreased on Thursday and started to rise 
on Friday, perhaps indicating therapeutic use. Only week-long sampling could identify individual 
spikes and trends and gives a clear picture. Shorter sampling events (one to two days) cannot identify 
such incidents and may provide misleading findings.  
 
The differences between the investigated hospitals in their contribution of target PhACs to the 
respective downstream WWTP loads can be explained by the differences in facility sizes. Higher 
contributions were observed for HS1 than HS2. HS1 was a relatively lager hospital (365 beds) than 
HS2 (263 beds). In contrast WWTP-HS1 (which received discharges from HS1) was a smaller facility 
(serving a community of 51,218 people) than WWTP-HS2 (171000 people). Thus, the effluent from 
the relatively bigger hospital (HS1) was discharged to a relatively smaller WWTP (WWTP-HS1) and 
vice-versa, which led to relatively higher contributions by HS1 than HS2. Similarly, higher 
contributions by LTC2 than LTC1 were probably caused by the relatively smaller community that 
contributed to the total pharmaceutical load of WWTP-LTC2 than that for WWTP-LTC1. WWTP-
LTC1 was more than double in size (80000 population) than WWTP- LTC2 (33000 population). This 
suggests that, in any comparison of healthcare facilities of their contribution of PhACs to downstream 
WWTPs, the size of the WWTPs should be considered in addition to facility sizes.  
 
Based on the maximum contributions by the investigated healthcare facilities to their respective 
WWTPs, the target PhACs could be divided into three groups. 1) compounds whose hospital 
contributions were below 5% (Acetaminophen, Carbamazepine, Venlafaxine and O-
desmethylvenlafaxine). Four compounds out of nine were in this group. 2) Contributions between 5 
and 15% (Sulfamethoxazole, Trimethoprim, Metoprolol and N-desmethylvenlafaxine), four 
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compounds were belong to this group. 3) Compounds whose hospital contribution exceeded 15% 
(Ciprofloxacin). Only one compound was found to be in this group. The average contribution of 
Ciprofloxacin by HS1 to WWTP-HS1 was 14.6%.  
 
The weekly maximum contributions by the long-term-care homes to the WWTP loads were less than 
5% for seven compounds. One compound (Trimethoprim) was between 5 to 15%, and one compound 
was more than 15% (Ciprofloxacin); the maximum observed contribution of Ciprofloxacin was 37% 






6.2 Comparison between the Healthcare Facilities for their Contribution of     
PhACs to WWTPs 
 Unlike mass flows of the target compounds in the healthcare facility effluents, seasonal variations are 
not expected to affect the contribution of these compounds by the facilities to the downstream 
WWTPs; as seasonal differences probably affect all the possible sources contributing to the loads of 
WWTPs in the same way.  Thus, PhAC contributions by the healthcare facilities were assumed to be 
a function of facility sizes and their service spectrum. Further, the facilities were located in different 
areas, and their effluents were discharged to different-sized WWTPs; thus, the additional factor 
affecting contributions may be the size of the communities that contribute PhAC loads to the same 
WWTPs. To study the effects of these factors, the investigated healthcare facilities were compared for 
their contributions to the respective WWTP influent loads using one-way ANOVA.  
 A comparison between HS1 and HS2 showed no significant differences in the contribution of 
Sulfamethoxazole, Carbamazepine, Metoprolol, and Venlafaxine. Significant differences were 
observed in Trimethoprim, Ciprofloxacin, Acetaminophen and Venlafaxine metabolites (P-values 
highlighted red in Table 6-2).   
Table 6-3 Target compound contributions by hospitals to respective downstream WWTPs 
Target Compounds Facility 
Contributions to the WWTPs (%) 
P-value 
Mon Wed Thu Fri 
Sulfamethoxazole 
HS1   4.21 4.86 2.32 0.662 
     HS2 2.27 5.65 5.34  
Trimethoprim  
HS1 2.70 1.84 1.92 1.49 0.031 
HS2 3.16 8.58 6.21  
Ciprofloxacin  
HS1 13.3 26.7 7.53 10.8 0.035 
HS2 0.27 0.30 0.23  
Acetaminophen  
HS1 3.31 2.57 2.35 1.95 0.001 
HS2 0.06 0.07 0.05  
Carbamazepine  
HS1 1.10 0.07 0.22 0.75 0.365 
HS2 0.50 0.07 0.12  
Metoprolol  
HS1 12.8 4.20 2.43 4.47 0.095 
HS2 0.19 0.37 0.40  
Venlafaxine  
HS1 1.79 2.87 2.68 2.91 0.380 
HS2 0.28 3.46 1.55  
N-desmethylvenlafaxine 
HS1 1.79 2.95 4.08 6.12 0.023 
HS2 0.23 0.12 0.28  
O-desmethylvenlafaxine 
HS1 0.90 1.02 2.82 2.29 0.044 




The similar contributions of Sulfamethoxazole and Venlafaxine compounds by HS1 and HS2 was due 
to the fact that the differences in mass flows of these compounds in their effluents were compensated 
for by the differences in the sizes of their respective WWTPs.  Higher mass flows of these 
compounds were observed in HS2 effluent than in HS1. The average mass flows of Sulfamethoxazole 
and Venlafaxine in HS2 effluent were 1400 and 800 mg/day as compared to 360 and 300 mg/day in 
HS1. However, the HS2 effluent was discharged to a relatively bigger wastewater treatment facility 
(WWTP-HS2) with mean influent loads of Sulfamethoxazole and Venlafaxine of 36700 and 45200 
mg/day, respectively, as compared to WWTP-HS1, with influent loads of Sulfamethoxazole (11200 
mg/day) and Venlafaxine (11900 mg/day). This reversal in proportion led to similar overall 
contributions.  
Similarly, the daily mass flow of Carbamazepine (60 mg) was higher in the HS2 effluent than in 
HS1 (40 mg). However, WWTP-HS2 had daily average Carbamazepine load of 29500 mg, as 
compared to 9900 mg and in WWTP-HS1. Thus, the overall contributions by the two hospitals to their 
respective WWTPs were found to be same. 
In contrast, the daily mass flows of Ciprofloxacin (370 mg), Acetaminophen (46240 mg), N-
desmethylvenlafaxine (150 mg) and O-desmethylvenlafaxine (570 mg) were higher in the HS1 
effluent than in HS2 (30, 2400, 30, 200 mg respectively). The higher mass flows from HS1 were 
discharged to relatively smaller a WWTP than from HS2 leading to higher contributions by HS1 than 
HS2 to their respective WWTPs.  
The contribution of Metoprolol by HS1 and HS2 were not statistically different, due to the higher 
variability in day-to-day contributions the HS1. The contributions by HS1 varied from 2.4 to 12.8% as 
compared to HS2 (<1%). This discrepancy was probably due to the higher mass flows of Metoprolol 
in HS1 and also because its effluent was discharged to a relatively smaller than WWTP compared to 
HS2. In summary, the data on hospital sizes along with corresponding WWTP’s size defines the 
relative contributions by hospitals to WWTPs.  
The mass flow of Trimethoprim was higher in the HS2 effluent than in the HS1’effluent (1500 and 
180 mg/day respectively). Although the HS2 effluent discharged into a larger WWTP, the difference 
between the WWTP influent mass flows for this compound was less than the difference between the 
mass discharged by these facilities (WWTP-HS2 and WWTP-HS1 influent mass flow were 24.7 and 
9.2 g/day respectively), leading to different overall contributions.     
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A comparison between LTC1 and LTC2 (Table 6-4) for their contributions to the respective WWTP 
influent loads showed no significant difference in the contributions of Trimethoprim, Ciprofloxacin, 
Metoprolol, Venlafaxine and N-desmethylvenlafaxine.  Significant differences were observed in 
Sulfamethoxazole, Acetaminophen, Carbamazepine, and O-desmethylvenlafaxine contributions.   
 
Table 6-4 Contribution of target PhACs by long-term-care homes to respective downstream 
                  WWTPs  
Target Compounds Facility 
Contribution to the WWTPs (%) 
P-value 
Mon Tue Wed Thu Fri 
Sulfamethoxazole  
LTC1 0.16 1.13 0.06 0.04 0.13 
0.04 
LTC2 1.45 0.21 1.70 1.27 0.86 
Trimethoprim 
LTC1 0.60 0.59 0.31 4.36 0.36 
0.18 
LTC2 1.38 1.08 11.71 4.98 2.48 
Ciprofloxacin  
LTC1 0.64 0.84 1.60 0.51 0.53 
0.36 
LTC2 0.73 0.30 0.52 37.27 0.62 
Acetaminophen  
LTC1 0.25 0.23 0.21 0.31 0.20 
000 
LTC2 1.24 1.58 1.50 1.43 1.56 
Carbamazepine  
LTC1 0.19 0.17 0.29 0.52 0.17 
0.01 
LTC2 1.07 0.73 0.33 0.53 0.80 
Metoprolol  
LTC1 0.82 1.36 0.94 4.43 0.38 
0.53 
LTC2 0.81 1.59 0.99 1.18 0.97 
Venlafaxine  
LTC1 0.23 0.20 1.03 0.05 0.09 
0.33 
LTC2 0.90 0.36 0.25 0.09 1.95 
N-desmethylvenlafaxine  
LTC1 0.12 0.43 0.14 0.07 0.19 
0.32 
LTC2 0.94 0.26 0.00 0.00 0.91 
O-desmethylvenlafaxine  
LTC1 0.04 0.08 0.13 0.02 0.39 
0.02 
LTC2 0.90 0.60 0.39 0.65 1.83 
Long-term-care homes provide similar services; therefore, the mass flows of the target PhACs in 
their effluents were not significantly different except for Acetaminophen (Table 6-4).  Differences in 
the contributions by each home presumably depend on the size of the downstream WWTPs. 
Additional consideration may be other healthcare facilities upstream of the respective WWTPs. 
WWTP-LTC1 has a small hospital (68 beds) upstream, thus leading to lower overall contributions 
from LTC1 to WWTP-LTC1.  The highest contribution of Ciprofloxacin by LTC2 was 37%, as 
compared to 1.6% by LTC1, but since this finding was a single event, the contributions were not 
found to be significantly different.  
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6.3 Comparison with other Hospital Effluent Studies 
The contributions of target compounds by the investigated hospitals were compared with findings 
from other hospital studies (Table 6-5). Higher contributions of Sulfamethoxazole and Metoprolol 
(5.6 and 12.8 % respectively) were observed in this study than those reported in the other hospital 
studies (2.5 % for Sulfamethoxazole and 7 % for Metoprolol). In contrast, lower contributions of 
Trimethoprim (3 and 8.5%) and Acetaminophen (0.1 and 3.3 %) were observed in this study than in 
other studies (18.3 and 10.5 % of Trimethoprim and 5.8 and 9.8 % of Acetaminophen). The 
contribution of Carbamazepine by the hospitals investigated had a similar contribution range (0.5 and 
1 %) to that reported in other hospital studies (0.5 and 1.3 %).  
 
Table 6-5 : Comparison with other studies for maximum contributions from the hospitals to the 
                    downstream WWTPs 
Target 
Compounds 













Sulfamethoxazole 365 51218 7.1 5 This study 
200 45000 4.4 2.2 (Ort et al., 2010) 
1200 440000 2.7 <1 (Thomas et al., 2007) 
263 171000 1.5 5.6 This study 
Trimethoprim 200 45000 4.4 18.3 (Ort et al., 2010) 
1200 440000 2.7 10.5 (Thomas et al., 2007) 
263 171000 1.5 8.5 This study 
365 51218 7.1 3 This study 
Carbamazepine  200 45000 4.4 1.3 (Ort et al., 2010) 
263 171000 1.5 0.5 This study 
300 1000000 0.3 0.5 (T. Heberer et al., 2005) 
365 51218 7.1 1 This study 
 Metoprolol 365 51218 7.1 12.8 This study 
200 45000 4.4 7 (Ort et al., 2010) 
1200 440000 2.7 <1 (Thomas et al., 2007) 
263 171000 1.5 0.5 This study 
Acetaminophen  200 45000 4.4 9.8 (Ort et al., 2010) 
1200 440000 2.7 5.8 (Thomas et al., 2007) 
263 171000 1.5 0.1 This study 
365 51218 7.1 3.3 This study 
 
The differences in contributions of target compounds by the hospitals to their respective WWTPs 
(Table 6-5) can be explained by, the differences in the relative sizes of the hospitals to their 
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community. The capacity of the hospital (number of beds per 1000 population) that relates the size of 
the hospital to its community size can be used to illustrate this assumption. Relatively higher 
contributions were observed for the hospitals with higher bed capacity. For instance, contributions of 
Sulfamethoxazole by hospitals with capacities of 7.1, 4.4, and 2.7 beds/1000 population to their 
respective WWTPs were respectively 5, 2.2, <1 %. Similarly, Trimethoprim contributions by 
hospitals with a capacity of 4.4, 2.7, and 1.5 beds/1000 population were 18.3, 10.5, and 8.5 % 
respectively. This concept held true for all compounds in most of the hospitals, as shown in Table 6-5 
(green background).  
 
The contributions of the investigated long-term-care homes followed similar patterns; a higher 
contribution of target compounds was observed for LTC2 (capacity 6 beds/1000 population) than for 
LTC1 (capacity of 2.8 beds/1000 population). Thus, based on the available data, it is concluded that 
the capacity of the hospital may be a useful indicator of relative contributions by hospitals to their 
local WWTPs. 
 
In addition the services provided by the hospitals are important, as some provide more specialized 
types of treatment than others; thus, compounds specific to their specialty have a higher probability of 
being contributed by these facilities. The higher contribution (5.5 %) of Sulfamethoxazole by the 
hospital of lower capacity (1.5 beds/1000 population), presumably occurred because the difference in 
the service spectrum (Table 6-5). Similarly, lower contributions of Trimethoprim, Carbamazepine and 
Acetaminophen by a hospital with higher capacity (7.1 beds/1000 population) may be attributed to 
such differences. These findings indicate that in addition to the size of the hospital, it is also important 
to identify the services provided by the hospitals while comparing the results.  
 
In this study only parent compounds were investigated, with the exception of the antidepressant 
Venlafaxine, therefore, the results may under estimate the contributions by healthcare facilities of 
certain compounds that are excreted in conjugated forms in considerable amounts. Studies have 
revealed that the conjugates (i.e., glucuronides) may be cleaved back to the parent compound during 
sewer transit (Ascenzo et al., 2003; Johnson et al., 2004). For example 93% of Acetaminophen is 
excreted as hydrolysable conjugates (Khan et al., 2004). Similarly, up to 50% of Sulfamethoxazole is 
excreted as the metabolite N4-acetylsulfamethoxazole, that has the tendency to cleave back to the 
original compound (Gobel et al., 2005). The conjugates in wastewater are expected to be de-
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conjugated through bacterial hydrolysis, as intestinal bacterial flora (Escherichia coli) have been 
reported to have the ability to transform the conjugates into their parent compounds. This process 
may occur because these organisms (E-coli) synthesize considerable amounts of ß-glucuronidase 
enzyme (Baronti et al., 2000). Eldere et al. (1988) reported that conjugated steroids were mostly de-
conjugated in the large intestine; similarly, Ascenzo et al. (2003) found that most of the fecal 
estrogens were free estrogens (de-conjugated), indicating the ability of the intestinal bacterial flora 
(E-coli) to transform the conjugates into the original compound (de-conjugation). The ability of fecal 
bacterial flora to de-conjugate glucuronide and sulfate conjugates of estrogens has also been reported 
by (Eldere et al., 1988; Lombardi et al., 1977; Ternes et al., 1999). Furthermore, Ascenzo et al., 
(2003) found that de-conjugation of estrogens, especially glucuronated conjugates, occurred during 
the sewer transit from a condominium building to the influent of a WWTP. Since these organisms are 
largely present in sewers, the de-conjugation process is also expected to occur for the pharmaceutical 
compound conjugates in the sewer systems. Hence, Henschel et al., (1997) have suggested that both 
glucuronic and sulfate conjugates of Acetaminophen may transform back to original compound in 
sewers. In short, measurement of conjugates of the compounds would be expected to increase the 
relative contributions of certain compounds by the healthcare facilities.   
 
This study revealed that long-term-care homes may contribute significant amounts of certain 
compounds to WWTPs. Therefore it is important to consider discharges from these facilities in 
addition to hospitals to assess the overall contributions of pharmaceutical loads by the healthcare 









Conclusion and Recommendations  
7.1 Conclusions 
Healthcare institutions are suspected to be the major contributors of pharmaceutical compound loads 
to the aquatic environment. Still, very few studies have exclusively measured their contributions to 
WWTPs. Further, these studies have only considered hospital contributions and totally ignored long 
term care homes, and with this approach they have largely underestimated the overall healthcare 
facility pharmaceutical contributions. This study has considered both types of healthcare facility and 
investigated their effluents for the occurrence of target pharmaceutical compounds, daily mass flows 
and their relative contributions to downstream WWTPs. The results are summarized as follows: 
 
7.1.1 Frequency of Detection and Occurrence of PhACs in Healthcare Facility 
Effluents 
1. All the nine target PhACs were detected in all samples from the hospitals and long term care 
home effluents except one metabolite of the antidepressant venlafaxine (N-
desmethylvenlafaxine). This compound was not detected on two days in the effluent of a 
long-term-care home otherwise it occurred in all samples.  Thus the frequency of detection of 
target PhACs was almost 100%. 
2.  The antibiotic compounds were detected in relatively higher concentrations in hospital 
effluents than in long-term-care homes. The highest detected concentrations in hospital 
effluents were of Sulfamethoxazole (10.9 μg/L), Trimethoprim (10.3 μg/L) and Ciprofloxacin 
(1.24 μg/L), compared to 1.3 μg/L, 6.6 μg/L, and 1.47 μg/L respectively in long-term-care 
home effluents.   
3. Seasonal variations in drug consumption were observed to be affecting the Sulfamethoxazole 
and Trimethoprim concentrations in hospital effluents. For instance higher concentrations of 
these compounds were observed in November than in July. The average detected 
concentration of Sulfamethoxazole (7900 ng/L) and Trimethoprim (8200 ng/L) was in 
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November, compared to 775 ng/L of Sulfamethoxazole and 371 ng/L of Trimethoprim in 
July. 
4. Individual concentration peaks of antibiotic compounds were observed in the long-term-care 
home effluents and are attributed to either a single therapeutic dose or disposal of unneeded 
and expired compounds. This finding also suggests that single-day sampling events may lead 
to inaccurate conclusions about the occurrence of these compounds in healthcare facility 
effluents. Five weekday sampling is recommended to indentify such peaks.  
5. Ciprofloxacin concentrations followed similar patterns over week days in the hospital 
effluents, with lower concentrations on the first and last days of the week (Monday and 
Friday), and maximum were observed on Wednesdays.  
6. Among all the detected compounds, Acetaminophen was the compound in highest 
concentrations in both types of healthcare facility effluents. The Acetaminophen 
concentration was measured in levels up to 134 g/L in hospital and 116 g/L in long-term-
care home effluents.  
7. A higher concentration of Venlafaxine was detected in the effluent of the hospital with a 
cancer clinic; up to 36 g/L of Venlafaxine was measured in this clinic’s effluent.  
8. Target compound concentrations were found to vary more between hospital effluents than 
between long-term-care homes, probably because of the similar services provided by the 
long-term-care homes.  
9. The day-to-day variability in the target compound concentrations was observed to be higher 
in long-term-care home effluents than in hospitals, except for Acetaminophen and 
Carbamazepine. The least variability in Acetaminophen (CV =.08) in long-term-care home 





7.1.2 Mass Flow in healthcare facility effluents and WWTP Influents. 
 
1. The mass flows of target compounds were significantly different between the hospital 
effluents, except for Carbamazepine, Venlafaxine, and O-desmethylvenlafaxine. No 
significant differences were observed between the long-term-care facilities except for 
Acetaminophen.   
2. The per-capita mass contribution of target compounds to the four WWTPs varied, indicating 
that the concentration predictions using typical per-capita mass contributions may lead to 
considerable underestimation of the actual values.  
3. The estimated wastewater flows were 1.8 times higher in the relatively smaller long-term-
care facility (200 beds); a finding that suggests that the mass flow estimates using typical 
average wastewater flows/bed may lead to wide variation to the actual mass flows.  
4.  The larger size hospitals (as defined by the number of beds) do not necessarily discharge all 
pharmaceutical compounds in higher amounts than do smaller hospitals. Rather, the number 
of staffed and in-operation beds can define the expected mass discharges of PhACs into the 
wastewater. 
 
7.1.3 Contributions of PhACs by the Healthcare Facilities to WWTPs  
 
1. Relatively higher contributions of antibiotic compounds by the investigated healthcare 
facilities to the influent load of WWTPs were observed. The maximum contributions of 
antibiotic compounds by hospitals to their respective WWTPs were Sulfamethoxazole 
(10%), Trimethoprim (8.5%), and Ciprofloxacin (26.7%).  The long-term-care home’s 
maximum contributions were 1.7 % for Sulfamethoxazole, 11.7 % for Trimethoprim, and 
37% for Ciprofloxacin.  
2. Up to 12.8% of Metoprolol contribution by hospitals and 4.4% by long-term-care homes 
was observed. For all the other target compounds, the contributions by the investigated 
healthcare facilities were less than 4%.  
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3. Relatively higher contributions of most of the target compounds were observed for 
hospitals with higher bed capacity (number of beds/1000 population). For instance, the 
Sulfamethoxazole contributions by hospitals with bed capacities of 7.1, 4.4 and 2.7 
beds/1000 population were 5, 2.2, and <1% respectively.  
 
4. The target compound contributions by a healthcare facility varies, depending upon the size 
of the facility itself, and the size of the community that contributes pharmaceutical 
compound loads to the same WWTP. For most of the target compounds, higher 
contributions were observed for large size facilities (number of beds) that discharge their 
effluents to WWTPs serving relatively smaller communities.  
 
5. Since hospitals vary considerably in the services they provide, and thus the drugs they use, 
thus the findings of this study may not be representative of all the hospitals (in Ontario). 
Long-term-care homes on the other hand, do tend to provide similar services. This fact is 
supported by statistical findings  
  
 
7.2 Recommendations  
 
1. This study revealed that long-term-care homes can contribute significant amounts of certain 
PhACs to downstream WWTPs. Therefore, these facilities, in addition to hospitals must be 
considered in any assessment of PhAC contributions by healthcare units to downstream 
WWTPs in relations to other sources.  
2. The direct involvement of hospitals in hospital effluent studies is recommended because the 
information they can provide is expected to improve interpretation of the study results. 
Moreover, the pharmaceutical compound consumption data for the facility will be readily 
available to compare with the measured concentrations.  
3. Prediction models can be a useful tool in assessing emissions from healthcare facilities. 
Existing health-related databases contain useful information, and so an assessment of the 
possible use of these databases to predict discharge of pharmaceuticals from healthcare 
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facilities is recommended.  The available databases include the IMS Canada database, which 
maintains comprehensive purchase data on hospitals, long term care homes, and drug stores 
across Canada; the Canadian MIS database (CMDB), which contains statistical information 
about all types of Canadian hospitals;  the Discharge Abstract Database (DAD), which 
contains patient details including diagnoses; the Hospital Morbidity Database  (DHMDB), 
which contains clinical information with a focus on acute care; and the Health Canada Drug 
Product Database (DPD) , which provides information about the drugs currently registered in 
Canada for human and  veterinary applications. The IMS database is maintained by IMS 
Canada; CMDB, DAD and DHMDB are maintained by the Canadian Institute of Health 
Information (CIHI), and DPD is maintained by Health Canada.  
4. The free chlorine concentration in hospital effluent that has been reported presumably occurs 
due to the use of disinfectants containing chlorine within hospitals. Certain antibiotic 
compounds (Ciprofloxacin and Sulfamethoxazole) are highly susceptible to chlorine 
oxidation. Their oxidation products have also been well studied by some researchers. A study 
of hospital wastewater on the occurrence of these compounds after use of various 
disinfectants is recommended.  Oxidation of these compounds by use of suitable disinfectants 
containing appropriate doses of chlorine may be a good onsite treatment option. The 
possibility of halogenated by-products would be an important consideration for such a study.   
5. The significance of healthcare facilities as potential point sources of PhACs, needs to be 
determined to allow the evaluation of long-term risks. To do so, requires understanding of 
trends in the health sector (hospitals and long term care homes) in terms of number of staffed 
beds and average inpatient days.  A literature review shows that these trends have been both 
negative and positive over the years. For instance the average inpatient days decreased from 
13 in 1978-79 to around 10 in 2002-2003, while the ambulatory care visits increased during 
this period. Such an assessment for both hospitals and long-term-care homes is 
recommended. 
6. Examination of the top 50 drug prescriptions in recent years shows that the use of certain 
compounds is increasing, while some other are decreasing and some show similar usage (IMS 
Canada). Further, therapeutic doses of these compounds vary widely, so it is possible that a 
large mass of a relatively less-prescribed compound will be discharged instead of a highly 
prescribed one because of the differences in the therapeutic dose.  Thus, developing a priority 
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list of compounds based on their consumption tends and therapeutic dose is recommended for 
future studies.  
7. Due to time constraints the conjugates of the target compounds were not measured in this 
study, as the method development and validation was expected to take a longer time than the 
project duration. It is recommended that the conjugated form of target compounds be 
measure, as there is evidence that these compounds, especially glucuronides, have a tendency 
to revert to the original compounds during sewer transit.  Measuring conjugates will provide 
more accurate assessment of the contributions by healthcare facilities to downstream 
WWTPs. 
8. The biodegradation and sorption properties of biofilm in sewers have been reported. It is 
recommended that such a process be considered while comparing discharges from healthcare 
















Preliminary list of compounds (IMS databse,2008)  
Preliminary list of compounds of in extended units (number of tablets, capsules etc) 
Therapeutic class   Compound Ontario Hospital purchases 
Anti-Infective 
 CIPROFLOXACIN 43,778,610 
 MOXIFLOXACIN 22,292,690 
 LEVOFLOXACIN 7,439,350 
 NYSTATIN 4,013,199 
 AMOXICILLIN 3,558,440 
 CEPHALEXIN 3,371,750 
 LINEZOLID 2,056,500 
 FLUCONAZOLE 1,892,911 
 CLINDAMYCIN 2,056,254 
 TRIMETHOPRIM 1,781,215 
 SULFAMETHOXAZOLE 1,737,815 
 PENICILLIN V 1,290,800 
 ISONIAZID 2,259,900 
 ERYTHROMYCIN 436,647 
 METRONIDAZOLE 1,756,855 
Anesthetics 
 PROPOFOL 30,123,410 
 SEVOFLURANE 6,931,500 
Psychotherapeutics 
 CLOZAPINE 8,313,300 
 MIDAZOLAM 5,703,735 
 LORAZEPAM 4,368,757 
Cardiovasculars 
 METOPROLOL 9,965,140 
 NITROGLYCERIN 3,177,090 
 RAMIPRIL 2,532,468 
 DILTIAZEM 2,401,165 





Therapeutic class   Compound Ontario Hospital purchases 
Analgesics 
 ACETAMINOPHEN 32,613,040 
 ACETYLSALICYLIC ACID 8,073,365 
 FENTANYL 7,120,697 
 MORPHINE 5,212,095 
Neuro disorder 
 VALPROIC ACID 3,903,720 
 PHENYTOIN 3,178,288 
 GABAPENTIN 2,687,900 
 CARBAMAZEPINE 1,850,000 
Hemostatic modifier 
 WARFARIN 5,667,450 
Oncology (Cytostatic agents) 
 FLUOROURACIL 3,521,920 
 CISPLATIN 2,077,050 
 RITUXIMAB 970,280 
 GEMCITABINE 1,012,648 
Contraceptives 
 ETHINYLESTRADIOL 4,669,831 
 LEVONORGESTREL 1,670,612 
Antihistamines 
 DIPHENHYDRAMINE 2,421,908 
Thyroid Therapy 
 LEVOTHYROXINE 2,268,102 
Hormones 
 PREDNISONE 3,285,200 
 HYDROCORTISONE 2,523,210 
 DEXAMETHASONE 2,126,963 
Anti diabetic 
 METFORMIN 4,636,220 
Lipid Regulators 






Comparison of CV values for healthcare facility effluents 
Table B1 Comparison between CVs 






HS1 & HS2 
Sulfamethoxazole  














































































Calculation of CV for WWTP influent concentrations 
WWTP-HS1 
Target Compounds Day-1 Day-2 Day-3 Day-4 Day-5 Mean sd CV 
Sulfamethoxazole   605 420 171 277 368 188 0.51 
Trimethoprim 389 412 309 153 330 319 102 0.32 
Ciprofloxacin 97 41 82 105 63 77 26 0.34 
Acetaminophen 83067 75867 65600 39907 51200 63128 17660 0.28 
Carbamazepine 269 261 897 151 168 349 311 0.89 
Metoprolol 49 179 207 145 161 148 60 0.41 
Venlafaxine 632 439 389 259 325 409 142 0.35 
N-desmethylvenlafaxine 248 120 170 81 99 144 67 0.47 





       
WWTP-HS2 
Target Compounds Day-1 Day-2 Day-3 Day-4 Day-5 Mean sd CV 
Sulfamethoxazole 548 436 216 389 408 399 120 0.30 
Trimethoprim 296 237 217 316 285 270 41 0.15 
Ciprofloxacin 84 91 112 130 103 104 18 0.17 
Acetaminophen 43600 41600 47600 41680 39573 42811 3033 0.07 
Carbamazepine 255 191 207 719 230 321 224 0.70 
Metoprolol 86 71 104 82 95 88 13 0.14 
Venlafaxine 521 476 509 499 467 494 23 0.05 
N-desmethylvenlafaxine 178 165 170 162 171 169 6 0.03 











Target Compounds Day-1 Day-2 Day-3 Day-4 Day-5 Mean sd CV 
Sulfamethoxazole 441 378 461 407 445 426 34 0.08 
Trimethoprim 226 292 264 271 353 281 47 0.17 
Ciprofloxacin 57 76 69 80 74 71 9 0.13 
Acetaminophen 64400 67333 66533 67600 70267 67227 2113 0.03 
Carbamazepine 175 164 158 181 184 172 11 0.06 
Metoprolol 235 257 217 199 261 234 26 0.11 
Venlafaxine 444 394 402 432 513 437 47 0.11 
N-desmethylvenlafaxine 190 115 124 114 126 134 32 0.24 
O-desmethylvenlafaxine 5493 2897 3185 2328 3269 3435 1208 0.35 
         
WWTP-LTC2 
Target Compounds Day-1 Day-2 Day-3 Day-4 Day-5 Mean sd CV 
Sulfamethoxazole 472 540 476 349 252 418 115 0.28 
Trimethoprim 200 244 186 194 100 185 52 0.28 
Ciprofloxacin 78 151 68 45 57 80 41 0.52 
Acetaminophen 67600 63200 64133 68400 42267 61120 10769 0.18 
Carbamazepine 69 104 75 72 81 80 14 0.18 
Metoprolol 282 227 219 244 135 221 54 0.24 
Venlafaxine 427 449 439 456 308 416 61 0.15 
N-desmethylvenlafaxine 145 145 143 177 103 143 26 0.18 
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Healthcare facility effluent pH 
D1) HS1  
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(May 26, 21:30 to May 27, 16:00) 
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(May 29, 10:30 to May 29, 05:00) 
 


















































































































































































































































































































































































































































































































































































































































































Buffer Check pH 10
Buffer Check pH 4
Start of pH monitoring
Buffer Check pH 7







































































































































































































































































































































































































































































































































































































































































































































































































































































































































Buffer Check pH 10
Buffer Check pH 7
Buffer Check pH 4
 


































Measured concentrations of target compounds in all samples 
 
HS1 effluent and WWTP-HS1 influents (R1, R2, R3 are the triplicates analyzed for each sample) 




HS1 (ng/L) WWTP-HS1 (ng/L) 
R1 R2 R3 Avg R1 R2 R3 Avg 
Sulfamethoxazole  Tue  3772 3392 3664 3609 696 664 456 605 
Wed  1068 1020 900 996 432 496 331 420 
Thu  900 916 848 888 159 171 182 171 
Fri  428 436 456 440 240 303 288 277 
Trimethoprim 
 
Mon 524 492 520 512 397 384 386 389 
Tue  540 544 568 551 408 432 397 412 
Wed  360 304 297 321 268 298 360 309 
Thu  366 268 308 314 106 207 145 153 
Fri  444 188 376 336 305 320 365 330 
Ciprofloxacin  Mon 691 611 594 632 107 111 74 97 
Tue  382 408 575 455 42 ND 40 41 
Wed  1240 1220 1,260 1240 86 62 99 82 
Thu  873 846 811 843 ND 108 101 105 
Fri  464 459 472 465 84 ND 41 63 
Acetaminophen  Mon 143200 122000 137200 134133 88800 81200 79200 83067 
Tue  115200 116400 111600 114400 74400 75600 77600 75867 
Wed  96800 95600 92800 95067 65200 64800 66800 65600 
Thu  110000 99200 92400 100533 40800 37720 41200 39907 
Fri  72400 66400 66800 68533 52400 52800 48400 51200 
Carbamazepine  Mon 143 142 146 144 270 258 279 269 
Tue  41 48 42 44 262 262 259 261 
Wed  34 34 35 34 872 908 912 897 
Thu  39 33 34 36 152 144 157 151 
Fri  90 82 87 86 164 168 173 168 
Metoprolol  Mon 356 352 210 306 36 65 46 49 
Tue  586 550 602 579 293 191 52 179 
Wed  524 466 480 490 201 209 211 207 
Thu  341 344 450 378 141 149 145 145 
Fri  475 557 447 493 161 156 166 161 
Venlafaxine  Mon 512 528 616 552 628 636 - 632 
Tue  344 321 378 348 468 452 396 439 
Wed  636 612 640 629 363 377 428 389 
Thu  736 740 756 744 282 246 249 259 
Fri  688 608 644 647 326 321 328 325 
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HS1 (ng/L) WWTP-HS1 (ng/L) 
R1 R2 R3 Avg R1 R2 R3 Avg 
N-des-venlafaxine  Mon 128 139 383 217 247 249 - 248 
Tue  177 232 149 186 125 115 120 120 
Wed  290 285 275 283 148 178 185 170 
Thu  340 340 380 353 88 77 78 81 
Fri  424 404 420 416 101 104 92 99 
O-de-venlafaxine  Mon 2540 2692 3408 2880 7920 5240 - 6580 
Tue  2252 3172 1456 2293 1484 1352 2612 1816 
Wed  1140 952 812 968 1,444 1860 1744 1683 
Thu  1788 1744 1860 1797 596 560 628 595 
Fri  1368 1176 1104 1216 776 760 792 776 
 
Detected target compound concentrations in HS2 effluent and WWTP-HS2 influent 




HS2 (ng/L) WWTP-HS2 (ng/L) 
R1 R2 R3 Avg R1 R2 R3 Avg 
Sulfamethoxazole Mon 6560 6560 6600 6573 544 536 564 548 
Tue  424 416 374 405 440 436 432 436 
Wed  6280 6520 5680 6160 206 221 220 216 
Thu  11080 10520 11200 10933 420 379 367 389 
Fri  325 338 318 327 420 432 372 408 
Trimethoprim 
 
Mon 5200 4760 4880 4947 307 275 306 296 
Tue  302 351 314 322 225 249 236 237 
Wed  9200 9520 9520 9413 220 234 198 217 
Thu  10480 10080 10400 10320 314 277 356 316 
Fri  440 428 408 425 276 295 284 285 
Ciprofloxacin  Mon 105 103 149 119 81 84 88 84 
Tue  156 149 155 153 81 75 116 91 
Wed  182 156 168 169 120 128 88 112 
Thu  168 164 134 155 131 113 145 130 
Fri  149 139 139 142 111 122 75 103 
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HS2 (ng/L) WWTP-HS2 (ng/L) 
R1 R2 R3 Avg R1 R2 R3 Avg 
Acetaminophen  Mon 13280 14040 12440 13253 40000 46800 44000 43600 
Tue  11600 14320 14200 13373 41600 40800 42400 41600 
Wed  15760 15440 16720 15973 46800 48800 47200 47600 
Thu  12440 11600 11280 11773 47200 42000 35840 41680 
Fri  10960 11960 11280 11400 39720 40400 38600 39573 
Carbamazepine  Mon 752 652 624 676 243 258 265 255 
Tue  632 608 644 628 191 195 187 191 
Wed  80 74 74 76 210 199 212 207 
Thu  596 360 400 452 708 688 760 719 
Fri  175 189 150 171 222 234 235 230 
Metoprolol  Mon 88 84 91 88 91 80 88 86 
Tue  348 327 337 337 61 72 79 71 
Wed  196 190 195 193 106 103 102 104 
Thu  181 165 178 175 83 82 81 82 
Fri  166 152 163 160 93 97 96 95 
Venlafaxine  Mon 808 692 784 761 496 556 512 521 
Tue  38400 34920 34640 35987 468 452 508 476 
Wed  8840 8880 8960 8893 544 484 500 509 
Thu  4400 3696 4080 4059 484 476 536 499 
Fri  4640 4240 4840 4573 416 480 504 467 
N-des-venlafaxine  Mon 222 203 226 217 176 177 181 178 
Tue  291 318 294 301 172 161 164 165 
Wed  114 92 94 100 179 169 161 170 
Thu  241 236 236 238 162 154 171 162 
Fri  452 476 444 457 170 176 166 171 
O-de-venlafaxine  Mon 1012 908 948 956 1,520 1676 1644 1613 
Tue  7840 5520 5960 6440 1348 1364 1360 1357 
Wed  1152  1072  1156  1127  1276  1220  1204  1233  
Thu  2476  2496  2632  2535  1092  1088  1156  1112  




Detected target compound concentrations in LTC1 effluent and WWTP-LTC1 influent 




LTC1 (ng/L) WWTP-LTC1 (ng/L) 
R1 R2 R3 Avg R1 R2 R3 Avg 
Sulfamethoxazole Mon 364 404 366 378 394 440 488 441 
Tue  2188 2328 2360 2292 358 391 386 378 
Wed  154 147 141 147 460 468 456 461 
Thu  78 100 107 95 351 476 393 407 
Fri  303 324 363 330 460 448 428 445 
Trimethoprim 
 
Mon 712 744 752 736 230 209 238 226 
Tue  948 888 936 924 313 293 270 292 
Wed  472 420 460 451 275 284 233 264 
Thu  7000 6320 6400 6573 296 261 256 271 
Fri  696 756 652 701 408 370 282 353 
Ciprofloxacin  Mon 189 146 256 197 55 65 50 57 
Tue  304 363 369 345 70 82 78 76 
Wed  644 583 586 604 77 58 71 69 
Thu  258 211 204 224 84 73 83 80 
Fri  203 242 196 214 68 81 72 74 
Acetaminophen  Mon 93200 89600 74000 85600 65200 64800 63200 64400 
Tue  84000 92000 75600 83867 66800 68400 66800 67333 
Wed  65200 89600 81200 78667 68400 65200 66000 66533 
Thu  121200 102000 125600 116267 68000 65200 69600 67600 
Fri  78800 78000 76400 77733 70800 68000 72000 70267 
Carbamazepine  Mon 186 185 174 182 187 174 165 175 
Tue  158 142 158 153 154 173 164 164 
Wed  254 254 247 252 156 169 149 158 
Thu  516 524 540 527 182 181 181 181 
Fri  177 177 174 176 190 183 178 184 
Metoprolol  Mon 888 940 1272 1033 219 276 210 235 
Tue  1952 1648 2024 1875 302 254 214 257 
Wed  936 1284 1172 1131 262 202 188 217 
Thu  4480 4880 5400 4920 232 186 180 199 
Fri  424 624 576 541 264 223 296 261 
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LTC1 (ng/L) WWTP-LTC1 (ng/L) 
R1 R2 R3 Avg R1 R2 R3 Avg 
Venlafaxine  Mon 536 524 580 547 444 480 408 444 
Tue  408 408 420 412 358 428 395 394 
Wed  2320 2236 2268 2275 420 388 399 402 
Thu  107 111 107 108 456 368 472 432 
Fri  225 244 261 243 516 496 528 513 
N-des-venlafaxine  Mon 121 122 134 126 224 186 160 190 
Tue  260 266 272 266 118 107 120 115 
Wed  95 92 96 95 138 124 110 124 
Thu  47 42 44 44 130 96 115 114 
Fri  136 142 121 133 126 125 127 126 
O-des-venlafaxine  Mon 1248 1232 1424 1301 5400 6720 4360 5493 
Tue  1292 1276 1260 1276 2864 3016 2812 2897 
Wed  2336 2356 2124 2272 3548 3264 2744 3185 
Thu  330 327 311 323 2052 2200 2732 2328 
Fri  7960 6160 6840 6987 3140 3344 3324 3269 
 
Detected target compound concentrations in LTC2 effluent and WWTP-LTC2 influent 




LTC2 (ng/L) WWTP-LTC2 (ng/L) 
R1 R2 R3 Avg R1 R2 R3 Avg 
Sulfamethoxazole Mon 592 - - 592 448 492 476 472 
Tue  105 108 87 100 524 500 596 540 
Wed  672 752 724 716 468 460 500 476 
Thu  381 448 342 391 337 354 357 349 
Fri  254 230 296 260 266 238 253 252 
Trimethoprim 
 
Mon 238 - - 238 233 150 216 200 
Tue  240 228 232 234 182 274 275 244 
Wed  1920 1924 1928 1924 200 181 176 186 
Thu  864 880 796 847 206 170 205 194 
Fri  306 307 280 298 88 90 122 100 
Ciprofloxacin  Mon 49 - - 49 75 72 88 78 
Tue  48 37 36 40 121 178 153 151 
Wed  26 27 41 31 54 56 95 68 
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LTC2 (ng/L) WWTP-LTC2 (ng/L) 
R1 R2 R3 Avg R1 R2 R3 Avg 
Ciprofloxacin  Thu  1630 1240 1540 1470 38 44 53 45 
Fri  55 41 31 42 73 48 51 57 
Acetaminophen  
 
Mon 72800 - - 72800 65200 71200 66400 67600 
Tue  88000 86400 92000 88800 62000 62000 65600 63200 
Wed  82800 81200 92000 85333 65600 66400 60400 64133 
Thu  83600 86400 87200 85733 70000 69600 65600 68400 
Fri  80400 80000 76400 78933 42800 41600 42400 42267 
Carbamazepine  Mon 64 - - 64 70 70 68 69 
Tue  66 67 69 67 98 103 112 104 
Wed  21 23 22 22 77 79 68 75 
Thu  35 33 31 33 68 68 79 72 
Fri  76 76 78 77 74 76 91 81 
Metoprolol  Mon 198 - - 198 266 225 354 282 
Tue  313 312 337 321 222 261 200 227 
Wed  168 198 211 192 182 225 251 219 
Thu  246 262 250 253 255 225 251 244 
Fri  179 147 143 157 128 140 136 135 
Venlafaxine  Mon 334 - - 334 424 416 440 427 
Tue  136 150 146 144 444 448 456 449 
Wed  99 93 99 97 460 412 444 439 
Thu  37 37 38 38 480 448 440 456 
Fri  712 696 740 716 297 322 304 308 
N-des-venlafaxine  Mon 119 - - 119 142 137 158 145 
Tue  34 31 35 33 143 154 138 145 
Wed  0 0 0 0 163 104 161 143 
Thu  0 0 0 0 175 170 184 177 
Fri  116 113 108 112 106 112 93 103 
O-de-venlafaxine  Mon 892 - - 892 1212 1132 1076 1140 
Tue  580 640 644 621 1152 1112 1216 1160 
Wed  476 476 504 485 1528 1238 1404 1390 
Thu  716 776 716 736 488 1564 1832 1295 
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